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 ABSTRACT 
 
Introduction: An association between maternal human immunodeficiency virus (HIV) 
infection and Necrotizing Enterocolitis (NEC) in preterm infants has been reported. The 
impact of probiotics in an HIV-exposed very low birth weight (VLBW) infant on the 
occurrence of NEC is uncertain at present; however it is known that probiotics have 
protective effects against inflammation and prevent NEC. Postnatal growth restriction is 
a major issue in preterm, especially extremely-low-birth-weight (ELBW) infants and 
probiotics have been found to improve feeding tolerance in preterm infants. Human milk 
oligosaccharides (HMO) also known as the prebiotics of human milk, are known to have 
bifidogenic and anti-adhesive effects.  Infants that receive human milk show a reduced 
incidence of NEC compared to those who receive infant formula. Very little is known 
about the composition of breast milk in the HIV-infected mother.  
Objective: The primary objective of the study was to assess the effect of probiotics on 
the incidence and severity of NEC in high-risk infants born to HIV-positive and HIV-
negative women. The secondary objectives were to assess the effect of probiotic 
administration on feeding tolerance and growth outcomes of HIV-exposed but 
uninfected preterm infants, to describe the HMO composition of HIV-infected mothers 
breast milk and lastly to determine if HMO composition affects the incidence of NEC in 
HIV-exposed preterm very low birth weight infants. 
Patients and Methods:  A randomized, double blind, placebo controlled trial was 
conducted for the period July 2011 to August 2012. HIV-exposed and HIV-unexposed 
premature (<34 weeks gestation) infants with a birth weight of ≥500g and ≤1250g were 
Stellenbosch University  http://scholar.sun.ac.za
iii 
randomized to receive either a probiotic or a placebo. The probiotic consisted of 1x109 
CFU, L. rhamnosus GG and B. infantis per day and was administered for 28 days. NEC 
was graded according to Bell’s criteria. Anthropometrical parameters and daily intakes 
were monitored.  Breats milk samples were analysed for oligosaccharide content. 
Results: 74 HIV-exposed and 110 HIV-unexposed infants were enrolled and 
randomized (mean birth-weight, 987g; mean gestational 28.7 weeks). The incidence of 
death and NEC did not differ significantly between the HIV-exposed and unexposed 
groups but a significantly higher  NEC incidence was found in the control group. There 
was no difference in the average daily weight gain for treatment groups or HIV 
exposure. The HIV-exposed group achieved significantly higher z-scores for length and 
head circumference at day 28 than the unexposed group (p<0.01 and p=0.03, 
respectively). There were no differences in the incidence of any signs of feeding 
intolerance and abdominal distension between the groups. Our results show 
significantly higher absolute concentrations of 2’-fucosyllactose, laco-N-tetraose and 
lacto-N-fucopentaose 1 and higher relative abundance of 3’-sialyllactose, difucosyl-
lacto-N-tetraose and fucosyl-disialyllacto-N-hexaose in HIV-infected compared to -
uninfected Secretor women. DSLNT concentrations were significantly lower in the 
breast milk of mothers whose infants developed NEC compared to infants without NEC.  
Conclusion: Probiotic supplementation reduced the incidence of NEC in the premature 
infants; however results failed to show a lower incidence of NEC in HIV-exposed 
premature infants. Probiotic supplementation did not affect growth outcomes or the 
incidence of any signs of feeding intolerance in HIV-exposure. The data confirms 
previous reports that HIV-infected mothers have higher 3’sialyllactose milk 
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concentrations. Most intriguing though, the data also indicates that low levels of DSLNT 
in the mother’s milk increase the infant’s risk for NEC, which is in accordance with 
results from previously published animal studies and warrants further investigation.    
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OPSOMMING 
 
Inleiding: ŉ Verwantskap tussen moederlike menslike immuniteitsgebreksvirus (MIV) 
en nekrotiserende enterokolitis (NEK) in premature babas is aangemeld. Die impak van 
probiotika in ŉ MIV-blootgestelde baie lae geboortemassa (BLGM) baba op die 
voorkoms van NEK is tans nog onseker, maar dit is wel bekend dat probiotika ŉ 
beskermende effek het teen inflammasie en die voorkoms van NEK. Nageboortelike 
groei beperkings is ŉ groot probleem in premature, veral ekstreme lae geboortemassa 
(ELGM) babas. Daar is gevind dat probiotika voeding toleransie in premature babas kan 
verbeter. Menslike melk oligosakkariede (MMO), ook bekend as die prebiotika van 
menslike melk, is bekend om bifidogeniese en anti-kleef effekte te hê. Babas wat 
moedersmelk ontvang toon ŉ verlaagde voorkoms van NEK in vergelyking met diegene 
wat baba formule melk ontvang. Baie min inligting is bekend oor die samestelling van 
borsmelk in die MIV-positiewe moeder. 
Doel: Die primêre doel van die studie was om die effek van probiotika op die voorkoms 
en die graad van NEK in hoë risiko babas van MIV-positiewe en MIV-negatiewe vroue 
te bepaal. Die sekondêre doelwitte was om die effek van probiotika op voeding 
verdraagsaamheid en groei uitkomste van MIV-blootgestelde, maar nie- geinfekteerde 
premature babas te evalueer sowel as die MMO samestelling van MIV-positiewe 
moeders se borsmelk te beskryf en laastens om die invloed van die MMO samestelling 
op die voorkoms van NEK in baie lae geboortegewig MIV-blootgestelde premature 
babas te beskryf. 
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Pasiënte en Metodes: ŉ Gerandomiseerde, dubbelblinde, plasebo-beheerde studie is 
vir die tydperk Julie 2011 tot Augustus 2012 onderneem. MIV-blootgestelde en nie-
blootgestelde premature (<34 weke) babas met 'n geboorte gewig van ≥500g en 
≤1250g was ewekansig verdeel om  probiotika of plasebo te ontvang. Die probiotika het 
bestaan uit 1x109 kolonie vormende eenhede, L. rhamnosus GG en B. infantis per dag 
en is toegedien vir 28 dae. NEK is gegradeer volgens Bell se kriteria. Antropometriese 
parameters en daaglikse inname is gemonitor. Borsmelk monsters is geanaliseer vir 
oligosakkaried inhoud. 
Resultate: 74 MIV-blootgestelde en 110 MIV-nie-blootgestelde babas is ingesluit en 
ewekansig ingedeel (gemiddelde geboorte gewig, 987g, gemiddelde gestasie 28,7 
weke). Die voorkoms van die sterftes en NEK het nie beduidend verskil tussen die MIV-
blootgestelde en nie-blootgestelde groepe nie, maar 'n beduidende verskil is gevind vir 
NEK voorkoms tussen die studie en die kontrole groep. Daar was geen verskil in die 
gemiddelde daaglikse gewigstoename tussen die behandelings groepe of MIV-
blootstelling nie. Die MIV-blootgestelde groep het beduidend hoër z-tellings vir lengte en 
kopomtrek op dag 28 getoon teenoor die nie-blootgestelde groep (p <0.01 en p = 0,03, 
onderskeidelik). Daar was geen verskille in die voorkoms van voeding 
onverdraagsaamheid en abdominale distensie tussen die twee groepe nie. Ons 
resultate dui op aansienlik hoër absolute konsentrasies van 2'-fucosyllactose, laco-N-
tetraose en lakto-N-fucopentaose 1 en hoër relatiewe voorkoms van 3'-sialyllactose, 
difucosyl-lakto-N-tetraose en fucosyl-disialyllacto-N-hexaose in MIV-positiewe vroue in 
vergelyking met-negatiewe Sekretor vroue. DSLNT konsentrasies was aansienlik laer in 
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die melk van moeders wie se babas NEK ontwikkel het in vergelyking met babas sonder 
NEK. 
Gevolgtrekking: Probiotika aanvullings verminder die voorkoms van NEK in premature 
babas, maar die resultate kon nie ŉ laer voorkoms van NEK in MIV-blootgestelde 
premature babas bewys nie. Probiotiese aanvulling het geen invloed op groei uitkomste 
of die voorkoms van voeding onverdraagsaamheid in MIV-blootstelling getoon nie. Die 
data bevestig vorige verslae wat aandui dat MIV-besmette moeders hoër 3'sialyllactose 
borsmelk konsentrasies het. ŉ Interessante aspek is dat lae vlakke van DSLNT in die 
moeder se melk beduidend is van ŉ verhoogde risiko vir NEK, wat in ooreenstemming 
is met die resultate uit voorheen gepubliseerde dier studies en regverdig verdere 
ondersoeke.  
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MOTIVATION FOR THE STUDY 
 
Necrotizing enterocolitis (NEC) is a condition predominantly seen in premature infants 
and is the leading cause of death due to gastrointestinal disease in neonatal intensive 
care units.1 An association between maternal human immunodeficiency virus (HIV) 
infection and NEC in preterm infants has been reported.2 Protocols for NEC treatment 
include nondrug treatments such as infants being nil per os, drug treatments and 
surgical interventions. Each of these has its own detrimental effects on patient outcome 
such as poor growth and neurodevelopmental delays.3 Furthermore, HIV infection with 
acquired immunodeficiency syndrome (AIDS) is well known to be associated with a 
worse outcome in surgical patients.4  
Evidence suggests that intestinal microbiota play an important role in general health and 
more importantly in the prevention of NEC in premature infants. Infants cared for in 
neonatal intensive care units develop very different intestinal microbiota with 
bifidobacteria being significantly less common.5 Preterm very low birth weight (VLBW) 
and extremely low birth weight (ELBW) infants’ initial exposure to environmental 
microorganisms is most often from equipment, air and other neonates, with the nursing 
personnel acting as carriers.6 Furthermore, the effect of antibiotic treatment and the 
type of feed (breast milk vs formula milk) administered further determine the abundance 
of beneficial intestinal bacteria.5  
The primary objective of the study was to evaluate the efficacy of probiotics in reducing 
the incidence and severity of NEC in premature, HIV-exposed, VLBW infants. 
Prophylactic probiotic treatment could be an effective, affordable and appropriate way of 
reducing the incidence of NEC in this highly vulnerable population. A reduction in the 
incidence of NEC would decrease mortality, morbidity, medical costs and length of 
hospital stay and improve the long-term neurodevelopmental outcomes of VLBW 
infants.  
Secondly, this study aimed to determine the prebiotic quality (human milk 
oligosaccharides) of the breast milk of HIV-infected and HIV-uninfected mothers and to 
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determine whether there was an association between the prebiotic quality (human milk 
oligosaccharides) and NEC. If the results of this study could prove that the prebiotic 
quality of breast milk (HIV exposed/unexposed) reduced the incidence of NEC and 
thereby mortality and morbidity of preterm, VLBW babies, it could strengthen the views 
and perspectives of mothers and medical personnel on the importance of breastfeeding. 
Furthermore, breastfeeding may decrease the household financial burden and improve 
hygiene and safety measures. Prebiotics are available in breast milk, making the study 
highly sustainable as breast milk is free.  
A systematic review of 16 randomised control trails indicated a significant reduction in 
the risk of NEC and death with the supplementation of probiotics. It is necessary to note 
that the majority of these trials included the use of both formula milk and breast milk. No 
research was found on the influence of HIV status on the use of probiotics and the 
effect that it had on the incidence of NEC in premature, VLBW infants. Limited research 
has been done on the prebiotic quality of breast milk in HIV-positive women, more 
specifically those who have given birth to a preterm infant. Very limited research also 
exists on the use of probiotics in a developing country such as South Africa.  
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BRIEF OUTLINE OF THE THESIS 
 
This thesis is devided into four chapters. A brief overview of each chapter wil now be 
given. 
Chapter 1 covers the literature background and consist of the following three review 
articles:  
Probiotics in premature infants: a focus on Necrotizing enterocolitis, focusses on 
the pathogenisis and diagnosis of necrotizing interocolitis (NEC) and provides broad 
guidelines on the use of probiotics in premature low-birth weight infants.  
The use of probiotic bacteria in HIV-exposed premature infants: A focus on NEC, 
provides a in depth discussion on the role that HIV has in the development of NEC and 
the potential benefits that probiotics hold in affected infants.  
Human milk oligosaccharides: Possible links to necrotizing enterocolitis and HIV-
exposure. This article aims to describe the prebiotic and anti-adhesive effects of human 
milk oligosaccharides (HMO’s) and how they contribute to the development of NEC in 
the presence of HIV infection.  
Chapter 2 consist of the methodology of this randomized controlled trail.  
Chapter 3 covers the results of the study and consists of three articles.  
Probiotics and necrotizing enterocolitis in HIV-exposed premature infants. This 
article adresses the primary and a secondary outcome of the study. The primary 
objective of the study was to evaluate the efficacy of probiotics in reducing the incidence 
and severity of all stages of NEC in premature very-low birth weight infants that are 
exposed to HIV. The secondary objective that this article aimed to adress, assessed the 
incidence of NEC in very-low birth weight and extremely low birth weight infants born to 
HIV-infected and HIV-uninfected women. 
Probiotics, feeding tolerance and growth: a comparison between HIV-exposed 
and unexposed very low birth weight infants. This article aimed to elucidate the role 
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of probiotics on feeding tolerance and subsequent growth in HIV exposed versus 
unexposed premature VLBW infants in a resource limited setting where practice 
involves early initiation of enteral feeds with expressed breast milk. 
Human milk oligosaccharides differ between HIV-infected and -uninfected 
mothers and are related to necrotizing enterocolitis incidence in their preterm 
very low birth weight infants. This article adresses the final objectives of this study, 
namely to determine the oligosaccharides quality of own mother’s breast milk of HIV-
infected and HIV-uninfected mothers and wheather there is an association between the 
oligosaccharide quality of breast milk and the incidence of NEC in premature very-low 
birth weight infants. 
Chapter 4 concludes the study objectives. This chapter briefly accepts or rejects the set 
null hypothosis of this clinical trail and provides recommendations.  
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ABSTRACT 
Necrotizing enterocolitis is a condition predominantly seen in premature infants and is 
the leading cause of mortality and morbidity in neonatal intensive care units. Recently 
an association between maternal human immunodeficiency virus (HIV) infection and 
necrotizing enterocolitis (NEC) in preterm infants was reported. The administration of 
probiotics to this vulnerable population may be an effective way to change the 
colonization pattern. However the effect of probiotics on the incidence of NEC in 
premature and low birth weight infants exposed to HIV is unknown. Published research 
indicates that probiotics reduce the risk of NEC and death in HIV-unexposed infants.  A 
recent clinical trial by Van Niekerk et al found a reduction in the severity of disease per 
Bells criteria in HIV-exposed preterm infants. This article aims to provide an overview 
the general factors associated with NEC in premature low birth weight infants, to 
discuss factors that contribute to the incidence of NEC specific to HIV-exposed infants 
and to speculate on the role that probiotics may play in reducing the occurrence of NEC 
in HIV-exposed infants. 
 
Key words: Human Immunodeficiency Virus, Necrotizing Enterocolitis, Premature 
infant, Probiotic, Very Low Birth Weight 
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INTRODUCTION 
Necrotizing enterocolitis (NEC) is a condition predominantly seen in premature infants 
and is the leading cause of gastro-intestinal associated mortality and morbidity in 
neonatal intensive care units (NICU).1  This acute gastrointestinal disease presents an 
overall incidence of 2-5% in all premature infants and 5 -15% in babies weighing less 
than 1500gr at birth.2, 3 Recently an association between maternal human 
immunodeficiency virus (HIV) infection and NEC in preterm infants was reported.4 Two 
mechanisms are proposed to explain the increased risk of NEC in premature infants 
exposed to HIV. Firstly fetal HIV exposure and secondly the use of antiretroviral 
medication during pregnancy.4  Probiotics are live microbial food ingredients which have 
been shown to have health promoting effects.5  Lactobacillus Rhamnosus GG and 
Bifidobacterium Infantis have been used as probiotics to reduce the incidence of NEC.6 
A recent meta-analysis of sixteen randomized, controlled trials indicated significant 
reduction in the risk of NEC and death in HIV unexposed infants following the use of 
probiotics.7 The purpose of this review is to provide an overview of the factors that 
contribute to the incidence of NEC in HIV-exposed infants and the role that probiotics 
may play in reducing the occurrence of NEC.  
 
INCIDENCE OF PREMATURE AND LOW BIRTH WEIGHT INFANTS BORN TO 
MOTHERS THAT ARE HIV INFECTED 
Fetal complications such as preterm birth and intrauterine growth restriction are more 
common in untreated HIV-infected women than in women without HIV infection and 
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their occurrence correlates with the severity of HIV disease.8 An association has also 
been found between the presence of maternal HIV infection and the incidence of small 
for gestational age (SGA) premature births.3, 9, 10. A recent cohort study found  that the 
prevalence of low birth weight (LBW)  (<2500g) deliveries in HIV-affected pregnancies 
was 11.5%.11 Also in a randomized trial, Kawai et al reported prematurity rates were as 
high as 19% amongst HIV-infected mothers with a median CD4 cell count of 500 
cells/ml.11, 12 Stratification by stage of disease shows that symptomatic HIV-positive 
women tend to have a higher risk of LBW than do asymptomatic women.13 
 
FACTORS CONTRIBUTING TO THE DEVELOPMENT OF NECROTIZING 
ENTEROCOLITIS  
Gastrointestinal immunity of the preterm infant and NEC  
Although the pathogenesis of NEC has been researched it has not yet been fully 
elucidated but it is considered multifactorial.1, 14 The most common risk factors are 
prematurity, timing, volume and choice of enteral feeding, intestinal ischaemia and 
bacterial colonization.14 The majority of premature infants may also be exposed to 
antibiotic treatment during hospitalization, which alters intestinal micro-flora to facilitate 
colonization by more pathogenic organisms.15 Aberrant colonization16 of the intestinal 
tract may  activate the inflammatory cascade, leading to high expressions of pro-
inflammatory mediators.15, 16 The combination of these events leads to the manifestation 
of NEC.15  
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A strong association exists between prematurity and NEC because of structural and 
functional gastrointestinal incompetence.  The intestinal epithelium’s primary function is 
to provide a physical barrier between the inside of the body and the luminal environment 
of the gastrointestinal tract. The barrier function would however be  incomplete in the 
absence of immunologic components of the intestinal defense system.17 
The immunity of the newborn bowel is dependent upon the innate rather than the 
adaptive immune system. During this developmental phase, Toll-like (TLR) receptors 
survey the lumen for macromolecules with pathogenic characteristics. If they are 
activated, they induce apoptosis to entrap the pathogen. A bacterial receptor such as 
Toll-like receptor 4 (TLR4) is vital, as it senses lipopolysaccharides (LPS).18 LPS is an 
endotoxin and a major component of the outer membrane of Gram-negative bacteria.  
Elevated circulating levels of LPS have been identified in patients with NEC. 19 
 
TLR4 expression correlates well with increasing gestational age, until term birth, where 
after it decreases rapidly. Furthermore TLR4 expression also increases in response to 
LPS.18 Recent published research indicates that TLR4 expression is up regulated in 
infants that developed NEC. 18, 20 The more TLR4 is expressed, the more apoptosis will 
occur, therefore increasing the severity of NEC.18 Chan et al suggest that bowel 
distension in overfed premature neonates potentiates LPS action on innate TLR4 
immunity. It is hypothesized that bowel distension injures the intestinal mucosa, and 
exposes the enterocytes to bacterial LPS.20 
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Upon exposure to bacterial products such as LPS, fetal intestinal epithelial cells 
produce more interleukin (IL)-8 and may also produce tumor necrosis factor (TNF), IL-1, 
IL-6, and platelet-activating factor (PAF).19 Concentrations of IL8 and IL10 have been 
found to be significantly higher in infants with stage 3 NEC than in infants with less 
severe stages of NEC.21 
This inflammatory hyper-responsiveness of neonatal gut correlates with increased 
nuclear factor kappa B (NF-κB)-mediated gene transcription which, in turn, is related to 
a developmental deficiency of the inhibitor of kappa B (IκB). NF-κB signals undergo 
gradual down regulation in fetal intestinal epithelial cells following birth at term 
gestation.18 The NF-κB pathway is important in microbial recognition and subsequent 
inflammatory response in the mature gut.22 
The role of T cells in the pathogenesis of NEC has been understudied. 18 T cells are 
traditionally not considered in the pathogenesis of NEC. Studies on the genetic risk 
factors for NEC suggest that a Th1-mediated immune response is associated with more 
severe disease. 23  Weitkamp et al24 investigated the effector T cell and T-regulated cell 
(Treg) proportions.  They found a robust presence of CD4 and CD8 effector T cells in 
human NEC tissue. The proportion of lamina propria Treg is significantly reduced in the 
ileum of premature infants with NEC.24 
 
Factors that may contribute to the incidence of NEC in HIV-exposed infants 
The pathogenesis of NEC in neonates born to HIV-infected mothers has not been 
clearly elucidated, a few contributing factors will now be discussed. 
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Antiretroviral treatment schedules 
Although there is a scarcity of data on the outcomes of premature infants born to HIV-
infected mothers, maternal HIV infection and its treatment have been identified as 
independent risk factors for neonatal NEC. 4, 10 Furthermore a high incidence of preterm 
labour and premature birth has been found as treatment has evolved into regimens of 
highly active antiretroviral therapy (HAART).25  
Normally pregnancy is characterized by an increase in Th2 cytokines and suppression 
of Th1 cytokine production, this is said to protect the pregnancy.26, 27 The progression of 
HIV disease is also characterized by a shift from Th1 to Th2 cytokine production.28 
HAART counteracts this cytokine shift.28 It has been hypothesized that the increased 
risk for preterm delivery observed in HIV-infected, HAART-exposed women is mediated 
through changes in the cytokine environment in pregnancy.29 Fiore et al showed that 
HAART use in pregnancy was associated with increased IL-2 and decreased IL-10.29 An 
inverse relationship exists between gestational ages (prematurity) and the incidence of 
NEC.30 This could be a possible reason for the increased risk of NEC in infants born to 
HIV-infected mothers.  
Thus although antiretroviral prophylaxis has decreased perinatal transmission of HIV 
and the benefit of antiretroviral prophylaxis in preventing HIV transmission outweighs 
the risks of side effects, the burden of NEC in the HIV-exposed newborn population is 
significant.8, 31 A case report by De Carolis et al speculates that, rather than the maternal 
therapy, it is the neonatal therapy that plays a main role in increasing the risk of NEC. 32  
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Anaemia of prematurity and transfusion of packed red blood cells (PRBCs) are common 
in very low birth weight infants.33 A strong association has been shown between red 
blood cell transfusions and the incidence of NEC in premature infants.33-35 Possible 
reasons why PRBC transfusions may lead to NEC include a decrease in nitric oxide in 
stored red blood cells36 and an exaggerated intestinal immune response to PRBC 
transfusion.33, 34 Locke et al could not show a systemic cytokine response after PRBC 
transfusion.37 However, Paul et al points out that because intestinal ischaemia is part of 
the pathophysiology of NEC, any inflammatory response after transfusion may be 
initially limited to the intestine. 33  A recent meta-analysis concludes that transfusion-
associated NEC has a higher risk of mortality than NEC which was not preceded by 
transfusion.35 Feiterna-Sperling et al found a high proportion of ARV-exposed infants 
with anaemia, and the risk for anaemia was generally enhanced by the intensity of 
maternal ART.38 Josephson et al also reported increased odds of NEC after transfusion 
in infants older than 4 weeks.34 
 
Immunological abnormalities:  
The pathogenesis of NEC in neonates born from HIV-positive mothers is still unclear. 32 
Possible reasons for an increased incidence of NEC in neonates of HIV-infected 
mothers is the use of HAART,25 an increased incidence of preterm births amongst HIV 
infected woman, 8 early-onset sepsis and lastly that HIV-infected mothers with advanced 
HIV disease may have lower antibody titers.39, 40 The intricate immunological changes, 
involving cytokine production and T cell function, observed in HIV-exposed infants also 
support the hypothesis of a possible link between HIV-vertical-exposure and NEC.41, 42 It 
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has been thought that exposure to HIV determines an alteration of interleukin (IL)-12 
expression in the gut mucosa and  decreased T-cell function.32 IL-12 has been shown to 
induce and enhance cell-mediated immune responses. Thus, abnormalities in IL-12 
regulation could contribute to the decreased cellular responses observed in infants who 
are vertically infected with HIV. Chougnet et al found that IL- 12 production was 
undetectable in infants born to HIV-positive mothers.43 
Uninfected infants born to HIV-infected mothers also demonstrate immune deficiencies 
which could influence outcome, particularly in advanced NEC.31 The absence of any HIV 
infection at follow-up of the infants does not rule out this hypothesis, as significant 
haematological and immunological abnormalities have been reported in HIV-uninfected 
infants of HIV-positive mothers. These deficiencies may make these infants more prone 
to infections, and possibly to developing NEC.4, 41 Karpelowsky et al were the first to 
document an increased mortality among HIV-uninfected neonates with NEC born to 
HIV-infected mothers.40 A recent retrospective study provided conflicting results. It 
reviewed cases of stage III NEC; HIV-exposed infants were compared with HIV-
unexposed infants and the findings indicate that HIV-exposed infants do not have more 
severe disease or more adverse outcomes in stage III NEC than unexposed infants.31 It 
is suggested by Desfrere et al that premature newborn infants of HIV-positive mothers 
should be monitored very carefully for a possible increased risk of NEC.4  
 
Cytomegalovirus:  
Similar to HIV, cytomegalovirus (CMV) transmission occurs during birth as the infant is 
exposed to the mother’s infected cervical and vaginal secretions or post-natally through 
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breast milk. Approximately 50%–60% of infants fed breast milk containing CMV become 
post-natally infected with CMV, with a higher risk of symptomatic CMV among preterm 
infants and this may lead to a sepsis-like illness. 44 Identified risk factors for postnatal 
CMV transmission include a high viral  load, early shedding of CMV in milk, duration of 
breast-feeding, and lower infant gestational age and birth weight.45 HIV-1 viral load and 
CMV co-infection synergistically increased the frequency of activated CD4 T cells, 
suggesting that CMV co-infection may play an important role in CD4 T cell depletion 
during acute infant HIV-1 infection.46 HIV-infected infants who acquire CMV infection 
have a significantly higher rate of disease progression than those infected with HIV-1 
alone.46, 47  
Premature infants receive significant nutritional and immunologic benefits from breast 
milk, because breast milk feeding is associated with lower incidence of NEC and late-
onset sepsis.48 Pasteurisation is highly effective method of removing viable CMV and 
HIV, but will also damage lymphocytes and immunoglobulins in the milk.45 Postnatal 
CMV infection in preterm infants may present clinically as enterocolitis. Since CMV 
transmission via breast milk can occur early during postnatal life, CMV may be an 
infectious cause of NEC.49 Clinical signs may range from minor to severe. It is 
suggested that clinical features such as diarrhoea, abdominal distension and abdominal 
tenderness in the absence of radiological features of NEC should increase concerns of 
acquired CMV infection in the preterm baby.50 Despite the fact that CMV infection is well 
known to be an opportunistic infection in patients with HIV infections, contradictory 
Chokoe et al indicated in a retrospective study that CMV is not a risk factor for NEC in 
immune-compromised neonates.51 
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Maternal sepsis: 
As intrauterine infection is a major cause of premature labor and delivery a high sepsis 
related mortality and morbidity rate is found in premature infants.52  Chorioamnionitis is a 
common cause of pre-term labor and it is inversely correlated with gestational age,52 
furthermore an association exists between HIV transmission and the histologic findings 
of chorioamnionitis.41 
 
Increased risk for preeclampsia: 
With the routine use of HAART, the reported incidence of preeclampsia in HIV-infected 
pregnant women has increased.8 Furthermore an association exists between 
preeclampsia and the development of NEC in the infant. This correlates with the 
pathological basis of NEC as it is suggested that NEC is due to antenatal ischemia 
secondary to redistribution of blood flow away from the bowel leading to ischemia.53 
 
Pasteurization of breast milk:  
Breast milk is important in NEC prophylaxis54 and contains up to 106 microbes/mL in 
healthy mothers.55, 56 In fact, breast milk has been shown to be an uninterrupted source 
of probiotic bacteria to the infant gut, including Lactobacillus sp. and Bifidobacteria.55-58 
Pasteurization of breast milk potentially destroys these beneficial bacteria. Go´mez de 
Segura et al emphasized that pasteurization at 62.58ºC for 30 minutes leads to the loss 
of beneficial micro-biota present in breast milk.57 The World Health Organization (WHO) 
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recommends exclusive breastfeeding. Modifications to breast-feeding, such as breast 
milk expression and pasteurization is recommended by the WHO to reduce the risk of 
HIV transmission while providing breast milk’s immune properties.59 This same 
pasteurization conditions that was indicated by de Segura et al is used to pasteurize 
breast milk of HIV infected mothers and breast milk for donor purposes.57, 59 The effect of 
this two edged intervention is firstly that by pasteurizing breast milk of HIV infected 
mothers it reduces the risk for mother to child HIV transmission although destroying the 
potential health promoting bacteria available in breast milk and thereby placing the 
infant at risk for the development of NEC.  
 
THE ROLE OF PROBIOTICS IN THE MANAGEMENT OF NEC 
Until recently the intestinal tract has been considered sterile at birth. However, some 
studies suggest that the meconium from healthy hosts is not sterile and that gut 
colonization may start before birth.60, 61 The  intestinal microbial community of full term 
infants is furthermore derived from the birth canal and close parental contact after 
birth.62 In contrast, preterm infant’s acquire colonizing bacteria from the intensive care 
environment, rather than their mother’s vaginal canal and skin surface.63 Postponed 
colonization with healthy bacteria, such as Lactobacillus and Bifidobacterium species, 
are seen in preterm infants. This delay may lead to an inappropriate gut microbial 
community and immune functions. Antibiotic treatment peri-natally to prevent acute 
sepsis also further alters the composition of intestinal bacteria.63, 64 
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The administration of probiotics to this vulnerable population may be an effective way to 
change the colonization pattern. It is suggested that introducing probiotics to preterm 
infants might be beneficial by preventing overgrowth of pathogenic organisms; probiotic 
supplementation may increase feeding tolerance, decrease the number of days until full 
feeds are reached and prevent nosocomial infections; probiotics potentially compete 
with other organisms for binding sites and substrate in the bowel.7 The focal health-
promoting effect of probiotics is their enhancement of mucosal immune response 
through increasing macrophage activity, elevating numbers of killer cells, T cells and 
interferon, the suppression of NF-κB signaling40 and their action against pathogenic 
microbial colonization and translocation.44 
Bengmark et al proposed that probiotic administration protects the gut surface and 
could delay progression of HIV.65 The loss of intestinal CD4+ Th17 cells, which 
differentiate in response to normal micro-flora, occurs early in HIV disease. The 
depletion of Th17 cells from the gut in HIV infection is associated with microbial 
translocation, chronic immune activation, and disease progression.66, 67 Disturbance of 
the micro-biota early in HIV infection leads to increases pathogen dominance, reduced 
levels of Bifidobacteria and Lactobacillus species and increased mucosal inflammation. 
Furthermore it has recently been hypothesized that probiotic bacteria may stabilize 
CD4+ T cell numbers in HIV-infected children and are likely to have protective effects 
against probable gastrointestinal inflammation.67 
Based on the observation that NEC is known to develop after the intestine has been 
colonized with gram-negative bacteria, several research groups have sought to 
establish whether TLR4 may play a role in the pathogenesis of NEC. There are ten 
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known individual TLRs (TLR1 - TLR10). As previously mentioned TLR4 is known to be 
the receptor for the outer membrane component of gram-negative bacteria, namely 
LPS. The reciprocal expression of TLR9 and TLR4 was found to influence the extent of 
TLR4 signaling, and the development of NEC was accompanied by a relative increase 
in TLR4 with a related reduction in the protective TLR9. These findings support the 
relative protective value of probiotic administration to infants with NEC, as these 
probiotic preparations are rich in bacterial DNA, through which activation of TLR9, which 
is essential to mediate the anti-inflammatory effect of probiotics on the host, would be 
expected to limit TLR4 signaling and reduce NEC severity.68, 69 
The latest updated Cochrane review summarizes the evidence of probiotics efficacy 
from sixteen randomized trials and more than 2700 preterm infants. Results show that 
probiotics reduced the incidence of severe NEC, mortality, and NEC related mortality.70  
Bifidobacteria and Lactobacilli has been found to be the most promising probiotic 
cultures, given the development of the intestinal flora in preterm neonates.71, 72 It is 
important to bear in mind that there are different mechanisms producing the clinical 
benefits of probiotics and there are also strain-specific effects.71 Bifidobacteria are the 
dominant strains in infancy, and the combination of Lactobacilli and Bifidobacteria is 
known to enhance the bifidogenic effect.62 Lactobacillus and Bifidobacteria produce 
acidic end products during their metabolism; these lower the pH of the intestinal 
environment and create a locally unfavourable setting for pathogens. 73 Literature 
indicates that Lactobacillus binds to mucins and intestinal epithelial cells, and may be 
able to reverse the permeability of the immature gut.73 
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A recent randomized control trail evaluated the efficacy of probiotics in reducing the 
incidence and severity of all stages of NEC in premature very-low birth weight infants 
that are exposed to HIV. The study group received breast milk plus a daily probiotic 
supplement of L. rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis 
(0.35 x 109 CFU). The control group received breast milk plus a placebo consisting of 
medium chain triglyceride (MCT) oil.74  Furthermore this trail found the use of probiotics 
to be safe in HIV-exposed infants with no difference found in the incidence of positive 
blood cultures.74  Results from this randomized control trail (RCT) indicate that the 
overall incidence of NEC was 5% which is within the lower range of other reported 
studies.75, 76 Among the nine cases of NEC that occurred, four episodes (2%) were 
severe NEC Bell’s stage III cases.  Furthermore the study found a reduced incidence of 
NEC (Bell’s II and III) in the study group when compared to the control group (3% vs. 
6% NEC incidence respectively), not specific to the HIV status. This study failed to show 
that probiotics lowered the incidence of NEC in HIV-exposed premature infants however 
it appears to reduce the severity of disease per Bells criteria.  
 
CONCERNS REGARDING PROBIOTIC TREATMENT 
Probiotics are often regulated as dietary supplements rather than as pharmaceuticals or 
biological products. Dietary supplements usually do not demonstrate requirements of 
safety, purity, or potency before marketing. 77 Probiotics are different from conventional 
drugs; there are many types, strains, and optimum production, transport, storage, 
dosage, and contraindications are unclear.78 
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Because the pathogenesis of NEC involves various complex pathways, different 
probiotic strains may create benefit by different pathways. Evidence suggests that the 
use of a multi-strain or multi-species probiotic should be more effective and more 
consistent than that of a mono-strain probiotic.71 Randomized controlled trials that used 
a multi-strain probiotic reported a significant decline in NEC, whereas those reporting a 
lesser decline used a single organism, such as Lactobacillus rhamnosus GG.7, 14, 71 
Luoto et al. suggests that it may be prudent to avoid the use of this single strain alone, 
pending further evidence. 71, 79 However Deshpande et al also emphasized that using 
more than two or three strains (each with an optimal mass) may increase the risk of 
translocation because of the substantial increase in the total dose. Furthermore it is 
better to avoid untested combinations, because strain combinations can be 
antagonistic, compatible or synergistic.71 
The most important area of concern with probiotic use is the risk of sepsis77 AlFaleh et al 
reported that there was no significant difference among the probiotic and placebo group 
in the rate of culture proven sepsis from thirteen eligible trials.70 This updated review of 
available evidence supports a change in practice.70 
 
CONCLUSION 
After considering the evidence provided from randomized control trails, researchers 
conclude that probiotics should be offered as a routine therapy for the prevention of 
NEC in preterm infants.  With an awareness of the association between perinatal HIV 
exposure and the increased risk of NEC in premature infants, probiotic bacteria might 
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help to improve the management of these infants by reducing inflammation and 
improving immune function. Furthermore HIV-exposed infants that receive pasteurized 
breast milk from their HIV-infected mothers receive less health promoting bacteria 
available in breast milk compared to their HIV-unexposed counterparts, again 
increasing their risk for NEC. It should however be noted that live probiotic bacteria 
have the potential to become pathogenic when host defenses are compromised. At this 
time little evidence exists on the use of probiotics in HIV-uninfected neonates born to 
HIV-infected mothers. A recent clinical trial by Van Niekerk et al found a reduction in the 
severity of disease per Bells criteria in HIV-exposed preterm infants.   We therefore 
support the use of probiotics is an effective method in reducing the risk for NEC in 
VLBW and ELBW birth weight infants. Furthermore studies are encouraged to establish 
the efficacy of probiotics in reducing the incidence of NEC in HIV-exposed infants.  
 
List of abbreviations: CMV: cytomegalovirus; HAART: highly active antiretroviral 
therapy; HIV: Human Immunodeficiency Virus IgA: immunoglobulin A; IκB: inhibitor of 
kappa B; LPS: lipopolysaccharide; NEC: necrotizing enterocolitis; NF-κB: nuclear factor 
kappa B; PAF: platelet-activating factor; SGA: small for gestational age; TLR4: Toll-like 
receptor 4; TNF: necrosis factor; VLBW: very low birth weight.  
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2.    RESEARCH DESIGN AND METHODOLOGY 
2.1 RESEARCH QUESTION 
Does the administration of probiotics reduce the incidence and severity of necrotizing 
enterocolitis (NEC) in premature, very low birth weight (VLBW) infants exposed to HIV? 
2.2 AIM OF THE INVESTIGATION 
The aim of this study was to determine whether the administration of probiotics reduced 
the incidence and severity of NEC in premature, VLBW infants exposed to HIV.  
2.3 OBJECTIVES 
2.3.1 Primary objective 
The primary objective of the study was to evaluate the efficacy of probiotics in reducing 
the incidence and severity of NEC, as per Bell’s criteria,1 in premature, VLBW infants 
exposed to HIV.  
2.3.2 Secondary objectives  
The secondary objectives included the following: 
2.3.2.1. To assess the incidence of all stages of NEC in VLBW infants born to HIV-
infected and HIV-uninfected women. 
2.3.2.2. To determine the prebiotic quality (human milk oligosaccharides) of own 
mother’s breast milk of HIV-infected and HIV-uninfected mothers; 
2.3.2.3. To determine whether there was an association between the prebiotic quality 
(human milk oligosaccharides) of breast milk and the incidence of NEC in 
premature, VLBW infants; and 
2.3.2.4. To evaluate weight gain for both probiotic-exposed and -unexposed 
premature, VLBW infants. 
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2.4 NULL HYPOTHESES 
The following null hypotheses guided the current study: 
2.4.1 H0: The administration of probiotics does not reduce the incidence and severity of 
NEC in premature, VLBW infants exposed to HIV. 
2.4.2 H0: There will be no difference in the incidence of NEC stages in VLBW and 
ELBW infants born to HIV-infected and -uninfected women; 
2.4.3 H0: There will be no difference between the prebiotic quality (human milk 
oligosaccharides) of the breast milk of HIV-infected and -uninfected mothers; 
2.4.4 H0: There will be no association between the prebiotic quality (human milk 
oligosaccharides) of breast milk and the incidence of NEC in premature, VLBW 
infants;  
2.4.5 H0: There will be no difference in weight gain for probiotic-exposed and -
unexposed premature, VLBW infants. 
 
2.5 CONCEPTUALISATION  
The conceptual framework of the study is outlined in Figure 1 on the following page. As 
shown in this diagram, the aim of the study was to determine whether the administration 
of probiotics reduced the incidence of NEC in premature, VLBW infants exposed to HIV. 
The prebiotic quality of each breast milk sample was measured for oligosaccharide 
composition. Paediatric anthropometric measurements include the head circumference, 
length and weight. 
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Figure 1: Conceptual framework of the study 
 Mother 
HIV +  
Mother’s own BM 
HIV -  
Mother’s own BM 
Infants  
Weight: < 1 250g 
Gestational age: < 34/40 
HIV-exposed  
Study/ 
Probiotics 
Control/ 
Placebo 
HIV-unexposed 
Study/ 
Probiotics 
Control/ 
Placebo 
Incidence and severity of NEC 
HIV: human immunodeficiency virus; BM: breast milk; NEC: necrotizing 
enterocolitis  
•Bell’s criteria 
Anthropometric 
measurements:  head 
circumference, weight, 
height 
Oligosaccharides Oligosaccharides 
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The key words and phrases used in Figure 1 were defined for the purposes of this study 
as follows:  
Premature infant: This refers to any infant born before 37 completed weeks’ gestation, 
regardless of birth weight.2  
Very low birth weight (VLBW) infant: This refers to any infant weighing less than 
1 500 g at birth.3  
Breast milk oligosaccharides: These are the third most abundant solid component in 
breast milk after lactose and lipids. The most abundant neutral oligosaccharides found 
in human milk are fucosylated tri- to hexasaccharides and the precursors to these, 
namely lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT).4 
Necrotizing enterocolitis (NEC): This is an acute inflammatory bowel disorder 
predominantly seen in premature infants. It is the leading cause of mortality and 
morbidity in neonatal intensive care units.5-7 
Probiotics: Probiotics are live microbial food supplements or components of bacteria 
that have been shown to have beneficial effects on human health.8 
Anthropometric measurements: This refers to the measurement of body size, 
proportion and weight. These measurements include length, weight and head 
circumference. Anthropometric measurements can be used to evaluate the nutritional 
status of an individual.9 
Human immunodeficiency virus (HIV): An initial HIV infection causes an acute phase 
of HIV-specific humoral and cell-mediated immune responses. HIV primarily infects cells 
expressing the CD4 receptor molecule. The resulting T-cell depletion leads to 
decreased immune surveillance and thus receptiveness to opportunistic infections and 
progression to acquired immunodeficiency syndrome (AIDS).10  
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2.6 SETTING 
Wards G1, G2, J3 and G8 of Tygerberg Children’s Hospital (TBCH), situated in 
Tygerberg Academic Hospital (TAH), were selected for data collection. Infants who had 
been transferred from TBCH to the Khayelitsha Kangaroo Mother Care (KKMC) unit 
continued to form part of the study population. The KKMC unit is situated in TAH. The 
standard study procedures applied at the KKMC unit.  
 
2.7 STUDY DESIGN  
A double-blind, placebo-controlled, randomised clinical trial was conducted.  
 
2.8 STUDY POPULATION 
The study population consisted of male and female premature, VLBW infants who were 
HIV-exposed and HIV-unexposed. These patients had been born at TBCH and admitted 
or transferred to wards G1, G2, J3 and G8. Infants who had been transferred from 
TBCH to the KKMC unit continued to form part of the study population. 
2.8.1 Sample size 
According to the 2009 live birth statistics of TBCH, 1 883 infants were born with a birth 
weight of < 2 500 g and 498 infants were born with a birth weight of < 1 500 g. 
According to the 2009 statistics from the Prevention of Mother-to-Child Transmission 
(PMTCT) clinic at TAH, 541 HIV-infected mothers gave birth to 449 live low birth weight 
infants (< 2 500 g) or premature infants (< 37 weeks’ gestation), of which 97 (19%) were 
VLBW babies (< 1 500 g). 
Infants with a birth weight of < 1 250 g were included in this study due to the increased 
length of stay of these infants in hospital and to ensure that the majority of the study 
population was not exited prematurely from the study. The sample size was estimated 
according to the statistics mentioned above, the inclusion and exclusion criteria (refer to 
2.8.2.1 and 2.8.2.2) and the recommendations of a statistician. The total study 
population consisted of 184 infant participants, of which 74 were HIV-exposed and 110 
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were not. A power analysis for two-way analysis of variance (ANOVA) with two levels 
for each factor with a power of 90% to detect interaction effect sizes of δ = 0.55 yielded 
samples of size n = 36 in each of the four groups (probiotic or placebo group for each of 
the HIV-exposed or HIV-unexposed groups). The sample sizes of n = 37, n = 37 (in the 
HIV-exposed group) and n = 54, n = 56 (in the HIV-unexposed group) exceeded this 
power specification. An effect size of δ = 0.55 is regarded as a smaller-than-medium 
effect. 
Concerning the secondary objectives of the study that entailed the oligosaccharide 
analysis, the study population that consisted of HIV-infected and HIV-uninfected 
mothers also amounted to 184 participants. A sample size of 184 participants was 
calculated by the statistician to give a power of 80% to detect a minimum difference in 
core oligosaccharides of 7% between the HIV-infected and HIV-uninfected groups. It 
also gave an 80% power to detect a minimum difference of 5% at each of the measured 
time points. The infant mortality due to NEC was estimated at 30 patients within the last 
two years at TBCH. According to research, the incidence of NEC is approximately 5–6% 
in VLBW infants, with a significant morality rate of 20–25%.11  
2.8.2 Sample selection 
Preterm infants (< 34 weeks’ gestation) with a birth weight of < 1 250 g who had been 
admitted or transferred to wards G1, G2, J3 and G8 at TBCH and the KKMC unit were 
randomly assigned, by a random number sequence, to either the placebo administration 
group (control group) or the probiotic administration group (study group). Randomisation 
was done by the assigned statistician. The inclusion and exclusion criteria that were 
used are outlined below. 
2.8.2.1 Inclusion criteria 
The following inclusion criteria were used for mothers: 
a. HIV-infected and HIV-uninfected women who had given birth to a premature, 
VLBW infant at TBCH and who had consented to participate in the study were 
included and 
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b. Only mothers who had decided to breastfeed after counselling, regardless of 
their HIV status, were included. All HIV-infected mothers are counselled routinely 
at TBCH about the risks and benefits of breastfeeding and bottle-feeding in 
accordance with the PMTCT scheme. 
c. HIV-infected mothers on the PMTCT treatment regimen were included. Mothers 
who received antiretroviral (ARV) medication (nevirapine, zidovudine [AZT] 
and/or highly active antiretroviral therapy [HAART]) were included in the study. 
The following inclusion criteria were used for premature, VLBW infants: 
a. Infants who had been admitted or transferred to wards G1, G2, J3 and G8 at 
TBCH were included; or 
b. Infants who had been transferred to the KKMC unit in TBH were also included; 
and 
c. Birth weight had to be below 1 250 g; and 
d. Premature infants, born with < 34 weeks’ gestation, were included; and 
e. Male and female subjects formed part of this study; and 
f. Infants born via either normal vaginal delivery or a caesarean section were 
included; and 
g. Infants who received antibiotic treatment and those who did not were included in 
the study. The majority of infants in the wards received an initial dose of antibiotic 
treatment with penicillin G; and 
h. Initially all infants were fed via an orogastric tube. Once infants had reached full 
enteral feeds, the orogastric tube was removed and infants received feeds via 
cup feeding; and 
i. Patients had to receive their own mothers’ breast milk; and  
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j. All infants had to receive their own mothers’ breast milk with the use of donor 
breast milk in exceptional cases. Patients received donor breast milk when 
mothers own breast milk was not available. Donor breast milk was included in the 
following circumstances:  
 As a supplemental feed due to insufficient breast milk supply from the 
mother.  
 When the mother was unavailable, for example on home visits over 
weekends or for continuation of work.  
 If the mother was ill and unable to breastfeed the infant, for example if the 
former had been admitted to an intensive care unit. 
Due to the high costs involved and sparse availability of donor breast milk, it is 
only provided to infants when there is no alternative or in scenarios as sketched 
above. Donor breast milk is usually not provided for extended periods of time.  
k. Premature VLBW infants who were HIV-exposed or HIV-unexposed were 
included in the study. 
l. HIV-exposed, premature, VLBW infants who received ARV medication also 
formed part of the study population. Nevirapine was prescribed by the attending 
neonatologist. The dose administered did not affect infant inclusion in the study. 
Nevirapine doses were noted on the data collection forms.  
2.8.2.2 Exclusion criteria 
The following exclusion criteria were used for mothers: 
a. Mothers who received medication that was contraindicated for breastfeeding 
were not included in this study. These medications include the following drug 
classes: anticoagulants (e.g. wafarin), cytotoxics and psychoactive drugs (e.g. 
tricyclic antidepressants and antipsychotics such as chlorpromazine) and 
individual drugs detectable in breast milk that pose theoretical risk. Examples of 
these drugs are listed in Table 112 ; or 
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b. Mothers with active Mycobacterium tuberculosis infection who were still 
potentially infectious and who should not have been in direct contact with their 
infants were excluded from this study 13; or 
c. HIV-infected mothers who presented clinically sick with a CD4 cell count 
< 200 cells/µl were also excluded. 
The following exclusion criteria were used for premature, VLBW infants: 
a. Infants with birth weight < 500 g were excluded; or 
b. Infants who received total parenteral nutrition and were nil per os (NPO) were 
excluded; or 
c. Premature infants with a birth age of < 25 weeks’ gestation were excluded; or 
d. Infants with a pre- or postnatal diagnosis of gastroschisis, large omphalocele or 
congenital diaphragmatic hernia did not form part of the study population; or 
e. Infants with congenital intestinal obstruction or perforation were excluded; or 
f. Infants with major congenital malformations and/or developmental disabilities 
pertaining to the gastrointestinal tract were excluded; or  
g. Infants with a diagnosis of a complex heart disease were excluded; or 
h. Infants with perinatal asphyxia were excluded. Perinatal asphyxia was defined as 
an Apgar score < 3 at five minutes and the need for resuscitation after birth.  
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Table 1: Some individual drugs contraindicated for breastfeeding mothers12 
 
Medication 
 
General concern and specific effects 
 
Chloramphenicol  Can cause possible idiosyncratic bone marrow suppression. 
Sulfapyridine, 
sulfisoxazole 
Use with caution in infant with jaundice or G6PD deficiency and ill, 
stressed or premature infant. 
Iodides, iodine Can cause goitre. 
Clofazimine  Potential for transfer of a high percentage of maternal dose; possible 
increase in skin pigmentation. 
Corticosteroids  When given to the mother in large doses for weeks or months, high 
concentrations can be achieved in breast milk. This may suppress 
growth and interfere with endogenous corticosteroid production in the 
infant. 
Lamotrigine  Potentially therapeutic serum concentrations can be reached in the 
infant. 
Aspirin (salicylates)  
 
Metabolic acidosis may occur in the infant. With large maternal doses 
and sustained use, breastfed infants < 1 month may achieve plasma 
concentrations that increase the risk of hyperbilirubinemia.  
Clemastine  Can result in drowsiness, irritability, refusal to feed, a high-pitched cry 
and neck stiffness. 
Primidone  Can cause sedation and feeding problems. 
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2.8.3 Exit criteria and adverse events 
Infants who conformed to the exit criteria of the study were followed-up. Treatment 
(probiotic/placebo) was withdrawn and daily monitoring was continued. All exit criteria 
were discussed with the attending neonatologist. Participants were exited from the 
study in the following circumstances:  
a. Infants who were NPO remained in the study until enteral feeds had been 
recommenced. These infants did not receive probiotic/placebo supplementation 
until feeds had been restarted;  
b. Infants who had been NPO for more than three days and required the use of total 
parenteral nutrition were exited from the study, and probiotic/placebo 
supplementation was not reinstated. These infants remained part of the study 
population and continued to be assessed on a daily basis without 
probiotic/placebo supplementation;  
c. Infants who developed any stage of NEC according to Bell’s criteria were exited. 
Although Bell’s Stage I is not recognised as definite NEC, it still has the potential 
to evolve into Stage II or Stage III NEC if managed inappropriately. For the 
purpose of this trial, infants with Stage I NEC were included in the analysis as no 
information existed on the effect of probiotics on HIV-exposed VLBW infants; 
d. Infants who developed diarrhoea that lasted for more than three days were 
removed from the study. The enteral feeds of these infants were stopped and, for 
this reason, these infants no longer conformed to the inclusion criteria of the 
study (see 2.8.2.1); 
e. HIV-exposed infants with a positive polymerase chain reaction (PCR) result after 
Day 14 of life did not remain in the study. The aim of this study was to determine 
the outcome of HIV-exposed infants;  
f. Infants who developed an adverse event attributed to the use of probiotics, such 
as septicaemia with positive blood cultures containing probiotic strains,14 were 
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also exited from the study. The following major risk factors for probiotic sepsis 
were proposed:  
 An immune-compromised state, including a debilitating state, such as 
advanced HIV; 
 Prematurity.15 
g. All infants were exited at the end of the neonatal period, in other words Day 28 of 
life.   
 
2.9 SUBJECT RECRUITMENT 
2.9.1 Establishment of the HIV-exposed and HIV-unexposed groups 
All admitted preterm VLBW infants in Ward G2 in TBCH who conformed to the inclusion 
and exclusion criteria with informed parental consent formed part of the total study 
population. Assessment continued for those patients who had been transferred to wards 
G1, G8 and J3 and the KKMC unit during the study period. 
The HIV-exposed group consisted of all consenting HIV-infected mothers who had a 
confirmed HIV-infected rapid-test result, as obtained from the PMTCT programme 
during the prenatal period. The HIV-unexposed group consisted of all consenting HIV-
uninfected mothers. 
A total of 184 infant participants were included in the study. The HIV-unexposed group 
consisted of 110 participants. It was expected that the recruitment of the HIV-
unexposed group would be faster than that of the exposed group. The HIV-exposed 
group consisted of approximately 20% of infants born, according to statistics (see 
2.8.1). Due to limited funding and resources, data collection for the HIV-exposed group 
was halted at 74 participants, with the agreement of the statistician.   
2.9.2 Establishment of the control and study groups  
Study infants were allocated to the HIV-exposed or HIV-unexposed groups according to 
the mother’s HIV status. All consenting HIV-infected mothers who had a confirmed HIV 
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rapid-test result, as obtained from the PMTCT programme during the prenatal period, 
were included in the study. 
Randomisation was performed by HIV status; therefore, the exposed and unexposed 
infants were randomised separately. Participants from the two groups (HIV-exposed 
and HIV-unexposed) received a sequential number as they were entered into the study 
(hereafter described as the participant’s number). Participants were randomised into the 
study or control groups (probiotic vs. placebo supplementation) with a random number 
sequentially allocated to each participant. All randomisation procedures were completed 
by the study statistician before commencement of the study. The attending physician 
and nurses caring for the infants were blinded to the group assignment. The 
investigator, research assistants and study participants were also blinded to the group 
assignment. Participants were exited from the study on Day 28 after birth (end of the 
neonatal period) or when infants were discharged from the hospital, if this was earlier.  
 
2.10 METHODOLOGY: MEASUREMENTS, METHODS AND 
INSTRUMENTS 
The methodology of this study consisted of different components. Firstly, infants were 
supplemented with either the probiotic or the placebo, breast milk samples were 
collected from the mother three times during the 28 days of the study and maternal 
saliva samples were collected as soon as possible after participant enrolment. 
Secondly, infants were weighed on a daily basis, and length and head circumference 
were measured on five occasions during the 28-day follow-up period. Lastly, infants 
were assessed on a daily basis, and clinical, medical and nutritional data were 
collected. It was also during these assessments that the presence of NEC was 
evaluated. The specific measurements, methods and instruments used to collect the 
data will be discussed in further detail below.  
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2.10.1 Probiotic and placebo supplementation 
2.10.1.1 Blinding and storage of probiotic and placebo 
The probiotic used in this trial was Pro-B2, produced and manufactured by C Pharm. 
Pro-B2 is an oil suspension that is stable at room temperature (see Addendum A for 
stability reports). The product was stored at cool room temperature in sealed containers.  
Blinding of the product was done by C Pharm, a pharmaceutical company based in 
Cape Town, South Africa. Medium-chain triglyceride (MCT) oil was chosen as the most 
suitable control agent with aesthetical properties similar to those of Pro-B2. No 
differences in the colour and appearance of the probiotic and placebo were noted. The 
probiotic and placebo were blinded with the use of a colour-coded label (orange or 
purple). After an infant had been included in the study and informed consent had been 
granted, the infant received a participant number. Each participant number had an 
allocated colour code (orange or purple). Each infant had his/her own container of either 
probiotic or placebo (labelled as orange or purple) for the 28 days that he/she was 
enrolled in the study. The participant number was noted on the container to ensure 
anonymity. Colour-coded (orange or purple) containers were kept in separate plastic 
holders. The investigator and assistants were blinded throughout the study. Blinding 
was terminated once the data collection had been completed.  
2.10.1.2  Supplementation with the probiotic or placebo  
Lactobacillus rhamnosus GG and Bifidobacterium infantis have been used as probiotics 
to reduce the incidence of NEC.11 The product used in the current study was Pro-B2, 
which contains L. rhamnosus GG and B. infantis. The probiotic and placebo were 
supplied by C Pharm. The study group received L. rhamnosus GG and B. infantis for 
four weeks (28 days). This provided L. rhamnosus GG (0.35 x 109 colony-forming units 
[CFU]) and B. infantis (0.35 x 109 CFU) daily. The control group received MCT oil. A 
daily dose of five drops of the probiotic/placebo was administered to the infants. Table 2 
indicates the daily supplement dose for the study and control groups.  
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Table 2: The daily supplement dose Pro-B2 that the study group received 
Probiotic strain Five drops Pro-B2 
Lactobacillus rhamnosus GG 500 million cells 
Bifidobacterium infantis  500 million cells 
Total probiotics (CFU) 1 billion cells  
(1 X 109 CFU) 
 
The probiotic/placebo was administered by the research assistants or investigator who 
followed the group randomisation assignment. Supplementation was monitored daily by 
the investigator or the research assistants. The date, time and signature of the research 
assistants or investigator were recorded each time that administration of the 
probiotic/placebo took place.  
Hygiene practices were strongly adhered to during this study. Before supplementation 
with the probiotic/placebo, the investigator or research assistants washed their hands 
with an antiseptic soap and thereafter D-germ (a sterilising spray) was applied. Only 
after this had been done the infants received their supplementation.  
The standard feeding protocol of the ward applied during the study. The breast milk of 
HIV-infected mothers was pasteurised using the flash method. Pasteurisation is 
standard protocol in the ward and was therefore not part of the methodology of this 
study. Flash heating will, however, be briefly described. Four hundred and fifty millilitres 
of water was brought to a boil in an aluminium pot and then removed from the heat. 
Breast milk in a glass peanut butter jar with a lid was placed in the water bath for 20 
minutes; it was then removed from the water bath, uncovered and allowed to cool to 
37 ºC.16 Pasteurisation decreases HIV activity in human milk and has been found to be 
an effective way of preventing mother-to-child transmission of the virus.17 
2.10.1.3 Events that may have affected the administration of the probiotic/placebo 
The following probiotic/placebo supplementation guidelines were followed when the 
following events occurred:  
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 When newborn infants were admitted to Ward G2 in TBCH and were NPO, the 
probiotic/placebo was not administered until enteral feeds had commenced.  
 Infants with reoccurring apnoea who were NPO did not receive the 
probiotic/placebo until the infant had been started on enteral feeds again.  
 Infants with reoccurring apnoea who were not NPO received their 
probiotic/placebo supplementation through the enteral feeding tube and not 
orally. The probiotic was added to the mothers’ breast milk and inserted into the 
feeding tube with a sterile syringe.   
 When suspected NEC was noted in the patient folder, the infant continued with 
treatment until an abdominal X-ray had confirmed a diagnosis of NEC Stage I. If 
the infant remained a suspected NEC case and was NPO, the infant did not 
receive a probiotic/placebo until the enteral feeds had recommenced.  
 
2.10.2 Breast milk samples 
A full sample of expressed breast milk was used for the determination of prebiotic 
quality. Samples of HIV-infected and HIV-uninfected breast milk were tested. All breast 
milk samples were raw untreated specimens; therefore, milk samples did not undergo 
any pasteurisation procedures. Breast milk was collected in sterilised containers with 
lids. Expression of breast milk was by hand. Each sample contained a volume of 
5-10 ml of breast milk for analysis.  
It has been found that the highest oligosaccharide concentration is present on Day 4 of 
lactation and that it decreases by about 10% by Day 10 and by another 10% by Day 
30.18 The frequency at which the milk samples were collected was determined 
according to these results. Three milk samples were collected from each mother on the 
following days:  
Milk sample 1: The first milk sample was collected on Day 4 of lactation. 
Milk sample 2: The second milk sample was collected on the tenth day of lactation, 
namely six days after the first sample had been collected. 
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Milk sample 3: The third sample was collected on the final day of the study, Day 28 
after birth and the end of the neonatal period.  
If a mother was unavailable during the breast milk sample collection, the breast milk 
samples were collected at the first available opportunity. All milk samples were collected 
by the investigator or research assistants in a manner standardised for all protocol 
procedures. Milk samples were stored at -25 ºC prior to oligosaccharide extraction.  
2.10.2.1 Subject selection for human milk oligosaccharide analysis 
Out of the 184 mother-infant pairs enrolled in the original clinical trial, all infants who 
developed NEC and whose mothers had sufficient milk samples available for analysis 
were included in the substudy. Thereafter, using a random number sequence table, the 
study statistician equally included mother-infant pairs stratified according to the mother’s 
HIV status (infected/uninfected) and the mother’s secretor status (secretor/nonsecretor). 
When the included mother-infant pair did not have sufficient milk samples available, the 
next random participant sample was selected. In total, 82 mother-infant pairs (41 with 
HIV-infected and 41 with HIV-uninfected mothers) were included in the substudy, and 
the mothers’ breast milk was analysed for oligosaccharide composition  
The breast milk samples were analysed for oligosaccharide content at the University of 
California, San Diego, by Dr. Bode. The appropriate routes were followed to ensure 
export of the samples. The South African Department of Health (DOH) and 
Stellenbosch University had approved the export. The material transfer agreement and 
DOH permit are included in Addendum B. The samples were stored in sealed ziplock 
plastic packets and placed in a large waterproof container. Each container had dry ice 
inserted to ensure that the samples were kept frozen during transport. After the samples 
had been delivered at the University of California, the investigator was notified that the 
samples were intact and frozen.  
2.10.2.2 Laboratory techniques used to analyse breast milk samples  
Raffinose was added to 10 µL milk to serve as an internal standard. Samples were 
applied to HyperSEP HyperCarb columns, followed by HyperSEP C18 columns to 
remove lipids, proteins and salt. Human milk oligosaccharide (HMO) eluates were 
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lyophilised and labelled with 2-aminobenzamide (2AB) for two hours at 65 ºC. Samples 
were applied to HyperSEP Silica columns to remove unlabelled 2AB. HMO-containing 
eluates were incubated with beta-galactosidase for four hours at 37 ºC to remove 
lactose. 2AB-labelled HMO was analysed by HPLC on an amide-80 column 
(4.6 mm ID x 25 cm, 5 µm, Tosoh Bioscience, Tokyo) with a 50-mm ammonium 
formate/acetonitrile buffer system. Separation was performed at 25 ºC and monitored 
with a fluorescence detector at 360 nm excitation and 425 nm emissions. Peak 
annotation was based on standard retention times and mass spectrometric analysis on 
a Thermo LCQ Duo Ion trap mass spectrometer equipped with a Nano-ESI-source. 
HMO concentrations in nmol/ml were calculated based on the area under the curve for 
each HMO relative to the area under the curve for the internal standard raffinose. HMO 
concentrations in mg/ml were calculated based on the molecular weight of the 
respective oligosaccharide.19  
2.10.3 Saliva samples  
A saliva sample was collected from all consenting mothers to determine the ABH 
secretor status. This refers to the secretion of ABO blood group antigens. Saliva 
samples were collected in sterilised containers with lids. A saliva sample of 1–2 ml 
(excluding foam) was sufficient for analysis. All saliva samples were collected by the 
investigator or research assistants in a manner standardised for all protocol procedures. 
Saliva samples were taken by the investigator to the National Health Laboratory 
Service, situated in TAH, directly after collection for analysis. The collection of saliva 
samples was carried out as follows: 
The participants were instructed to allow saliva to pool in the mouth. With the head tilted 
forward, the saliva sample was collected in the test tube. The test tubes were twice the 
capacity of the desired sample volume that was used as the saliva was expected to 
foam. 
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2.10.3.1 Laboratory techniques to determine salivary secretor status  
Samples were analysed by Mrs. Rosemary de Beer, a medical technologist at TAH’s 
Blood Grouping Department. The following laboratory techniques were used to analyse 
the saliva samples that had been collected as described above20, 21:  
 One to two millilitres of saliva was collected and placed in the autoclave at 
120 ºC for 10 minutes and then spun down at 3 200 rpm for 10 minutes.  
 The clear supernatant was transferred to a clean tube and frozen at -20 ºC until 
tested.  
 After thawing, saliva was again spun at 3 200 rpm for 10 minutes. 
 The reagent used was Anti-H (Ulex europaeus), manufactured by Immucor 
Gamma. 
 In a test tube, two drops Anti-H were added to two drops of saliva and mixed. 
 This was incubated at room temperature for 10 minutes (neutralisation stage). 
 One drop of 3–4% Group O red blood cells in saline was added and mixed. 
 This was incubated for five minutes at room temperature. 
 Tubes were then spun for 20 seconds at 900 rcf, gently resuspended and read 
macroscopically for agglutination.  
 Positive and negative controls were included. 
 
If the red blood cells were agglutinated, the Anti-H reagent was not neutralised by H 
substance and the saliva was from a nonsecretor; if the red blood cells were not 
agglutinated, the saliva contained H substance, which neutralised the reagent, so no 
agglutination was observed. 
 
 
 
2.10.4 Clinical, medical and nutritional data 
The clinical, medical and nutritional data were collected on four data collection forms 
(please refer to Addendum C). These data collection forms consisted of the following 
forms: the patient medical background, daily monitoring, infection screening and NEC 
Stellenbosch University  http://scholar.sun.ac.za
 74 
screening forms. Some of the sections in these data collection forms were repeated in 
the various forms, such as the blood sample collection section, birth anthropometrical 
measurements, infant medication received and phototherapy treatment, which merely 
served as a cross-check for quality control purposes. The data collection forms had 
been precoded. The coding list was supplemented as new possibilities/options 
occurred.  
2.10.4.1 Patient medical background data collection form 
This form was used to collect medical background information of the infants as well as 
the mothers. This information was documented by the investigator or research 
assistants upon the infants’ entry into the study. The maternal information was divided 
into three sections and included general information, medical information and 
medication received. The infant information also consisted of these three sections with 
the addition of a section on blood sample collection. The blood samples collected in this 
study were all routine blood samples taken in the ward, and they were not specifically 
collected for this study.  
 
The mode of delivery, namely either normal delivery or caesarean section, was noted 
for all mothers participating in the study. The premature rupture of membranes was 
noted. This information was documented by the investigator or research assistants upon 
the infant’s entry into the study. 
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 Table 3: Medical background information 
Maternal information 
General information  Age 
 Race 
 Gravida/parity 
 Mode of delivery 
 Whether prolonged rupture of membranes 
had occurred 
 Maternal HIV status  
 Maternal CD4 cell count 
 Whether the mother was enrolled on the 
PMTCT scheme and the duration of 
enrolment 
 Maternal tuberculosis history and 
treatment 
 Maternal syphilis (Venereal Disease 
Research Labarotory [VDRL] test) history 
and treatment 
Medical information Whether the following conditions were applicable 
to the mother:  
 Hypertension/preeclampsia 
 Diabetes  
 Antepartum haemorrhage 
 Abruptio placentae 
Maternal medication  Maternal antibiotics and steroids given prior 
to/during labour were noted. 
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Table 3 continued: Medical background information  
Infant information 
General information  Gender  
 Date of birth 
 Apgar counts 
 Birth weight, length and head 
circumference 
 Gestational ages – dates  
 Ballard score 
 Infant syphilis (VDRL test) status and 
whether being treated 
Medical information  Respiratory complications 
Whether the infant had undergone any of the 
following: 
 Cardiac echo 
 Cranial ultrasound 
 Chest X-ray 
 Phototherapy 
Infant medication  The following medications were noted:  
 Nevirapine 
 AZT  
 Surfactant 
 Antibiotics 
 Other 
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Table 3 continued: Medical background information  
Infant information 
Blood sample collections Whether the following blood samples had been 
collected:  
 CRP  
 Full blood count at birth 
 Blood culture  
 Blood gas at birth 
 HIV PCR after Day 14 of life 
 
2.10.4.2 Daily monitoring form 
Table 4 indicates the routine examinations and the complications related to the 
dysfunction of an immature organ system that were documented. The daily clinical 
assessments of the study babies by the attending doctors were documented by the 
investigator or research assistants.     
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Table 4: Complications related to the dysfunction of an immature organ system 
that were documented22 
Organ/area that complication affected  Data that were documented 
Lungs Respiratory distress syndrome (RDS) Medical notes and diagnosis of RDS 
were documented. 
Central 
nervous 
system 
Poor sucking and swallowing reflexes 
before 34 weeks’ gestation 
Apnoea due to hypopharyngeal 
obstruction or immaturity of the 
respiratory system in the brain 
Medical notes were documented. 
Infections Sepsis Haematology results: White blood 
cell count, platelet count and 
bacterial cultures were documented. 
Temperature 
regulations  
Hypothermia Medical notes were documented. 
Metabolic 
problems 
Hypoglycaemia and hyperglycaemia  Haematology results and medical 
notes were documented. 
 
All medications, intravenous fluids and blood transfusions administered to the study 
infants were documented on the medical form by the investigator or research assistants. 
ARV treatment was documented for the HIV-exposed infants. 
 
2.10.4.2.1 Daily feeding volumes  
The time of initial feeding was at the discretion of the attending physician. The daily 
volume of milk feeds was determined according to the feeding protocol of the institution. 
According to ward protocol, feeds are increased in daily increments of 25 ml/kg/d. 
Furthermore, per ward protocol, breast milk fortifier is introduced when infants reach 
daily feeds of above 100 ml/kg. Fortification of feeds is, however, dependent on feeding 
Stellenbosch University  http://scholar.sun.ac.za
 79 
tolerance and may differ from one individual to another. The volume of feeds was 
advanced slowly, if tolerated by the infant, and feeding was stopped if there were any 
signs of feeding intolerance such as vomiting or abdominal distension. The dietary 
intake of all study infants was documented on a feed monitoring form. Any feeding 
intolerance was documented. 
The following data were captured on the daily monitoring form:  
 The daily administration of a probiotic or placebo and the amount (number) of 
drops given. 
 The feeding route of the infant. 
 The infant’s weight, head circumference and length. 
 The volume/amount of breast milk, Neonatelyte (glucose-electrolyte-containing 
solution) and saline provided to the infant. 
 Supplementation with FM85 (a breast milk fortifier) and MCT oil, multivitamin and 
iron supplementation. 
 The urinary output.  
 The stool frequency and colour/consistency. 
 Phototherapy and blood products received. 
 Medication administered. All the medications that the infants received were 
noted.  
The methods and techniques pertaining to the anthropometrical measurements will now 
be discussed. No anthropometric measurements were taken for the time period that 
infants received nasal continuous positive airway pressure (NCPAP). The following 
anthropometric measurements were taken:  
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2.10.4.2.2 Weight 
All study infants, irrespective of whether or not these infants were incubated, were 
weighed daily by the nursing staff. Daily weights were recorded from each participant’s 
medical file by the investigator or research assistants. Any significant weight changes 
were queried, and the measurement was repeated under the supervision of the 
investigator or research assistants.  
The weight of each infant was determined as follows23: 
 An electric scale was used.  
 Electronic scales were calibrated once a week by the nursing staff.  
 All instruments were zero calibrated before beginning the measurements. 
 Infants were weighed without any clothing or a nappy. If a nappy was worn, the 
weight was corrected by subtracting the weight of the nappy. 
 The infant was placed in the middle of the scale and had to lie still before the 
reading was taken. 
 The measurements were read to the nearest 0.001 kg. 
 The average of three measurements was taken.  
2.10.4.2.3 Length 
Infants were measured on Day 1 of the study; thereafter, the length was measured 
weekly. Upon exiting the study (Day 28), the length was measured again; therefore, five 
measurements, on days 1, 7, 14, 21 and 28, were taken. Length measurements were 
performed by the investigator or research assistants, with the help of the infant’s 
mother, if needed.  
The length of each infant was measured according to the following criteria:  
 A standard nonstretchable measuring tape with 0.5-cm and 1-cm dimensions 
was used. 
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 All head coverings and socks were removed.23 
 The infant was placed supine on the tape measure with the head and shoulders 
held by an assistant.  
 The observer then extended the right leg and held the ankle at right angles to the 
surface. The length from the infant’s crown to heel was then measured. 
 Measurements were read to the nearest 0.5 cm.23 
 The average of three measurements was taken. 
2.10.4.2.4 Head circumference 
Each infant’s head circumference was measured on Day 1 of the study and 
subsequently measured on a weekly basis. Upon exiting the study (Day 28), the head 
circumference was measured again. Five measurements, on days 1, 7, 14, 21 and 28, 
were therefor recorded. Measurements were performed by the investigator or research 
assistants, with the help of the infant’s mother, if needed.  
The head circumference of each infant was measured according to the following 
criteria23:  
 A standard nonstretchable measuring tape with 0.5-cm and 1-cm dimensions 
was used. 
 All head coverings were removed. 
 The measuring tape was placed on the supraorbital ridge and on the occiput. 
 The tape was on the same plane on both sides of the head. 
 Measurements were read to the nearest millimetre. 
 The average of three measurements was used.  
All infants’ weight, height and head circumference measurements at birth and Day 28 of 
life were plotted on the Fenton-Babson growth chart (Addendum D).24  
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2.10.4.3 Blood cultures, routine bloods, blood gas and infection screening form 
As infection may be associated with the use of probiotics in premature infants, all 
episodes of infection were monitored. A routine HIV DNA PCR test was done on every 
HIV-exposed baby after Day 14 postpartum. These results were documented by the 
investigator or research assistants as soon as the results became available. The results 
of laboratory investigations requested by the attending doctors, namely full blood counts 
and CRP assays, were documented. 
The following data were captured on this form: 
 CRP results. 
 Culture results (blood cultures, stool cultures, swab cultures and lumbar puncture 
cultures).  
 Full blood count results. 
 HIV PCR results after Day 14 of life. 
 Blood gas results. 
 Possible sepsis diagnosis by the attending neonatologist.  
2.10.4.4 Necrotizing enterocolitis screening form 
Infants were evaluated daily for the development of NEC by the attending 
neonatologists. Whenever a study infant was suspected to have NEC, the infant was 
also evaluated by the attending neonatologist. If the diagnosis of NEC was made, it was 
staged according to Bell’s classification, as outlined below. The following diagnostic 
criteria of NEC, according to Bell’s staging, were used.1 This NEC staging system is 
based upon historical, clinical and radiographic data. 
Stage I (suspect) 
Any one or more of the following historical factors producing perinatal stress: 
 Systemic manifestations, such as temperature instability, lethargy, apnoea or 
bradycardia, are present. 
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 Gastrointestinal manifestations, for example poor feeding, increasing pregavage 
residuals, emesis (may be bilious or test positive for occult blood), mild 
abdominal distension or the presence of occult blood in the stool, are present. 
 Abdominal radiographs may show distension with mild ileus. 
Stage II (definite) 
Any one or more of the following historical factors: 
 The above signs and symptoms are present, along with persistent occult or gross 
gastrointestinal bleeding and marked abdominal distension. 
 Abdominal radiographs show significant intestinal distension with ileus, small 
bowel separation (oedema in bowel wall or peritoneal fluid), unchanging or 
persistent ‘rigid’ bowel loops, pneumatosis intestinalis or portal vein gas. 
Stage III (advanced) 
Any one or more of the following historical factors: 
 The above signs and symptoms are present, and there is deterioration of vital 
signs, evidence of septic shock or marked gastrointestinal haemorrhage. 
 Abdominal radiographs may show pneumoperitoneum, in addition to the other 
anomalies listed in Stage II. 
The basic feeding patterns (with any evidence of feeding intolerance), clinical staging, 
an abdominal X-ray and growth data for all infants were recorded during the 28 days of 
the study. The following data were captured on the NEC screening form:  
 Feeding intolerances: For the purpose of this study, a feeding intolerance was 
identified when vomiting and aspirates occurred. The colour of vomits and 
aspirates were noted. Furthermore, abdominal distension and stool volume 
and consistency were noted on the daily monitoring form. 
 The presence of abnormal clinical signs. The following were noted as 
abnormal signs: Breathing > 65/min, apnoea, bradycardia (< 100 beats/min), 
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tachycardia (> 180 beats/min), abdominal distension, convulsions, lethargy 
and jaundice.  
 The presence of bowl sounds. 
 Possible NEC complications (bowl perforations, shock). 
 The presence of an abdominal drain. 
 Bell’s staging grade. 
 Whether an abdominal X-ray had been performed. 
 
2.11 DATA COLLECTION 
The data collection took place at TBCH and KKMC. Patients who had been admitted or 
transferred to wards G1, G2, J3 or G8 were recruited for the study upon conforming to 
the inclusion and exclusion criteria (see 2.8.2.1 and 2.8.2.2). Infants who had been 
transferred to the KKMC unit continued to be included in the study. Written informed 
consent was obtained from the mother of each study infant after the full procedure had 
been explained to her, and she had the opportunity to ask any questions or clarify any 
uncertainty. The data were collected by the investigator and two research assistants. 
The investigator as well as the research assistants had received good clinical practice 
(GCP) training. The research assistants were a qualified nurse and a dietician. The 
assistants had received a month’s training to conform to the data collection procedures 
and to ensure standardisation. Data collection took place from 4 July 2011 to 31 August 
2012.  
 
2.12 DATA CAPTURING   
Data capturing was done using Microsoft Excel 2007®.  
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2.13 STATISTICAL ANALYSIS 
Microsoft Excel® was used to capture the data, and STATISTICA version 11 (StatSoft 
Inc. [2013] STATISTICA [data analysis software system], www.statsoft.com.) was used 
to analyse the data. Data were analysed by the investigator, with the help of a 
statistician.  
Summary statistics were used to describe variables such as the breast milk intake data 
of infants, routine examinations, medication, intravenous fluids, blood transfusions and 
mode of delivery. Distributions of variables were presented with histograms and/or 
frequency tables. Medians or means were used as the measures of central location for 
ordinal and continuous responses and standard deviations and quartiles as indicators of 
spread. Descriptive statistics were used to describe the incidence of NEC among the 
study infants. ANOVA was used to detect significant associations between the breast 
milk samples of HIV-infected and HIV-uninfected mothers. 
The relationships between continuous response variables and nominal input variables, 
for example different diets, were analysed using appropriate ANOVA or pooled or Welch 
t-tests if only two groups were involved. Appropriate repeated measures ANOVA were 
used when responses were measured at specific time intervals. When only two times 
were compared, this was done with paired t-tests.  
When ordinal response variables versus a nominal input variable were compared, 
nonparametric ANOVA methods were used. For completely randomised designs, the 
Mann-Whitney test (for two groups) was used, and for repeated measures designs at 
two times, the Wilcoxon test was used.   
Two factors influenced the variables, namely treatment (probiotic or placebo) and HIV 
exposure (HIV exposed or HIV unexposed). Two-way ANOVA was done to compare the 
treatment means per HIV exposure (in other words, to check the interaction effects), 
and no differences were observed. The residuals were checked for normality, and if 
they were nonnormal, bootstrap multiple comparisons were done to accommodate for 
the nonnormality. This analysis confirmed the nonsignificant interactions.  
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Furthermore, these variables were also compared with Mann-Whitney nonparametric 
tests for the treatments per HIV-exposure group, which confirmed the nonsignificance 
detected with the bootstrap multiple comparisons. The Mann-Whitney tests were 
reported, and the median (lower quartile, upper quartile) was included in the reported 
data (tables and text).  
The relation between nominal variables was investigated with contingency tables and 
appropriate chi-square tests, such as the likelihood ratio chi-square test. A p-value of 
p < 0.05 represents statistical significance in hypothesis testing, and 95% confidence 
intervals were used to describe the estimation of unknown parameters. 
2.13.1 Anthropometric measurements of infants 
All infants’ weight, length and head circumference measurements from birth to Day 28 
of life were plotted on the Fenton-Babson growth chart (Addendum D).24 Birth weight 
was classified as small for gestational age (SGA), appropriate for gestational age (AGA) 
or large for gestational age (LGA). Infants were subclassified as being VLBW and 
ELBW. Growth restriction (symmetrical and asymmetrical) was determined with the use 
of the weight, length and head circumference. A birth weight below the 10th percentile 
was used to identify infants who were SGA. Z-scores were used in the interpretation of 
anthropometrical data as these are superior to percentiles for infants whose size is 
outside the normal range of a growth chart, that is, beyond the 3rd and 97th percentiles.25 
Z-scores were calculated with the use of Microsoft Excel® spreadsheets provided by 
Professor Fenton (see URL link ucalgary.ca/fenton).26 These calculated spreadsheets 
were developed according to the Fenton-Babson growth chart.24  
 
2.14 PILOT STUDY 
A pilot study was performed to streamline all data collection procedures. All samples 
(breast milk and saliva) were collected during the pilot study. Ten pilot study participants 
were recruited for a period of one week. Since the protocol was not affected or changed 
during the pilot study period, it was decided that the participants in the pilot study could 
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be included in the main study. The use of these data was approved by the Human 
Research Ethics Committee of the Faculty of Health Sciences, Stellenbosch University. 
 
2.15 FINANCIAL DISCLOSURE 
Funding for this study was received from various sources, the main sources being the 
National Research Foundation, Nestlé Nutrition Institute Africa, the Medical Research 
Council and the Faculty of Medicine and Health Sciences, Stellenbosch University. 
 
2.16 ETHICS APPROVAL 
The study protocol was submitted to the Human Research Ethics Committee of the 
Faculty of Health Sciences, Stellenbosch University and TAH for approval 
(M10/09/035). The researcher herewith discloses that the study protocol was also 
submitted and approved by Karl Bremer Hospital for the continuation of data collection 
at the facility in the event that infants were transferred from TAH. Karl Bremer Hospital 
was, however, never used as a study site during the study period, so the details for this 
are not included in the study setting description (see 2.6). The South African clinical trial 
registration number was DOH-27-0413-4277. The trial was, furthermore, registered at 
the United States National Institutes of Health registry (www.clinicaltrials.gov), with 
reference number NCT01868737. Insurance for this study was provided by 
Stellenbosch University. The intellectual property of the study protocol will remain that of 
Stellenbosch University. 
 
2.17 GOOD CLINICAL PRACTICE 
2.17.1 Informed consent and voluntary participation 
The investigator and all others involved in the study adhered to GCP guidelines during 
the study period. All participating mothers were informed about the study in their first 
language (Afrikaans, English and Xhosa) (see Addendum E). In some instances, 
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participants received 24 hours to consider partaking in the study before the written 
consent form was signed. Each participant received a copy of the consent form. 
Participating in the study was voluntary. Participants could have left the study at any 
time and were not penalised or prejudiced in any way for doing so. 
2.17.2 Confidentiality and quality of care 
Confidentiality and anonymity were maintained during this study. All mothers received 
an allocated participant number that was used for the identification of milk samples as 
well as allocation to the control or study group. The attending physician and nurses 
caring for the infants were blinded to the group assignment, as were the researcher and 
research assistants. The HIV status of the mother and her infant was treated with 
confidentiality and was not revealed to any persons other than the nursing staff, the 
patient’s doctor, the research assistant and the investigator.  
The milk samples of the control and study groups were collected and analysed in the 
same manner, thereby maintaining patient confidentiality. No feeds were withheld from 
any study infant due to milk sample collection. If an infant needed to be fed at the time 
of milk sample collection, the infant was first either breastfed or fed expressed breast 
milk that had been collected previously. Infants of HIV-infected mothers received 
pasteurised expressed breast milk. Infants of HIV-uninfected mothers received 
unpasteurised breast milk (expressed or breastfed).  
Participation in this study did not affect the quality of care that infants and mothers 
received during or after the study. Appropriate medical care was provided to HIV-
infected mothers as determined by the provincial protocol for the treatment of HIV/AIDS.  
 
2.17.3 Probiotic product (Pro-B2) 
The product (Pro-B2) was supplied by C Pharm. It is registered with the Medicines 
Control Council (no 133279). It is classified as a complementary medicine. Stability 
reports (see Addendum A) were provided by C Pharm twice during the study duration, 
in other words every six months. The product proved to be stable during the study 
period. The results were analysed and repeated according to ethical standards.  
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2.17.4 Potential risk factors attributed to the use of probiotics.  
A potential risk factor attributed to the use of probiotics is septicaemia. Any infant with a 
positive blood culture containing a probiotic strain was exited from the study. 
Furthermore, an immune-compromised state such as advanced HIV and prematurity 
are major risk factors for septicaemia.  
 
2.18 POTENTIAL INDIVIDUAL AND COMMUNITY BENEFITS  
The primary objective of the study was to evaluate the efficacy of probiotics in reducing 
the incidence and severity of NEC in premature, VLBW infants exposed to HIV. 
Prophylactic probiotic treatment could be an effective and appropriate way of reducing 
the incidence of NEC in this highly vulnerable population. A reduction in the incidence of 
NEC will decrease medical expense, decrease length of hospital stay and improve 
overall patient outcomes. Secondly, this study aimed to determine the prebiotic quality 
(human milk oligosaccharides) of the breast milk of HIV-infected and HIV-uninfected 
mothers and to determine whether there was an association between the prebiotic 
quality (human milk oligosaccharides) and NEC. The results of this study could 
strengthen the views and perspectives of mothers and medical personal on the 
importance of breastfeeding. HIV-infected mothers might become more favourable to 
breast milk, thereby decreasing the household financial burden and improving hygiene 
and safety measures. Prebiotics are available in breast milk, making the study highly 
sustainable as breast milk is free. 
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Abstract 
Background: An association between maternal human immunodeficiency virus (HIV) 
infection and Necrotizing Enterocolitis (NEC) in preterm infants has been reported. The 
impact of probiotics in an HIV-exposed very low birth weight infant on the occurrence of 
NEC is uncertain at present; however it is known that probiotics have protective effects 
against inflammation and prevent NEC.  
Objective: To assess the effect of probiotics on the incidence of NEC in high risk infants 
born to HIV-positive and HIV-negative women. 
Patients and Methods: HIV-exposed and HIV-unexposed premature (<34 weeks 
gestation) infants with a birth weight of ≥500g and ≤1250g were randomized to either 
the probiotic or placebo group. The probiotic consisted of 1x109 CFU, L. rhamnosus GG 
and B. infantis per day and was administered for approximately 4 weeks. NEC was 
graded according to Bell’s criteria.  
Results: 74 HIV-exposed and 110 HIV-unexposed infants were enrolled and 
randomized (mean birth-weight, 987g; mean gestational 28.7 weeks). The incidence of 
death and NEC did not differ significantly between the HIV-exposed and unexposed 
groups but a significant difference (p=0.029) was found for total NEC incidence between 
the study and control groups. 
Conclusion: Probiotic supplementation reduced the incidence of NEC in the premature 
very low birth weight infants; however results failed to show a lower incidence of NEC in 
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HIV-exposed premature infants. A reduction in the severity of disease was found in the 
HIV-exposed group.   
 
Clinical trial registration number: NCT01868737 
The South African clinical trial registration number: DOH-27-0413-4277. 
 
Key words: Human Immunodeficiency Virus, Necrotizing Enterocolitis, Premature 
infant, Probiotic, Very Low Birth Weight. 
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Introduction: 
Necrotizing enterocolitis (NEC) is the most common gastrointestinal insult in preterm 
infants and major cause of infant mortality in neonatal intensive care units. 1 NEC occurs 
in 4–11% of all premature infants born with a very low birth weight (VLBW) and an 
inverse relationship exists between birth weight, gestational age and the incidence of 
NEC.1, 2 The precise pathogenesis of NEC is still unclear but is widely considered to be 
multifactorial 3 The most common risk factors are prematurity, enteral feeding, gut 
ischemia, patent ductus arteriosus (PDA), packed red blood cell (PRBC) transfusion 
and bacterial colonization. 4-6 
In recent literature an association between maternal human immunodeficiency virus 
(HIV) infection and NEC in preterm infants has been reported.7 Furthermore, the 
prevalence of low birth weight (LBW) and preterm birth among infants who are born to 
HIV infected women has increased as treatment has evolved into regimens of highly 
active antiretroviral therapy (HAART).8 The exposure to HIV during fetal life and 
maternal treatment with antiretroviral drugs are two probable mechanisms proposed to 
explain the increased incidence of NEC in this population.9   Changes in the cytokine 
environment in pregnancy due to maternal HAART use has been hypothesized to 
increase the risk for preterm delivery observed in HIV-infected woman.10 An inverse 
relationship exists between gestational age and the incidence of NEC.11 It is therefore 
hypothesized that the increase in lower gestational ages is associated with the 
increased risk of NEC in infants born to HIV-infected mothers. 
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Probiotic bacteria are live microorganisms that colonize the gastrointestinal tract and 
potentially provide benefit to the host.12, 13 There is increasing interest in the potential 
health benefits of proactive colonization of the gastrointestinal tract of preterm infants.14 
Probiotics may prevent NEC by promoting colonization of the gut with beneficial 
organisms, preventing colonization by pathogens, improving the maturity and function of 
the gut mucosal barrier, and modulating the immune system.15 The most frequently 
used probiotics are Lactobacillus and Bifidobacterium.15, 16 The potential impact of 
probiotics in an HIV-exposed VLBW preterm infant on the occurrence of NEC is at 
present uncertain. In view of this uncertainty we have studied the potential effect of 
probiotics in VLBW HIV-exposed infants. The null-hypothesis for this study was that the 
administration of probiotics does not reduce the incidence and severity of NEC in 
premature very-low birth weight infants that are exposed to HIV. A secondary aim of this 
study was to assess the incidence of NEC in very-low birth weight and extremely low 
birth weight infants born to HIV-infected and HIV-uninfected women. 
 
Patients and Methods: 
A randomized, double blind, placebo controlled clinical trial was conducted in the 
neonatal high care unit of Tygerberg Children’s Hospital (TBCH) Cape Town, South 
Africa for the period July 2011 to August 2012. All mothers and infants pairs that 
conformed to the inclusion criteria and provided written informed consent were included 
into the study. The infants were randomized into the study or control groups by a 
random-number table sequence assigned by a statistician. Randomization was 
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performed by HIV-status; therefore the exposed and unexposed infants were 
randomized separately. All randomization procedures were done before the study 
commencement by the study statistician and an independent entity for both the probiotic 
and placebo.  Sample size was determined by a statistician according to the live birth 
statistics for infants born to HIV-positive mothers at the institution. Only infants with a 
birth weight of <1250g were included in this study due to the increased length of stay of 
these infants in hospital and to ensure that the majority of the study population was not 
exited prematurely from the study. Participants were enrolled and assigned to the 
respective groups by the researcher and two research assistants. Inclusion criteria for 
the mothers included: (1) HIV-positive or-negative mothers who gave birth to a 
premature and very-low birth weight baby at TBCH and consented to participate in the 
study; (2) Only breastfeeding mothers, regardless of their HIV status and (3) HIV-
positive mothers that were on the prevention of mother to child transmission (PMTCT) 
treatment schedule. 
Babies were included if they (1) had a birth weight of of ≥500g and ≤1250g; (2) were 
HIV exposed or unexposed; (3) received breast milk (either from their mothers or donor 
breast milk). Breast milk of HIV-positive mothers was pasteurized (according to ward 
protocol) before it was administered to the infants. Infants were excluded if they had 
major abnormalities such as gastroschisis, a large omphalocele or congenital 
diaphragmatic hernia 
Pro-B2® (C Pharm, Cape Town, South Africa) is an oil suspension and may be stored at 
room temperature.  Stability reports were provided by C-Pharm twice during the study 
duration. The product proved to be stable during the study period.  Throughout the 
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study period, the standard of care protocol consisted of one dose (5 drops) 
probiotic/placebo daily for 4 weeks (28 days). This provided the study group with L. 
rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis (0.35 x 109 CFU) 
daily. The control group received placebo consisting of medium chain triglyceride (MCT) 
oil. MCT oil was chosen as the most suitable control agent with esthetic properties 
similar to that of Pro-B2. Supplementation of the probiotic/placebo was initiated when 
enteral feeds started. Probiotic/ placebo supplementation was delayed/ halted in the 
event of: the infants being nill per os (NPO); when a query NEC was suspected the 
infant continued with treatment until a confirmed a positive diagnosis of NEC I was 
made through abdominal X-ray; if the infant remained a query NEC and was NPO the 
infant did not receive probiotics/ placebo until the enteral feeds were commenced again. 
Supplementation was discontinued when HIV-exposed infants had a positive 
polymerase chain reaction (PCR) result on day 14 of life due to the uncertainty of 
probiotic associated septicemia in immune compromised HIV-positive VLBW infants on 
HAART 
All study participants received human breast milk. Both the probiotics and placebo were 
mixed with the mothers own breast milk or donor breast milk before administration via 
the orogastric tube or orally. The probiotic/ placebo was added to the breast milk by the 
researcher and two research assistants. The attending physician and nurses caring for 
the infants, as well as the researcher, research assistant and study participants were 
blinded to the group assignment. Participants exited the study on day 28 after birth or 
upon discharge from the hospital.  
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Data on birth weight, estimated gestational age, gender, type of delivery, and Apgar 
scores were collected. Gestational age was determined by the best estimate of the 
neonatal and obstetrical care providers based upon physical examination of the infants. 
Anthropometrical measurements (weight, length and head circumference), intake and 
output and daily clinical progress notes were reviewed. Infants were evaluated daily for 
the development of NEC by the attending neonatologists. Whenever a study infant was 
suspected to have NEC the infant was evaluated by the attending neonatologists in 
conjunction with the pediatric radiologist and categorized by modified Bell’s 
classification.  Infants who developed any stage of NEC according to Bells Criteria were 
exited. Although Bells stage I is not recognized as definite NEC, it still has the potential 
to evolve to stage II or III NEC if managed inappropriately. For the purpose of this trial 
the infants with stage I NEC were included in the analysis as no information exist on the 
effect of probiotics on HIV exposed VLBW infants. Infants with stage II and III NEC will 
however be described separately.  Ethical approval was granted by the Human 
Research Ethics Committee of the Faculty of Health Sciences, Stellenbosch University 
and Tygerberg Academic Hospital.  The clinical trial registration number: 
NCT01868737. A power analysis for two way-ANOVA with 2 levels for each factor with 
a power of 90% to detect interaction effect sizes of δ=0.55 yield samples of size n=36 in 
each of the four groups. Our sample sizes of n=37, n=37 (in the HIV exposed group) 
and n=54, n=56 (in the HIV-unexposed group) exceeds this power specification. Data 
analyses were performed with Statistica Software (version 11). Frequencies between 
groups were compared using the likelihood ratio chi-square test and means between 
groups using t-tests. Statistical significance was defined as a p-value less than 0.05.  
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Results: 
A total of 219 infants were screened for the study. Ten infants were not included in the 
trial due to declined parental consent and twenty five infants did not conform to the 
inclusion criteria, thus leaving 184 infants enrolled in the clinical trial (Figure 1). Of 
these, 74 (40%) infants were HIV-exposed and 110 (60%) were HIV-unexposed infants. 
Within the HIV-exposed group 37 (50%) infants were randomized into the study and 
control group respectively. The HIV-unexposed group was randomized into 54 (49%) 
study infants and 56 (51%) control infants. Of the 184 enrolled in the study, 156 
completed the full 28 day study follow-up period (Figure 1). Infant outcomes were as 
follows: 3 infants were withdrawn from the study, 7 discharges, 11 deaths occurred (5 
deaths were NEC associated), 4 NEC survivals and 3 positive PCR results at day 14 of 
life.  
Demographics and major characteristics are depicted in Table 1. The mean birth weight 
was 987g ±160.24 (range: 560g-1244g) and the mean gestational age 28.7 ±2.95 
(range: 24-36) weeks. Apgar scores at 5 minutes differed significantly between probiotic 
and placebo groups among HIV-exposed infants (p= 0.042).  
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Figure 1: Flow diagram of infants included in the clinical trial on the use of 
probiotics in HIV-exposed and unexposed premature infants.  
HIV: human immunodeficiency virus; NEC: necrotizing enterocolitis; PCR: polymerase 
chain reaction; RDS: respiratory distress syndrome. 
184 Infants enrolled 
 
194 Infants meeting the inclusion criteria 
10 Infants with declined parental 
consent 
25 Did not meet the 
inclusion criteria 
156 Completed day 28  
74 HIV-exposed 
infants 
110 HIV-unexposed 
infants 
3 Infants died  
Reason for deaths: 
1 RDS (prematurity)                    
1 Bell’s I/sepsis                                     
1 Bowl 
perforation/septicaemia  
1 Death   
Reason for death: 
1 Bell’s 
III/septicaemia 
2 Infants died 
Reason for deaths: 
1 RDS/prematurity  
1 Septicaemia  
5 Deaths  
Reason for deaths: 
1Prematurity/septicaemia 
1 Bell’s I/Septicaemia 
2 Bell’s III (perforation and 
septicaemia)                    
1 Sepsis  
Probiotic (n=37) Placebo (n=37) Probiotic (n=54) Placebo (n=56) 
3 Withdrawals  
3 Positive 
PCRs 
7 Discharged before day 
28  
1 Infant developed 
Bell’s III and 
survived                            
 
1 Infant developed 
Bell’s I and 
survived                            
1 Infant developed 
Bell’s I and survived                            
219 Infants screened for inclusion  
1 Infant developed 
Bell’s I and survived                            
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Table1: The demographic and clinical characteristics of all infants enrolled in study (n=184). 
 HIV-exposed HIV-unexposed 
Probiotic (n=37)  Placebo (n=37)  Significance Probiotic (n=54)  Placebo (n=56)  Significance 
Gender n=37   n=37 p = 0.24 n=54   n=56 p = 0.26 
Male 14 (38%) 19 (51%)  29 (54%) 24 (43%)  
Female 23 (62%) 18 (49%)  25 (46%)  32 (57%) 
Race n=37   n=37 p = 0.23 n=54   n=56 p = 0.22 
Black  32 (87%) 35 (95%)  20 (37%) 29 (53%)  
Mixed Race 5 (13%) 2 (5%) 33 (61%) 24 (42%) 
White   1 (2%) 2 (3%) 
Other    1 (2%) 
Birth weight (g) n=37   n=37 p = 0.68 n=54   n=56 p = 0.31 
500-750  4 (11%) 2 (5%)  4 (7%) 8 (14%)  
751-1000  14 (38%) 14 (38%) 21 (40%) 25 (45%) 
1001-1250  19 (51%) 21 (57%) 29 (53%) 23 (41%) 
Gestational age (wk.) n=34   n=35 p = 0.82 n=53  n=55 p = 0.39 
24-28 18 (53%) 16 (46%)  23 (43%) 31 (56%)  
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29-32 15 (44%) 18 (51%) 28 (53%) 22 (40%) 
33-36 1 (3%) 1 (3%) 2 (4%) 2 (4%) 
Apgar score (at 5 min) 
<4 1 (3%)  0.042* 
 
2 (4%) 1 (2%) 0.66 
 4-7 6 (16%) 15 (41%) 7 (13%) 10(18%) 
>7 29 (81%) 22 (60%) 45 (83%) 45 (80%) 
*Statistical significance p<0.05
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Table 2: Clinical characteristics of HIV infected and uninfected mothers 
PROM: Prolonged rupture of membranes 
 
Table 2 depicts the maternal clinical characteristics. The maternal CD4 cell counts 
ranged from 29 cells/dl - 1091 cells/dl, with a mean CD4 of 401.73 cells/dl. Seventy five 
percent (n=54) of the HIV infected mothers received ARV treatment for four weeks or 
more prior to labor and 15 (20%) mothers  received insufficient treatment (<4weeks). 
Three (4%) of the HIV-infected mothers did not receive any treatment and no treatment 
information was available for two (3%) of the mothers. All the infants that were HIV-
 Total 
Mothers 
(n=184) 
HIV-Infected 
Mothers (n=74) 
HIV-uninfected 
Mothers (n=110) 
Significance  
CD4 cell  
(mean, SD) 
 401 ±230.6   
ARV treatment 
duration 4 weeks or 
more 
 54 (75%)   
Delivery information 
PROM 17 (9%) 6 (9%) 11 (12%) 0.51 
Mode of delivery  n=183 n=74 n=109 0.53 
C-section 139 (76%) 58 (78%) 81 (74%)  
Vaginal delivery 44 (24%) 16 (22%) 28 (26%) 
Maternal medical treatment 
Maternal antibiotics 46 (25%) 21 (30%) 25 (24%) 0.42 
Steroids received 126 (68%) 54 (75%) 72 (67%)  0.23 
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exposed received nevirapine.  Three of the 74 infants had a confirmed HIV-positive 
PCR result and subsequently started AZT treatment (Figure 1). Interestingly, all infants 
with a positive PCR were within the study group and did not develop NEC. 
 
A total of 4 227 L. rhamnosus GG and B. infantis doses were administered (mean doses 
22.9 per infant). Nine cases of all stages of NEC occurred (incidence rate 5%); while 
four infants had developed Bells stage III (incidence rate 2.2%) (Table 3). None of the 
infants in the study developed NEC stage II. The incidence of all stages of NEC in the 
HIV exposed group differed significantly (p=0.045) for Bells staging criteria. Five percent 
(n=2) of the HIV-exposed study infants developed Bell’s I and two (5%) infants in the 
control group developed Bell’s III. There was no difference in the incidence of stage III 
NEC in the HIV-unexposed group compared to the HIV-exposed group [n=2 (4%) vs. 2 
(5%); p=1.0, respectively]. Only one of the infants in the HIV-exposed group with stage 
III NEC survived (Figure 1). The incidence of death [4 (5.4%) vs. 7 (6%); p=0.79] or all 
stages of NEC [4(5%) vs. 5(5%); p=0.76] did not differ significantly between the HIV-
exposed and unexposed groups (Figure 1). There was no difference in the incidence of 
positive blood cultures between the HIV-exposed group and the HIV-unexposed group 
[8 (11%) vs. 17 (16%); p<0.68 respectively] as well as between the study group and the 
control group [15 (16%) vs. 10 (11%); p<0.32 respectively]. None of the positive blood 
cultures grew Lactobacillus or Bifidobacterium species. The mean antibiotic treatment 
days did not differ significantly between the HIV-exposed an unexposed groups (p=0.3). 
Enteral feeds were started at 3.13 (±1.21) mean days of life, with full feeds achieved at 
10.21(±3.57) mean days of life. 
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Table 3: Clinical outcomes of HIV-exposed and unexposed infants 
 HIV-exposed HIV-unexposed 
 Probiotic 
(n=37) 
Placebo 
(n=37)  
Significance  
 
Probiotic 
(n=54)  
Placebo 
(n=56) 
Significance  
 
NEC  n=2 n=2  n=1 n=4  
NEC Bell’s I 2 (5%) None 0.045* 1 (2%) 2 (4%) 0.36 
NEC Bell’s III None 2 (5%) None 2 (4%)  
Positive Cultures 
†Positive Blood 
cultures 
5 (14%) 3 (8%) 1.00 10 (19%) 7 (12%) 0.13 
†Positive LP 
culture 
    1 (2%) 1 (2%)  
Days to 
achievement of 
full feeding (DOL, 
mean ±SE) 
10.19 
±0.62 
9.68 
±0.62 
0.56 9.63 ±0.47 11.14 
±0.46 
0.022* 
Use of antibiotics 
(mean days,±SD) 
3.99 
±1.85 
3.60 
±1.44 
0.35 3.39 ±1.60 4.00 
±2.47 
0.14 
LP: lumbar puncture; DOL: day of life; *: Statistical significance: p<0.05; † Gram–
bacteria: Acinetobacter baumannii, Enterococcus Faecium, Esterichia coli, Klebsiella 
Pneumonia, Proteus Mirabilis. Gram+bacteria: Corynebacterium, MRSA, Streptococcus, 
Staphylococcus. Viral: Herpes. Fungal: Candida. 
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Table 4: Characteristics of infants with Bell’s I and Bell’s III. 
 Bell’s I 
n=5 
Bell’s III 
n=4 
Significance 
Probiotic 3 (60%) None 0.029* 
Placebo 2 (40%) 4(100%) 
HIV-exposure 
HIV-exposed 2 (40%) 2 (50%) 0.76 
HIV-unexposed 3 (60%) 2 (50%) 
AGA 1 (20%) 2 (50%) 0.64 
SGA 4 (80%) 2 (50%) 
Weight (gr) 
500-750  1 (20%) 1(25%) 0.53 
751-1000  3 (60%) 3(75%) 
1001-1250  1(20%) None 
Maternal CD4 376.5 ±122.3 609 ±242.5 0.69 
Antenatal Steroids 4 (80%) 3 (75%) 0.86 
RBC transfusion 2 (4%) 1(25%) 0.71 
Antibiotic treatment 4.5 (±2.5) 4.7 (±2.4) 0.89 
Surfactant  2 (40%) 1 (25%) 0.63 
Blood cultures 2 (40%) None  
Total days CPAP 
(mean, ±SD) 
7.4 ±9.42 12 ±6.06 0.22 
AGA: Appropriate for gestational age; SGA: Small for gestational age; RBC: Red blood 
cell; *: Statistical significance: p<0.05  
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Apgar scores at 5 minutes were the only factor that affected the overall NEC incidence 
(p=0.014) (results not shown). As depicted in Table 4, the incidence of all stages of 
NEC was significantly lower in the study versus the control group [3(3%) vs. 6 (6%); 
p=0.029]. Four infants (4%) in the control group developed Bells Stage III. None of the 
infants that developed NEC had a clinical classification of PDA. Three of the infants that 
developed NEC had red blood cell (RBC) transfusions during clinical manifestations of 
NEC. Within 24 hours NEC was confirmed and both cases resulted in death due to 
NEC. The mean maternal CD4 cell count for HIV infected mothers whose infants 
developed NEC was 493 cells/µl (min: 290 cells/µl; max: 781cells/µl).  All of the HIV-
positive mothers (n=4) whose infants developed NEC received sufficient antiretroviral 
medication during pregnancy. 
 
Discussion: 
Supplementing probiotics to premature infants has emerged in recent years as a 
promising strategy to prevent NEC. The multifactorial pathogenesis of NEC is well 
discussed in literature and although many variables are associated with the 
development of NEC, prematurity and low birth weight remain a major risk factor.  
The heavy burden of maternal HIV infection in developing countries such as South 
Africa has resulted in a high prevalence of premature birth and NEC.17 There is a 
scarcity of data on the outcomes of premature infants born to HIV-infected mothers. A 
case control study in 2005 suggests an association between maternal HIV status and 
an increased risk of NEC in premature infants.7  A cohort analysis by Karpelowsky in 
2010 suggested an increase in mortality rates, but no increase in the severity of NEC.17, 
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18 The reported incidence of NEC was 5 - 15% between 2003 and 2007. 19, 20 In our 
study the overall incidence of all stages of NEC was 5% and 2.2% for severe stages of 
NEC which is within the lower range of other reported studies.20, 21 Furthermore the 
study found a reduced incidence of NEC (Bell’s I and III) in the study group when 
compared to the control group (3% vs. 6% NEC incidence respectively), not specific to 
the HIV status. Recent evidence shows that very-low–birth weight premature infants are 
deficient in anaerobic bacterial colonization of the intestinal tract and that lack of these 
organisms may allow for overgrowth of more pathogenic bacteria, leading to initiation of 
NEC.22 Evidence from our study supports the hypothesis of the immune stimulating 
properties that probiotics may hold in this at risk population.  The focal health-promoting 
effect of probiotics is their enhancement of mucosal immune defense; through 
enhancing macrophage activity, increasing numbers of killer cells, T cells and interferon;  
suppression of NF-κB signaling23 and action against pathogenic microbial colonization 
and translocation.24  
 
 The primary outcomes of this study were to determine the incidence and severity of 
NEC in HIV-exposed infants when treated with probiotic cultures. This has not 
previously been reported. The intricate immunological changes, involving cytokine 
production and T cell function, observed in HIV-exposed infants also supports the 
hypothesis of a possible link between HIV vertical exposure and NEC.25, 26 HIV-exposed 
uninfected infants may also demonstrate immune deficiencies,26-29 which could 
influence their outcome, particularly in advanced NEC.17 The incidence of all stages of 
NEC within the HIV group differed significantly (p=0.045). Five percent (n=2) of the HIV-
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exposed trial infants receiving probiotics developed Bell’s I and two (5%) infants in the 
control group developed Bell’s III.  Although there were cases of NEC reported within 
the study group, it is noteworthy that it was less severe cases of NEC (Bell’s I). Infants 
with stage I NEC were included in the analysis as there is no literature available on the 
implications of probiotic use as well as the role of oral anti-retroviral drugs in VLBW HIV-
exposed infants. A retrospective, double-blind study showed no difference between 
clinical presentation and histopathological features in HIV-exposed and HIV-unexposed 
infants.22  
 
The higher incidence of severe stages of NEC in the HIV-exposed and unexposed 
control group compared to the study group could be related to the administration of 
probiotics. The similar incidence of positive blood cultures between the HIV-exposed 
and unexposed infants are probably related to exclusive breast milk feeding. All infants 
that were enrolled in this trial received mothers own breast milk or donor breast milk. 
The breast milk of HIV-positive mothers was pasteurized before administration to 
infants. The use of breast milk is associated with a reduced incidence of NEC. Human 
milk may however also be a vehicle for microorganisms derived from the mother or the 
environment during collection. It has been found that coagulase-negative staphylococci, 
alpha hemolytic streptococci and pathogens such as Escherichia coli and others are 
present in 60-80% of all donor breast milk samples collected.30 Pasteurization is known 
to decrease the number of pathogens present in breast milk. Therefore it is possible that 
the pasteurization of breast milk could have served as a protective mechanism for the 
HIV-exposed infants. Limitations of the study: Although statistics are significant, a small 
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group of NEC cases limits an over enthusiastic interpretation of the results. All infants in 
this study were exclusively breast milk fed which is associated with a very low incidence 
of NEC.  
 
Conclusion: 
This study is the first to document the use of Probiotics L. rhamnosus GG and B. 
infantis in premature VLBW infants born to HIV-infected mothers. This study failed to 
show that probiotics lowered the incidence of NEC in HIV-exposed premature infants 
however it appears to reduce the severity of disease. Furthermore we support the use 
of probiotics as an effective method in reducing the risk for NEC in low and very low 
birth weight infants. These results support the need for further RCT’s in HIV-exposed 
preterm infants and the use of probiotics.  
 
Abbreviations: HIV: human immunodeficiency virus; MCT: medium chain triglyceride; 
NEC: necrotizing enterocolitis; TBCH: Tygerberg Children’s Hospital; VLBW: very low 
birth weight. 
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Abstract 
 
The heavy burden of maternal HIV infection has resulted in a high prevalence of premature birth and associated necrotizing 
enterocolitis (NEC). Human milk oligosaccharides (HMOs) were recently associated with HIV infection and transmission 
through breastfeeding and were also shown to reduce NEC in an animal model, particularly the HMO disialyllacto-N- 
tetraose (DSLNT). The primary aim of this study was to verify differences in HMO composition between HIV-infected and 
HIV-uninfected women. The secondary aim was to assess whether the HMO composition in the milk of mothers whose 
infants were diagnosed with NEC differs from that of mothers whose infants did not develop NEC. This study forms part of 
a larger clinical trial conducted at the Tygerberg Children's Hospital, Cape Town, South Africa, which recruited HIV-infected 
and HIV-uninfected mothers and their preterm infants (<34 wk gestation; $500 and #1250 g). Eighty-two mother-infant 
pairs were  selected for the substudy. Mother-infant  pairs were  stratified  according to the mother's  HIV (infected/ 
uninfected) and secretor status (secretor/nonsecretor). HMOs in 4- and 28-d postpartum milk samples were analyzed by 
HPLC and compared between groups. Our results confirm previous reports that HIV-infected mothers have higher relative 
abundances of 3#-sialyllactose in their milk compared with HIV-uninfected mothers (10.7% vs. 6.8%; P < 0.01). Most 
intriguingly, the data also indicated that low concentrations of DSLNT in the 4-d milk samples in the mother's milk 
increased the infant's risk of NEC (200 6 126 vs. 345 6 186 mg/mL; P < 0.05), which is in accordance with results from 
previously published animal studies and warrants further investigation. This trial was registered at clinicaltrials.gov as 
NCT01868737.  J. Nutr. 144: 1227–1233, 2014. 
 
 
Introduction 
 
The heavy burden  of maternal HIV infection has contributed to 
the prevalence  of premature birth  and necrotizing  enterocolitis 
(NEC)8 (1,2), one of the most common intestinal disorders in 
preterm   infants   (3).  Human   milk  oligosaccharides (HMOs) 
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3  Supplemental Figure 1 is available from the ‘‘Online Supporting Material’’ link in 
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8  Abbreviations used:  DFLNH, difucosyllacto-N-hexaose; DSLNT, disialyllacto- 
N-tetraose; FUT2, fucosyltransferase 2; HMO, human milk oligosaccharide; LNFP, 
lacto-N-fucopentaose; NEC, necrotizing enterocolitis; Se, secretor; TBCH, 
Tygerberg Children's Hospital; 3#SL, 3#-sialyllactose. 
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(4,5), complex carbohydrates that are highly abundant in breast 
milk but not in infant formula (6), were recently associated with 
HIV infection  and  transmission through  breastfeeding  (7) and 
were also shown to reduce NEC in an animal  model (8). More 
than 100 structurally distinct HMOs have been identified (9). 
Concentrations of individual  oligosaccharides vary with gestation 
(term  vs. preterm),  over  the  course  of lactation, and  from  one 
mother  to  another  (5).  Interpersonal HMO variations  are  most 
pronounced  for  a1-2-fucosylated HMO.  a1-2-Fucosylation of 
milk oligosaccharides is catalyzed by the enzyme fucosyltransferase 
2 (FUT2), encoded by the secretor (Se), which also affects a person's 
Se blood group status (10,11). Women with an active Se locus 
(secretors)  express  a  functional   FUT2  enzyme,  and  their  milk 
contains  high concentrations of a1-2-fucosylated HMOs [e.g., 2#- 
fucosyllactose  or  lacto-N-fucopentaose (LNFP)  1].  Nonsecretors 
lack a functional FUT2 enzyme, and their milk does not contain a1- 
2-fucosylated  HMOs. Given the accumulating evidence in support 
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of  the  beneficial  effects  of  individual   HMOs   (12),  mother-to- 
mother  variations  in HMO composition may provide an explana- 
tion for why some breast-fed infants are at lower risk of certain 
diseases than  others  and in the context  of HIV infection  (7) and 
NEC (12,13). 
A recent study in a cohort  of mother-infant pairs in Lusaka, 
Zambia, showed that HIV-infected  women with total  HMOs 
above the median were less likely to transmit  HIV via breast- 
feeding  (7).  However,   the  relative  abundance of  1  particular 
HMO, 3#-sialyllactose  (3#SL),  was significantly  higher  among 
transmitting versus nontransmitting women. Moreover, 3#SL 
concentrations and relative abundance were significantly higher 
in HIV-infected compared  with HIV-uninfected women. The 
primary aim of this study was to verify differences in HMO 
composition between  HIV-infected  and HIV-uninfected women 
in  an  independent  cohort   of  mother-infant  pairs  who  were 
selected from a larger clinical trial originally conducted in the 
neonatal  high   care   unit   of  Tygerberg   Children's   Hospital 
(TBCH), Cape Town,  South Africa (clinical trial registration at 
https://clinicaltrials.gov/: NCT01868737). 
In addition, the burden  of HIV infection increases the 
prevalence  of preterm  delivery  (1,2)  and  associated  complica- 
tions, including NEC. NEC risk is 6- to 10-times lower in breast- 
fed compared  with formula-fed  infants.  The results of a recent 
study in a neonatal rat model of NEC suggest that the presence 
of HMOs  in breast  milk and their absence in formula  could be 
one  of the  reasons  for  the  protective  effects of  breastfeeding 
against NEC (8). HMOs significantly improved survival and 
reduced  NEC  pathology  scores  in neonatal rats.  One  specific 
HMO,  disialyllacto-N-tetraose (DSLNT),   was  shown   to  be 
responsible   for  the  beneficial  effects.  It  remains   unknown, 
however,  whether  these results translate from the rat  model to 
human  preterm  infants. The secondary  aim of this study was to 
assess whether HMO composition in the milk of mothers whose 
infants  were diagnosed  with NEC differs from that  of mothers 
whose infants did not develop NEC. 
 
 
Participants and  Methods 
 
Original  clinical trial. This study is part of a larger randomized, double 
blind,   placebo-controlled  clinical   trial   that   was   conducted   in  the 
neonatal high care unit of TBCH. Between 4 July 2011 and 22 August 
2012,  184 mother  and  infant  pairs  that  met the inclusion  criteria  and 
whose  mothers  gave  written   informed  consent  were  enrolled  in  the 
clinical  trial.  Included  were  HIV-infected  or  HIV-uninfected mothers 
who consecutively gave birth to a premature infant with a birth weight of 
$500 and #1250 g at TBCH and consented  to participate in the trial. 
Only mothers  who decided to breastfeed  after counseling, regardless of 
their HIV status, were included. HIV-infected mothers who were on the 
prevention  of mother  to child transmission treatment schedule receiving 
nevirapine  and  zidovudine,  mothers  administered highly active antire- 
troviral medication, and HIV-exposed infants who were administered 
antiretroviral medication were enrolled  in the trial.  Infants  with major 
abnormalities such as gastroschisis,  a large omphalocele, or congenital 
diaphragmatic hernia were excluded. 
As part of the original clinical trial, infants were randomly  assigned to 
a study or a control group by a random-number table sequence assigned by 
a statistician. The study group consumed breast milk plus a daily probiotic 
supplement   of  Lactobacillus  rhamnosus  GG  (0.35  3 109 CFUs)  and 
Bifidobacterium infantis (0.35 3 109 CFUs). The control group consumed 
breast milk plus a placebo consisting of medium-chain TG (MCT) oil. Van 
Niekerk et al. (14) gave a detailed description  of the methodology and the 
results of the probiotics  administration. 
For  the  purpose   of  this  substudy,   the  data   collected  on  use  of 
probiotics are not discussed. The primary aim of this substudy was to 
determine  whether  HMO composition varies between HIV-infected and 
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HIV-uninfected  mothers.   The  secondary   aim  of  this  study  was  to 
determine whether HMO composition in the mother's milk can be linked 
to the incidence of NEC in her infant. Whenever an infant was suspected 
to have NEC, he or she was evaluated by the attending  neonatologists in 
conjunction with the pediatric  radiologist. If the diagnosis of NEC was 
made, it was staged according  to Bell's classification, ranging from Bell 
stage I (suspect) to Bell stage III (advanced)  (15). 
 
Participant  selection  for  the  substudy.  Of  the  184  mother-infant 
pairs enrolled in the original clinical trial, all infants who developed NEC 
and  whose  mothers  had  sufficient milk samples  available  for analysis 
were included in the substudy.  Thereafter, using a random-number table 
sequence, the study statistician  equally included mother-infant pairs 
stratified according to the mother's  HIV status (infected/uninfected) and 
the mother's  Se status  (secretor/nonsecretor). Fourteen  of the included 
mother-infant pairs  did  not  have  sufficient milk  samples  available,  in 
which case the next random participant sample was selected. In total, 82 
mother-infant pairs (41 with HIV-infected  and 41 with HIV-uninfected 
mothers)  were  included  in  the  substudy  and  their  milk  analyzed  for 
HMO composition (Fig. 1). 
 
Milk  sample  collection. A sample of hand-expressed breast  milk was 
collected from each mother  at 4 and 28 d postpartum. Untreated, 
unpasteurized milk samples were immediately  frozen at 225°C, and 
aliquots  were  shipped  on  dry  ice to  the  University  of California,  San 
Diego,   for   HMO  analysis.   HMO  analysis   was  performed   at   the 
University of California, San Diego, as previously described (7). 
 
Se status analysis. To determine the mother's  Se status (secretor/ 
nonsecretor), 1–2 mL of the mother's  saliva was collected in sterile 
containers  when  maternal consent  for the study was granted  or at the 
earliest time thereafter. Samples were immediately taken to the National 
Health  Laboratory Service at the TBCH for analysis (16,17). 
 
Trial  registration  and  statistical   analysis.   Ethical  approval   was 
granted  by the  Human  Research  Ethics  Committee of the  Faculty  of 
Health  Sciences, University of Stellenbosch, and Tygerberg Academic 
Hospital (clinical trial registration number:  NCT01868737). The study 
was conducted  in accordance with the Good Clinical Practice guidelines. 
 
 
 
 
 
FIGURE  1   Flow diagram of mother-infant pairs recruited in the 
original clinical trial and selected for the substudy. HMO, human milk 
oligosaccharide; NEC, necrotizing enterocolitis. 
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The South African Department of Health  and Stellenbosch University 
approved milk sample export to the United States. Data analyses were 
performed  with Statistica software (version 11; StatSoft). A power analysis 
to determine  sample sizes needed for this study was conducted  in which 2 
levels for each factor and a power of 90% to detect interaction effect sizes of 
d = 0.55 were used. The 2 factors mainly considered could be factors such as 
HIV status and NEC incidence. When comparing  continuous variables 
between  2 groups  (e.g., oligosaccharide concentrations for HIV groups), 
1-factor  ANOVA was used; if residuals  were not normally  distributed, a 
nonparametric test, the Mann-Whitney test, was used to confirm the 
conclusions from the ANOVA. Where necessary, heteroscedasticity was 
addressed with Welch-Satterthwait ANOVA. Nominal  variables (e.g., race, 
Se status) were compared  between groups with contingency tables and the 
maximum  likelihood  chi-square  test. When group means were compared, 
they were reported  as means 6 SDs, where the SD refers to the SD of the 
group. Significance was achieved in all hypothesis  tests if P < 0.05. 
 
 
Results 
 
Table 1 shows the clinical characteristics and medical treatments 
for all 82 mothers  included in this substudy,  separated by HIV- 
infected  (n = 41)  and  HIV-uninfected (n = 41)  women.  Most 
important for this study, there was no difference in Se status 
between HIV-infected and HIV-uninfected mothers.  However, 
there was a significant difference in the racial distribution 
between the 2 groups, with black women making up 93% of the 
HIV-infected  group but only 51%  of the HIV-uninfected group. 
There  was no significant  difference  between  HIV-infected  and 
HIV-uninfected mothers with respect to age, gravida and parity, 
mode  of delivery,  use of antibiotics  or steroids,  and  incidence 
of hypertension/pre-eclampsia or prolonged  rupture  of mem- 
branes.  CD4 cell counts in the HIV-infected  group ranged from 
29 to 862 cells/100 mL, with a mean CD4 of 373 cells/100 mL 
(normal  CD4 cell count range: 500–1000 cells/100 mL) (18). 
Thirty-four of the HIV-infected  mothers  (83%)  were adminis- 
tered  antiretroviral treatment for $4 wk prior  to labor  and  7 
mothers  (17%)  received insufficient treatment (<4 wk). 
Table 2 shows the demographic and clinical characteristics of 
all 82 infants included in this substudy, separated by HIV-exposed 
and HIV-unexposed infants.  There was no significant difference 
between HIV-exposed and HIV-unexposed infants with respect to 
gender distribution, birth weight, gestational  age, or 5-min Apgar 
scores. All HIV-exposed  infants were administered nevirapine. 
Because Se status dramatically affects HMO composition in 
the mother's  milk, results for secretor  and nonsecretor women 
were analyzed separately  and are shown in Figs. 2 and 3, 
respectively. Results are shown for the 2 different sample 
collection times (4 and 28 d postpartum) and given as absolute 
oligosaccharide concentrations in micrograms  per  milliliter  as 
well as relative abundancies in percentages  of all analyzed 
oligosaccharides. 
Among secretor women, those who were HIV infected had 
significantly   lower   concentrations  of  the  oligosaccharides 
 
 
TABLE  1   Maternal clinical characteristics and medical treatment1 
 
Total mothers 
(n = 82) 
HIV-infected mothers 
(n = 41) 
HIV-uninfected mothers 
(n = 41) P 2 
 
 
Race, n (%) 
Black 
 
 
59 (72) 
 
 
38 (93) 
 
 
21 (51) 
 
,0.0001 
Mixed 22 (27) 3 (7) 19 (46)  
White 1 (1) 0 (0) 1 (2)  
Age, y 27.7 6 5.4 28.7 6 5.1 26.7 6 5.5 0.08 
CD4 cells, cells/100  mL — 373 6 207.6 —  
Se status,3  n 82 41 41 0.66 
Secretor, n (%) 42 (51) 22 (54) 20 (49)  
Nonsecretor, n (%) 40 (49) 19 (46) 21 (51)  
Gravida/parity,3  n 82 41 41  
Gravida 2.5 6 1.3 2.3 6 1.2 2.6 6 1.3 0.22 
Parity 2.1 6 0.9 2.1 6 1.0 2.2 6 0.9 0.91 
Mode of delivery,3  n 81 41 40 0.0259 
Cesarean section, n (%) 63 (78) 36 (88) 27 (68)  
Vaginal delivery, n (%) 18 (22) 5 (12) 13 (32)  
Duration of antiretroviral treatment,3  n — 41 —  
$4 wk, n (%) — 34 (83) —  
,4 wk, n (%) — 7 (17) —  
Maternal medical treatments 
Maternal antibiotics,3  n 
 
67 
 
39 
 
37 
 
Prevalence, n (%) 19 (28) 11 (28) 8 (21) 0.51 
Maternal steroids,3  n 81 40 41  
Prevalence, n (%) 58 (72) 32 (80) 26 (63) 0.09 
Maternal medical conditions 
Hypertension/pre-eclampsia,3   n 
 
82 
 
41 
 
41 
 
Prevalence, n (%) 44 (54) 21 (51) 23 (56) 0.66 
Prolonged rupture of membranes,3 n 67 36 31  
Prevalence, n (%) 9 (13) 4 (11) 5 (16) 0.55 
1 Values are means 6 SDs unless otherwise indicated. Se, secretor. 
2 Determined by using chi-square test or 1-factor ANOVA. 
3 n indicates population with available data. 
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 0.45 
15 (37) 18 (44)  
26 (63) 23 (56)  
988.9 6 157.9 974.5 6 151.8 0.67 
28.5 6 1.9 28.8 6 1.7 0.39 
  0.28 
11 (27) 7 (17)  
30 (73) 34 (83)  
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TABLE  2   Demographic and clinical characteristics of infants1 (Supplemental   Fig.  1C).  There  was  no  difference  in  DSLNT 
concentrations whether  infants  were diagnosed  with  NEC Bell 
 
 
 
Gender, n (%) 
Male 
Female 
Birth weight, g 
Gestational age, wk 
Apgar score at 5 min, n (%) 
4–7 
.7 
HIV-exposed 
(n = 41) 
HIV-unexposed 
(n = 41) P 2 
stage I or stage III disease severity (each n = 4). DSLNT 
concentrations in the 28-d milk samples of the remaining 5 NEC 
cases were lower than in all infants without NEC (Supplemental 
Fig. 1D).  One  reason  for this lack of significance could be the 
lower number of 28-d milk samples available for analysis. Three 
of the infants diagnosed with NEC (1 with Bell stage I and 2 with 
Bell stage III) did not  survive until  the  28-d  milk sample  was 
collected. Thus, only the 5 remaining 28-d milk samples were 
available   for  HMO  analysis.   After  review  of  the  4-d  milk 
samples  of  infants  with  NEC,  DSLNT   concentrations  were 
indeed  lower  in  infants  who  did  not  survive  compared   with 
1 Values are means 6 SDs unless otherwise indicated. 
2 Determined by using chi-square test or 1-factor ANOVA, P , 0.05. 
 
 
 
2#-fucosyllactose  (697  vs. 1227  mg/mL;  P < 0.05),  lacto-N- 
tetraose (534 vs. 665 mg/mL; P < 0.05) and LNFP 1 (538 vs. 791 
mg/mL;   P  <  0.05)   compared   with   HIV-uninfected  secretor 
women   (Fig.  2A)  in  the  4-d  samples.   In  addition   to  these 
differences in absolute concentrations, the relative abundance of 
3#SL  (10.7% vs.  6.8%;   P < 0.01),  difucosyllacto-N-tetraose 
(14.1% vs. 10.2%; P < 0.05),  and fucosyl-disialyllacto-N- 
hexaose  (2.0%  vs. 1.4%;  P < 0.05) was higher in HIV-infected 
secretor  women  than  in HIV-uninfected secretor  women  (Fig. 
2B). There were no significant differences in HMO composition 
between  HIV-infected  and  HIV-uninfected secretor  women  for 
the 28-d milk sample (Fig. 2C, D). 
In   nonsecretors,  there   was   no   significant   difference   in 
absolute  HMO concentrations between  HIV-infected  and HIV- 
uninfected  women  in the 4-d milk samples (Fig. 3A). However, 
the  relative  abundance of difucosyllacto-N-hexaose (DFLNH) 
was higher in HIV-infected compared with HIV-uninfected 
nonsecretors (4.4%  vs. 2.8%;  P < 0.05) (Fig. 3B). 
In  the  28-d  milk  samples,  HIV-infected   nonsecretors had 
significantly lower concentrations of 3-fucosyllactose  (40 vs. 65 
mg/mL;  P < 0.01),  LNFP 3 (35 vs. 64 mg/mL;  P < 0.01),  and 
fucosyllacto-N-hexaose (31 vs. 74 mg/mL; P < 0.01) compared 
with milk of uninfected nonsecretors (Fig. 3C). Similar to the 4-d 
samples, the 28-d sample in HIV-infected  nonsecretors also had 
a higher relative abundance of DFLNH  compared  with the 
uninfected   group  (5.1%   vs.  3.3%;   P <  0.01)  (Fig.  3D).  In 
addition, HIV-infected  nonsecretors had a higher relative abun- 
dance of lacto-N-neotetraose (9.4%  vs. 4.0%;  P < 0.05) and a 
lower relative abundance of 3-fucosyllactose  (2.4%  vs. 1.6%;  P 
< 0.05) compared  with uninfected  nonsecretors. 
Nine NEC cases occurred within the larger clinical trial cohort 
(5% incidence). Five of the infants were diagnosed with Bell stage 
I and four with Bell stage III (2.2%  incidence). One infant  with 
NEC (Bell stage I) was excluded  because the mother's  milk was 
not sufficient for HMO analysis. The remaining 8 NEC cases were 
included in this substudy.  The HIV-exposed  and HIV-unexposed 
infant groups each had 2 NEC stage I and 2 NEC stage III cases. 
Comparing infants who developed NEC with infants who did 
not  develop  NEC  (irrespective   of  HIV  or  Se  status   of  the 
mother), the mother's milk showed no difference in the total 
concentration of all analyzed  HMOs  in the 4-d (Supplemental 
Fig. 1A) and  the  28-d  (Supplemental  Fig. 1B) samples.  There 
were no significant differences in the concentrations of any of the 
individual   HMOs,  except   for   1  HMO.  Concentrations  of 
DSLNT  were  significantly  lower  in  the  4-d  milk  samples  of 
mothers  whose  infants  developed  NEC  compared   with  all 
other  infants  (200  6 126  vs. 345  6 186  mg/mL;  P < 0.05) 
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infants  who survived past day 28. However,  the difference was 
not significant (P = 0.657), likely due to the very small number of 
samples in both groups. 
 
 
 
Discussion 
 
Our  results  confirm  data  from  a previous  study  conducted  in 
Zambia that reported  differences in HMO composition between 
HIV-infected  and HIV-uninfected women (7). The primary  goal 
of the previous study was to determine  whether  HMO compo- 
sition is linked to a higher transmission risk through  breastfeed- 
ing,  and  milk  from  uninfected  mothers  was  only  included  to 
serve as a control.  Surprisingly, the milk of HIV-infected women 
had  significantly higher concentrations of the sialylated  HMO 
3#SL, which is confirmed by the present study. 
A woman's  Se status  strongly  determines  what  oligosaccha- 
rides are present in her milk. Therefore, the HMO composition in 
the milk of secretor and nonsecretors is very different,  especially 
with  respect to fucosylated  HMOs. When selecting samples for 
this substudy, we purposely separated the cohort into secretor and 
nonsecretors and within each group compared  HMO profiles 
between HIV-infected and HIV-uninfected women. With this 
approach we were able to identify additional, mostly fucosylated 
HMOs whose concentrations significantly differed between HIV- 
infected and HIV-uninfected women. The biologic or path- 
ophysiologic relevance of these findings remains elusive, 
however.  At least 2 scenarios  are possible:  1) HIV infection 
changes the glycosylation machinery in the mammary gland 
epithelial  cell, which  changes  the composition of oligosaccha- 
rides that are secreted with the milk; 2) individuals who express 
more or less of certain  glycosylation-related genes are more or 
less likely to acquire an HIV infection. In parallel, these 
glycosylation-related genes  also  determine   what  oligosaccha- 
rides are synthesized and secreted with the milk and at what 
concentration. A combination of in vitro and in vivo studies will 
be required  to approach and answer this difficult question. 
Although the primary aim of this study was to determine 
whether  HMO composition varies  between  HIV-infected  and 
HIV-uninfected mothers,  secondary  data analysis revealed 
intriguing  results  that  link  HMOs  to  NEC.  Breast-fed  infants 
are known  to have a lower  risk of developing  NEC  (19),  but 
the components in human milk that are responsible for the 
protective  effects of breastfeeding  remain  to be elucidated.  A 
recent study suggested that the HMO DSLNT might be involved 
because  it  improved   survival  and  reduced   ileum  pathology 
scores in neonatal rats (8). The effects were highly structure- 
specific because the removal of just 1 sialic acid led to a complete 
loss of protection. So far, there has been no evidence that  these 
observations translate from  the  rat  model  to  human  preterm 
infants and that HMOs  in general or DSLNT in particular helps 
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FIGURE 2   HMO composition in the milk of HIV-infected (n = 22) and HIV-uninfected (n = 20) secretor women at 2 different stages of lactation. 
Values are means 6 SDs or percentages. Absolute HMO concentrations in 4-d milk samples (A); relative HMO abundance in 4-d milk samples (B); 
absolute HMO concentrations in 28-d milk samples (C); and relative HMO abundance in 28-d milk samples (D). *P , 0.05, **P , 0.01. DFLNH, 
difucosyllacto-N-hexaose; DFLNT, difucosyllacto-N-tetraose; DSLNH, disialyllacto-N-hexaose; DSLNT, disialyllacto-N-tetraose; FDSLNH, fucosyl- 
disialyllacto-N-hexaose; FLNH,  fucosyllacto-N-hexaose; HMO,  human  milk  oligosaccharide; LNFP, lacto-N-fucopentaose; LNnT,  lacto-N- 
neotetraose; LNT, lacto-N-tetraose; LST, sialyllacto-N-tetraose; 2#FL, 2#-fucosyllactose; 3FL, 3-fucosyllactose; 3#SL, 3#-sialyllactose. 
 
 
to  prevent  NEC.  Our  new  results  now  suggest  that  infants 
diagnosed  with NEC indeed received milk that contained lower 
concentrations of DSLNT  compared  with  infants  who  did not 
develop NEC. The effects seem to be structure-specific  because 
no  other  individual  HMO was  associated  with  NEC  and  the 
total  sum of all analyzed  HMOs  was not  different  whether  or 
not the infants was diagnosed with NEC. It is important to note 
that  only 4 of the 8 NEC cases were categorized  as confirmed 
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FIGURE 3   HMO composition in the milk of HIV-infected (n = 19) and HIV-uninfected (n = 21) nonsecretor women at 2 different stages of 
lactation. Values are means 6 SDs or percentages. Absolute HMO concentrations in 4-d milk samples (A); relative HMO abundance in 4-d milk 
samples (B); absolute HMO concentrations in 28-d milk samples (C); and relative HMO abundance in 28-d milk samples (D). *P , 0.05, **P , 0.01. 
DFLNH, difucosyllacto-N-hexaose; DFLNT, difucosyllacto-N-tetraose; DSLNH, disialyllacto-N-hexaose; DSLNT, disialyllacto-N-tetraose; FDSLNH, 
fucosyl-disialyllacto-N-hexaose; FLNH, fucosyllacto-N-hexaose; HMO, human milk oligosaccharide; LNFP, lacto-N-fucopentaose; LNnT, lacto-N- 
neotetraose; LNT, lacto-N-tetraose; LST, sialyllacto-N-tetraose; 2#FL, 2#-fucosyllactose; 3FL, 3-fucosyllactose; 3#SL, 3#-sialyllactose. 
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survivors and nonsurvivors was not significant (P = 0.657), likely due to the small number  of cases. 
Although the original clinical trial was not designed to determine whether individual HMOs in the mother's  milk are linked to 
infant NEC risk, our results indicate that DSLNT may indeed protect from NEC, not only in neonatal rats but also in human  
preterm  infants. Specifically designed and well-powered  cohort  studies will be required to verify the link between DSLNT 
and NEC. If confirmed, DSLNT concentrations in mother's  milk could serve as a noninva- sive marker  to determine  whether  a 
breast-fed  infant  is at risk of developing NEC. In addition, DSLNT or DSLNT-like compounds could be developed as novel 
and desperately needed supplements or drugs for the treatment or prevention  of NEC. 
Although  differences  were  significant,  the  small  group  of NEC  cases limits  the  interpretation of the  results.  All 
of the infants in this study were exclusively breast-milk fed, which is associated  with a very low incidence of NEC. 
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4.1 SUMMARY OF STUDY OBJECTIVES AND DESIGN 
 
During the 20th century, Nobel Prize winner Elie Metchinkoff proposed the idea that 
nonpathogenic bacteria were associated with a prolonged lifespan. The term ‘probiotic’ was 
first introduced in 1965, and the definition has since undergone many variations.1 The Food 
and Agriculture Organization of the United Nations and the World Health Organization 
defined probiotics in 2001 as “live microorganisms which when administered in adequate 
amounts confer a health benefit on the host”.2  
In 1999, Hoyos et al. were the first to report a significant reduction in the incidence of 
necrotizing enterocolitis (NEC) following probiotic supplementation. Lactobacillus acidophilus 
and Bifidobacterium infantis were given to preterm neonates. A significant decrease in NEC 
(85 cases vs. 34 cases) was noted in the probiotics group.3, 4 Numerous clinical trials have 
since been conducted to elucidate the role of probiotics in this fatal neonatal condition. 
Clinical trials that have used Lactobacillus rhamnosus or Lactobacillus infantis found a 
significant reduction in the incidence of severe Stage II–III NEC. These trials were not 
specific to HIV status.5-9 It is also noteworthy to mention that many of the clinical trials 
conducted on the use of probiotics and the incidence of NEC included formula milk and were 
not specific to only breast milk as the choice of feed.5 The literature indicates that the use of 
formula milk in preterm neonates increases the risk of developing NEC.10 
 
The primary objective of the current study was to evaluate the efficacy of probiotics in 
reducing the incidence and severity of all stages of NEC in premature, very low birth weight 
(VLBW) infants exposed to HIV. The secondary research objectives were as follows:  
i. To assess the incidence of all stages of NEC in VLBW and extremely low birth weight 
(ELBW) infants born to HIV-infected and HIV-uninfected women; and 
ii. To evaluate weight gain for both probiotic-exposed and probiotic-unexposed, 
premature, VLBW infants; and 
iii. To determine the prebiotic quality of the breast milk of HIV-infected and HIV-
uninfected mothers, in terms of oligosaccharide content; and  
iv. To determine whether there was an association between the prebiotic quality of 
breast milk in terms of oligosaccharide content and the incidence of NEC in premature 
VLBW infants. 
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A randomised, double-blind, placebo-controlled clinical trial was conducted in the neonatal 
high care unit of Tygerberg Children’s Hospital (TBCH), Cape Town, South Africa, during the 
period July 2011 to August 2012. Babies were included if the following criteria were met: (i) 
birth weight was in the range of 500–1 250 g and (ii) the baby received breast milk, either 
from the mother or a donor. Both HIV-exposed and -unexposed babies were included in this 
study. Throughout the study period, the standard of care protocol consisted of one dose (five 
drops) of either a probiotic or a placebo daily for four weeks (28 days). This provided the 
study group with L. rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis 
(0.35 x 109 CFU) daily. The product used was Pro-B2®. Pro-B2® (C Pharm, Cape Town, 
South Africa) is an oil suspension and may be stored at room temperature. The control group 
received a placebo consisting of medium-chain triglyceride (MCT) oil.  
Supplementation with the probiotic or placebo was initiated when enteral feeds started. 
Probiotic or placebo supplementation was delayed or halted in the following circumstances: 
(i) when an infant was nill per os (NPO) , the infant did not receive a probiotics or placebo 
until the enteral feeds had commenced again; (ii) when NEC was suspected, the infant 
continued with treatment until a positive diagnosis of NEC Stage I had been made through 
an abdominal X-ray; (iii) if the infant remained a possible NEC case and was NPO, the infant 
did not receive a probiotic or placebo until the enteral feeds had commenced again; (iv) 
supplementation was discontinued if HIV-exposed infants had a positive polymerase chain 
reaction (PCR) result on Day 14 of life, due to the uncertainty of probiotic-associated 
septicaemia in immunocompromised, HIV-positive, VLBW infants on highly active 
antiretroviral medication (HAART). 
All study participants received human breast milk. Both the probiotic and placebo were 
mixed with the mothers’ own breast milk or donor breast milk before administration via an 
orogastric tube or orally. The probiotic or placebo was added to the breast milk by the 
researcher and two research assistants. The attending physician and nurses caring for the 
infants as well as the researcher, research assistants and study participants were blinded to 
the group assignment. Participants exited the study on Day 28 after birth or upon discharge 
from the hospital.  
Medical and clinical data were collected. These included data on birth weight, estimated 
gestational age, gender, type of delivery, Apgar scores and daily intake and output. Daily 
clinical progress notes were also reviewed. Each infant’s weight was recorded from his/her 
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medical file on a daily basis, whilst the length and head circumference was measured by the 
investigator or research assistants on days 1, 7, 14, 21 and 28 of the study. Z-scores were 
used in the interpretation of anthropometrical data. Infants were evaluated daily for the 
development of NEC by the attending neonatologists. Infants who developed any stage of 
NEC, according to Bell’s criteria, were exited from the study. When an infant was exited from 
the study, the supplementation was halted and daily follow-up continued. NEC Stage I has 
the potential to develop into more severe stages of NEC. Therefore, the standard of care 
practice in the specific neonatal unit entails that those infants who develop NEC Stage I are 
treated as a confirmed NEC case. For the purpose of this trial, infants with Stage I NEC were 
included in the analysis as there was no information on the effect of probiotics on HIV-
exposed, VLBW infants.  
A full sample of expressed breast milk was used for determination of the human milk 
oligosaccharide (HMO) content of HIV-infected and HIV-uninfected mothers. All breast milk 
samples were raw, untreated specimens; therefore, milk samples did not undergo any 
pasteurisation procedures. An aliquot of 5–10 ml of breast milk, expressed by hand, was 
collected in sterilised containers with lids. Three breast milk samples were collected from 
each mother on Day 4 and Day 10 of lactation, and the final sample was collected 28 days 
postpartum. Only the first and final breast milk samples were analysed. A saliva sample (1–
2 ml) was collected from the mother when maternal consent for the study was granted or at 
the earliest opportunity thereafter in order to determine the maternal ABH secretor status. 
A total of 219 infants were screened for the study. Ten infants were not included in the trial 
due to parents not providing consent, while 25 infants did not conform to the inclusion 
criteria. This left a final sample size of 184 infants in the clinical trial. Of these, 74 infants 
(40%) were HIV-exposed and 110 (60%) were not. Within the HIV-exposed group, 37 infants 
(50%) were randomised into the study and control groups, respectively. In the HIV-
unexposed group, 54 infants (49%) were randomised into the study group and 56 infants 
(51%) into the control group.  
Of the 184 infants enrolled in the study, 156 completed the full 28-day study period. Infant 
outcomes were as follows: three infants were withdrawn from the study; seven were 
discharged; 11 deaths occurred, five of which were NEC associated; there were four NEC 
survivals; and there were three positive PCR results at Day 14 of life.   
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4.2 NECROTIZING ENTEROCOLITIS IN HIV-EXPOSED VERY LOW BIRTH 
WEIGHT AND EXTREMELY LOW BIRTH WEIGHT INFANTS: INCIDENCE 
AND SEVERITY 
NEC is the most common serious acquired disease of the gastrointestinal tract in preterm 
infants.11, 12 Infants with NEC have a higher incidence of nosocomial infections, supoptimal 
nutrient intake and inappropriate growth, and also have longer durations of intensive care 
and hospital stay.13 Possible risk factors for NEC are prematurity,14 enteral feeding,15 growth 
restrictions,16 preeclampsia and maternal hypertensive disease,17 low Apgar scores14 and 
red blood cell transfusions.18 Furthermore, the prevalence of low birth weight and preterm 
birth among infants who are born to HIV-infected women has increased as treatment has 
evolved into regimens of HAART.19 Exposure to HIV during foetal life and maternal treatment 
with antiretroviral (ARV) drugs are two probable mechanisms proposed to explain the 
increased incidence of NEC in this population.20 
The results of the current randomised control trail indicate that the overall incidence of NEC 
was 5%, which is within the lower range of other reported studies.6, 21 Among the nine cases 
of NEC that occurred, four episodes (2%) were classified as severe NEC, namely Bell’s 
Stage III. Furthermore, the study found a reduced incidence of NEC (Bell’s stages II and III) 
in the study group when compared to the control group (3% vs 6% NEC incidence, 
respectively), not specific to HIV status. 
This study failed to show that probiotics lowered the incidence of NEC in HIV-exposed 
premature infants; however, probiotic supplementation appeared to reduce the severity of 
disease, assessed using Bell’s criteria. The severity of NEC within the HIV-exposed group 
differed significantly (p = 0.045), with 5% (n = 2) of the infants in the study group developing 
Bell’s Stage I NEC and 5% (n = 2) of the infants in the control group developing Bell’s Stage 
III NEC (Refer to article 1: Probiotics and necrotizing enterocolitis in HIV-exposed premature 
infants: a randomised controlled trial – Table 3: Clinical outcomes of HIV-exposed and -
unexposed infants). The latest updated Cochrane review summarises the evidence of 
probiotic efficacy from 16 randomised trials and more than 2 700 preterm infants. The results 
show that probiotics reduced the incidence of severe NEC, mortality and NEC-related 
mortality.5 The incidence of death for all stages of NEC did not differ significantly between 
the HIV-exposed and -unexposed groups in this study.  
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The researcher therefore partially accepts the null hypothesis (see 2.4) that the 
administration of probiotics does not reduce the incidence of NEC in premature, VLBW 
infants exposed to HIV. We do, however, reject the null hypothesis that the use of probiotics 
does not reduce the severity of NEC in these infants. A secondary objective of this study 
(see 2.3.2) was to assess the incidence of NEC in VLBW and ELBW infants born to HIV-
infected and HIV-uninfected women. The results did not show a significant difference in the 
incidence of NEC in the case of HIV exposure. We therefore accept the null hypothesis (see 
2.4) that there is no difference in the incidence of NEC in VLBW and ELBW infants born to 
HIV-infected and HIV-uninfected women. 
4.3 FEEDING TOLERANCE  
The administration of probiotic organisms has been shown in previous studies to shorten the 
time to full feeds.5 This is supported by the results of the current study, in which it was found 
that infants in the HIV-unexposed study group reached full feeds in significantly fewer days 
than infants in the HIV-unexposed control group (9.63 ± 2.42 days vs 11.14 ± 4.15 days; 
p = 0.022). A different scenario was found in the HIV-exposed study group, in which infants 
reached full feeds later than in the HIV-exposed control group (10.19 ± 4.055 days vs. 9.68 ± 
3.46 days p = 0.56). The initiation of enteral feeds was on similar days for both the study and 
control groups.  
Feeding volumes on Day 7 of life were significantly lower for the HIV-exposed infants who 
received probiotic supplementation than for those who did not (63.83 ± 35.42 ml/kg vs. 
78.45 ± 28.09 ml/kg; p = 0.036). The quartile range in feeding volumes for the control group 
on Day 7 ranged from 51.68 ml to 105.55 ml. This increased feeding volume was a data 
outlier, and conclusions should not be drawn from it. Except for the abovementioned feeding 
volumes on Day 7, the results show that, overall, there was no difference in feeding volumes 
between the HIV-exposed and -unexposed groups or between the study and control groups. 
In contrast to other studies,22, 23 the current study did not show a difference in feeding 
intolerance and abdominal distension between the study and control groups.  
4.4 POSTNATAL GROWTH 
This study evaluated the weight gain of premature, VLBW infants receiving probiotic 
supplementation compared to similar infants who did not receive such supplementation. The 
results indicate that the use of probiotic cultures did not affect growth outcomes for head 
Stellenbosch University  http://scholar.sun.ac.za
 
 
138 
 
circumference, length and weight in VLBW infants. These results are supported by other 
clinical trials.22, 24-26  
In contrast to what was expected, the HIV-exposed group showed significantly higher z-
scores for length and head circumference at Day 28. After ruling out all other factors that 
could have affected growth, such as gestational age, the use of mechanical ventilation and 
NEC, the question remains why this group reached better z-scores for head circumference 
and length than the HIV-unexposed infants.  
The study found no difference in the incidence of positive blood cultures; however, the HIV-
exposed group showed a lower but nonsignificant trend of positive blood cultures than the 
HIV-unexposed group. A large cohort study found that neonatal infections amongst ELBW 
infants were associated with poor growth outcomes, specifically head circumference.27 The 
current study found no relationship between maternal CD4 cell count and infant birth weight. 
The majority (75%) of HIV-positive mothers had been receiving ARV treatment for more than 
four weeks. Three of the 74 infants (incidence rate of 4%) had a confirmed HIV-positive PCR 
result and were subsequently started on HAART. The results indicate that symmetrical 
intrauterine growth restrictions (SIUGR) were more prevalent in the neonates of HIV-positive 
mothers than in their HIV-unexposed counterparts. These results are supported by other 
studies that have found that maternal HIV status has a significant effect on neonatal 
anthropometric parameters.28 Although the z-scores for length and head circumference were 
significantly higher in the HIV-exposed group, growth was nevertheless inappropriate for 
both the HIV-exposed and HIV-unexposed groups, in which infants fell below their initial z-
scores at birth.   
We could not find any evidence of the effects of ARV drug use and growth in premature 
infants. The idea was postulated that the use of these medications had an immune-
supportive effect and gave an HIV-exposed premature infant an advantage above an HIV-
unexposed premature infant who was immune suppressed. This could, however, not be 
supported by the literature.   
There was no difference in feeding volumes between the HIV-exposed and -unexposed 
groups or between the study and control groups. Feeding volumes and the timing of initiation 
of enteral feeds had no effect on growth outcomes. The HIV-exposed group showed more 
days of growth velocity and a daily weight gain more in accordance with the American 
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Academy of Pediatrics recommendation29 than the HIV-unexposed infants. Lango et al. 
could not show an association between growth velocity and HIV exposure.30 The overall 
study population of the current study showed weight gain patterns similar to those reported 
in the literature.31-33 We therefore accept the null hypothesis (see 2.4) that there is no 
difference in weight gain between probiotic-supplemented and -nonsupplemented 
premature, VLBW infants. 
4.5 POSSIBLE RISK FACTORS ASSOCIATED WITH NECROTIZING 
ENTEROCOLITIS  
The literature indicates that possible risk factors are associated with the development of 
NEC. These include prematurity,14 enteral feeding,15 growth restrictions,16 preeclampsia and 
maternal hypertensive disease,17 low Apgar scores14 and red blood cell transfusions.18 The 
study observed some of these risk factors.  
i. The results of this study indicate that the prevalence of hypertension was significantly 
higher in HIV-negative mothers compared to HIV-positive mothers (64 [58%] vs. 35 
[47%]; p = 0.002). 
ii. Three of the infants who developed NEC had red blood cell transfusions during 
clinical manifestations of NEC. Within 24 hours, NEC was confirmed and both cases 
resulted in death due to NEC. 
iii. Apgar scores at five minutes differed significantly between the probiotic and placebo 
groups among HIV-exposed infants (p = 0.042). This was, however, not relevant to 
the interpretation of the results as it was purely due to chance and the process of 
randomisation.  
iv. Although the study found no difference in the incidence of positive blood cultures, the 
HIV-exposed group showed a lower but nonsignificant trend of positive blood cultures 
compared to the HIV-unexposed group. Furthermore, the severity of NEC in the HIV-
exposed study group was less compared to the HIV-exposed control group.  
It is suggested that introducing probiotics to preterm infants might be beneficial by preventing 
overgrowth of pathogenic organisms and potentially competing with other organisms for 
binding sites and substrate in the bowel.24 The focal health-promoting effect of probiotics is 
their enhancement of mucosal immune response through increasing macrophage activity, 
elevating numbers of killer cells, T-cells and interferon, the suppression of NF-κB signalling34 
and their action against pathogenic microbial colonisation and translocation.35 Bengmark et 
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al. have proposed that probiotic administration protects the gut surface and could delay the 
progression of HIV.36 These results support the findings of Bengmark et al. and should be 
further investigated.  
4.6    SAFETY OF PROBIOTICS 
A systematic review found a benefit in a trend towards the reduction of sepsis in preterm 
infants.5 The current study showed a 5% decrease in the incidence of positive blood cultures 
between the HIV-exposed and HIV-unexposed groups, but this was not statistically 
significant (8 [11%] vs. 17 [16%]; p < 0.68). There was also a 5% decrease between the 
study group and the control group, which was not statistically significant (15 [16%] vs. 10 
[11%]; p < 0.32). These results support Deshpande et al’s finding that there is no evidence of 
a reduced risk of late-onset sepsis in premature infants.24 None of the positive blood cultures 
in the current study grew Lactobacillus or Bifidobacterium species.  
The similar incidence of positive blood cultures in the HIV-exposed and -unexposed infants 
could be the result of the feeding protocol used in the specific unit, according to which each 
infant received the mother’s own breast milk or donor breast milk. The breast milk of HIV-
positive mothers was pasteurised according to ward protocol before administration to infants. 
Breast milk is known to prevent NEC. Human milk may, however, also be a vehicle for 
transmission of microorganisms derived from the mother or the environment during 
collection. It has been found that coagulase-negative staphylococci, alpha hemolytic 
streptococci and pathogens such as Escherichia coli and others are present in 60–80% of all 
donor breast milk samples collected.37 Pasteurisation is known to decrease the number of 
pathogens present in breast milk. Therefore, it is possible that the pasteurisation of breast 
milk could have served as a protective mechanism for the HIV-exposed infants. The use of 
probiotics in VLBW and ELBW infants exposed to HIV was thus found to be safe in this 
clinical trial.  
 
4.7 OLIGOSACCHARIDE QUALITY OF HIV-INFECTED MOTHERS’ 
BREAST MILK 
Distinct differences in oligosaccharides were found between the breast milk of HIV-infected 
and HIV-uninfected mothers. A significantly higher relative abundance of 3-fucosyllactose 
(3’SL), difucosyl lacto-N-tetraose (DFLNT) and fucosyl disialyllacto-N-hexaose (FDSLNH) 
was found in the HIV-infected secretor group. Higher sialyted HMO, 3’SL in the breast milk of 
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HIV-infected mothers have previously been postulated to have pro-inflammatory effects. The 
relative abundance of the neutral oligosaccharide difucosyllacto-N-hexaose (DFLNH) was 
significantly higher in the HIV-infected nonsecretors in the first and final samples, and there 
were higher concentrations of lacto-N-neotetraose (LNnT) in the second sample. Bode et al. 
found a nonsignificant trend towards higher concentrations of LNnT (mg/L) and postpartum 
HIV transmission.38  
The HIV-uninfected secretors showed significantly higher concentrations for the neutral 
oligosaccharides 2’-fucosyllactose (2’FL), lacto-N-tetraose (LNT) and lacto-N-fucopentaose 
(LNFP I) in the first milk sample than the HIV-infected secretors. The high content 
concentrations of oligosaccharides such as LNT, LNFP I and LNDFH I in early stage 
milk/colostrum could affect the formation of bifidus flora in the infant colon significantly.39 We 
therefore reject the null hypothesis (see 2.4) as distinct differences were found in the HMO 
content of HIV-infected and HIV-uninfected mothers. Furthermore, given previously 
mentioned supporting evidence, it seems that specific oligosaccharides found in higher 
quantities in HIV-infected mothers’ breast milk may have pro-inflammatory effects that could 
potentially affect disease transmission and progression.38  
Jantscher-Krenn et al. found that DSLNT had a protective effect against the development of 
NEC in neonatal rats.40 The results of the current study indicate that DSLNT levels were 
significantly higher in the group that did not develop NEC, supporting the possibility that 
DSLNT also protects against NEC in humans. Greenhill et al. concur that DSLNT could be 
used as a biomarker to determine the preterm infant’s risk of developing NEC. We therefore 
reject the final null hypothesis (see 2.4) that an association does not exist between the 
prebiotic quality of breast milk and the incidence of NEC in premature, VLBW infants. The 
results of this study are the first to support evidence from animal studies that certain 
oligosaccharides may be markers for the occurrence of NEC.  
The findings support the relative protective value of probiotic administration to infants with 
NEC. Microbiota disturbances early in HIV infection lead to greater dominance of potential 
pathogens, reduced levels of Bifidobacteria and Lactobacillus species and increased 
mucosal inflammation.41 HMO supports the growth of these beneficial bacteria, and it is 
therefore proposed that in conjunction with the use of probiotics, HMO potentially reduces 
the risk of NEC. 
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4.8 LIMITATIONS OF THE STUDY 
There were numerous limitations to this randomised control trail. The following limitations 
occurred and could have impacted the quality of the results:  
i. Due to slow enrolment of the HIV-exposed group, the sample sizes were recalculated 
by the study statistician. A power analysis for two-way ANOVA with a power of 90% to 
detect interaction effect sizes of δ = 0.55 was calculated. Only nine infants in this 
study developed NEC. Although the statistics are significant, a small sample size of 
NEC cases precludes an overenthusiastic interpretation of the research results. Of the 
nine NEC cases that occurred within the clinical trial, only eight were included for 
HMO analysis.  
ii. Of the eight cases included in the HMO analysis three of the infants that developed 
NEC Stage I were in the probiotic group. With the randomisation patients were 
included that received probiotics, however with the very small numbers of patients 
that did develop NEC, the role of probiotics would not be valid in testing. 
iii. All infants in this study received breast milk. Although we are delighted with the very 
low incidence of NEC, the use of breast milk alone may have affected the incidence of 
NEC. An ethical dilemma exists when conducting clinical trials in which NEC is the 
measured endpoint. It is known that the use of formula milk increases the incidence of 
NEC in premature infants.  
iv. The probiotic product used in this study underwent stability tests twice during the 
study period. This was done by C Pharm, and reports were not supported by an 
independent entity. 
v. The infants’ length was measured with a nonstretchable measuring tape and not with 
a length board. This technique was used to ensure that infants were handled to the 
minimum and for infection control purposes. However, using this technique could 
have affected the accuracy of length data. 
vi. Only a subsample of breast milk samples was analysed due to financial constraints. 
Analysis of the total sample of approximately 500 breast milk samples would have 
strengthened the data. Further funding is sought to analyse these samples.  
vii. The proportionate prevalence of HIV-exposed versus HIV-unexposed infants led to 
lower patient numbers and a strenuous data collection period with financial 
constraints. 
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viii. The 28-day data collection period did lead to seven infants being discharged to other 
institutions before the end of the 28-day follow-up period.  
ix. This study had a 5% incidence of declined parental consent. HIV status remains a 
sensitive matter in South Africa. Obtaining parental consent was a time-consuming 
procedure that had to be handled with respect and sensitivity.  
x. Before the supplementation of probiotics/ placebo the investigator/ assistant washed 
her hands with an antiseptic soap and thereafter D-germ (a sterilizing spray) was 
applied. Thereafter infants received their supplementation. Medical gloves are not 
routinely used in the unit where the study was performed. However, gloves were used 
during all patient-care activities that involved exposure to blood and all other body 
fluid. Although hygienic practices were strongly adhered to during this study, stricter 
guidelines should have been in place to ensure minimal contamination risks.  
 
Furthermore, interesting results could have been obtained by means of collection of the 
following data:  
i. A secondary PCR result at a later point in time could have been used to determine 
further HIV transmission risks and links to HMO content. 
ii. Faecal sample collection and analysis of stool cultures could have provided insight 
into bacterial colonisation in HIV-exposed infants.  
iii. Cytokine profiles in an HIV-exposed infant would have been novel and could have 
presented interesting results for future studies. 
4.9 RECOMMENDATIONS 
Practical recommendations to address the specific research problem are as follows: 
i. This study found a reduced incidence of NEC (Bell’s stages II and III) in the study 
group when compared to the control group (not specific to HIV status). This study 
supports the notion that a change in practice is needed and that the use of probiotics 
is an effective method to reduce the risk of NEC in VLBW and ELBW infants in 
general and infants who are immune compromised. Many important issues need to be 
addressed, however, before accepting probiotics as a routine therapy in preterm 
neonates. 
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ii. The optimal strains, dose and duration of probiotic organisms are not clear in 
published research. It is recommended that a probiotic organism and dose that have 
previously been evaluated in a well-designed clinical trial be used. 
iii. Maturity of the host is also an important factor in colonisation by probiotic organisms. 
Very little published literature is available on the use of probiotics in infants < 1 000 g. 
In the current study, probiotics proved to be safe in this vulnerable group but due to a 
lack of data, caution should be used in these infants.  
iv. Furthermore, probiotics have been found to be safe in VLBW and ELBW infants 
exposed to HIV. This study did not show a significant difference in the incidence of 
positive blood cultures, but it is evident from the results that the HIV-exposed group 
showed a lower trend of positive blood cultures than the HIV-unexposed group. The 
safety of probiotic supplements is an important issue in preterm neonates. It is 
reassuring to know that sepsis caused by probiotic organisms has not been reported 
in any of the trials included in the systematic reviews.24 However, caution is necessary 
before adopting probiotics for prophylaxis in immunocompromised hosts such as 
preterm and HIV-exposed neonates given that the possibility of probiotic sepsis can 
never be ruled out. 
v. Other practical issues include difficulties in accessing a suitable, stable and safe 
product with recognised probiotic properties. Should the use of probiotics become 
routine practice, it is essential that probiotic products be approved by the regulatory 
agencies to ensure the safety, viability and quality of probiotic organisms available. 
vi. A large cohort study found that neonatal infections amongst ELBW infants were 
associated with poor growth outcomes, specifically head circumference.27 It is 
recommended that poor growth patterns (as seen in this study) in VLBW and ELBW 
infants be supported by early and optimal initiation of enteral feeds, the use of 
probiotics to encourage achievement of full feeds, exclusive use of breast milk, 
appropriate supplementation of breast milk and optimal infection control in neonatal 
units. 
vii. Three of the 74 infants (incidence rate of 4%) had a confirmed HIV-positive PCR 
result. Low HIV transmission rates such as these should be upheld by strict 
adherence to prevention of mother-to-child transmission (PMTCT) protocols. It is 
therefore recommended that PMTCT guidelines be upheld postnatally with feeding 
protocols that adhere to baby-friendly guidelines. Furthermore, where possible, 
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exclusive breastfeeding should be encouraged; the breast milk of HIV-infected 
mothers should be pasteurised, and ARV treatment regimens should be properly 
implemented.   
 
 
The following are recommendations for future research:  
i. Postnatal growth failure is common in the VLBW and ELBW infant. Although growth 
was suboptimal, the significant difference in head circumference and length between 
the HIV-exposed and -unexposed groups in this study remains an area for further 
investigation. The results indicate that SIUGR did not contribute to the difference in 
growth between the HIV-exposed and -unexposed groups. Prenatal maternal dietary 
and lifestyle habits, maternal and infant ARV treatment and the infant’s nutritional 
intake may be areas of study to clarify this unexpected phenomenon. Longitudinal 
studies are also recommended to assess the progress, growth and outcomes, 
including neurodevelopmental outcomes, of premature, VLBW and ELBW infants 
infected with HIV. 
ii. The literature indicates that HMO may potentially protect against postnatal HIV 
transmission.38 The results of the current study indicate that low levels of DSLNT in 
the mother’s milk increase the infant’s risk for NEC, which is in accordance with the 
results of previously published animal studies and warrants further investigation. 
Future studies should also assess HIV-transmission risk and oligosaccharide quality 
of HIV-infected women. Cytokine profiles of HIV-exposed infants compared to their 
maternal oligosaccharide breast milk content might provide interesting results.  
iii. Large clinical trials are recommended to assess the use of probiotics in HIV-exposed 
VLBW infants. Additional outcomes of these trials should include stool analysis and 
cytokine profiles of HIV-infected infants.  
iv. It is suggested that oligosaccharides found within human milk may act as specific 
substrates for assisting the growth of selected beneficial bacteria. An important 
research question that remains is the possible relationship that exists between 
probiotic supplementation and maternal HMO profiles. Future studies should assess 
the use of different probiotic cultures and maternal HMO profiles on gut colonisation.  
Stellenbosch University  http://scholar.sun.ac.za
 
 
146 
 
v. Finally, several infant formula-producing companies searched for inexpensive 
alternatives to HMO and developed mixtures of galactooligosaccharides and 
fructooligosaccharides or inulin that mimicked the prebiotic effects of HMO. Extensive 
research is needed to clarify the specific effects of these ‘artificial’ glycans and, more 
importantly, to understand the mechanisms by which HMO benefits the breastfed 
infant.   
vi. From the study results, it is clear that it would be worthwhile to further investigate the 
synbiotic effect of probiotic supplementation in infants at risk of NEC.   
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ADDENDUM A: Stability reports for Pro-B2 
 
Stability report 1:  
 
Viability count is indicated as CFU/ml. this starts at increments of 1 x 100 and raises in 
increments of power 1. Therefore the claim made by C-Pharm is is 1 x 108. The product 
remained stable during months 0-6 of the study at 25ºC.  
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Stability report 2 
 
Viability count is indicated as CFU/ml. this starts at increments of 1 x 100 and raises in 
increments of power 1. Therefore the claim made by C-Pharm is is 1 x 108. The product 
remained stable during months 6-15 of the study at 25ºC. 
Stellenbosch University  http://scholar.sun.ac.za
 
 
152 
 
 ADDENDUM B: Export permit, material transfer agreement (MTA) 
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MATERIAL TRANSFER AGREEMENT 
Between 
STELLENBOSCH UNIVERSITY (“SU”) 
Physical Address Admin. Building B 3223, Victoria Street, Stellenbosch, 7600, South Africa 
Postal Address Private Bag X1, Matieland, Stellenbosch, 7602, South Africa 
Telefax Number +27 (0)21 808 4537 
Telephone Number +27 (0)21 808 3546 
Contact Person: Contract related matters 
Manager Research Contracts:  Mrs Cornelia Malherbe  
cmalherbe@sun.ac.za 
Contact Person: Project related matters  
Email Address 
Evette van Niekerk 
evettev@sun.ac.za 
Signature 
who warrants that s/he is duly authorised to sign 
 
Name Evette van Niekerk 
Position Lecturer Therapeutic Nutrition 
Date 12/06/2012 
and 
[   ] (“Recipient”) 
Physical Address 
UCSD Dept. Of Pediatrics 
9500 Gilman Drive, MC 8450 
La Jolla, CA 92093  USA 
 
Postal Address 
UCSD Health Sciences 
Asst. Vice Chancellor 
9500 Gilman Dr. MC 0602 
La Jolla, CA 92093  USA 
Telefax Number 858.822.6691 
Telephone Number 858.822.3474 
Contact Person 
Robin Samit  -contract matters 
Lars Bode –project matters 
Email Address 
rsamit@ucsd.edu 
lbode@ucsd.edu 
Signature 
who warrants that s/he is duly authorised to sign 
 
Name Lars Bode 
Position  
Date  
 Recipient Scientist 
Facility/Laboratory Address 
UCSD Dept. Of Pediatrics 
9500 Gilman Drive, MC 8450 
La Jolla, CA 92093  USA 
Telephone Number 858.822.3474 
Email Address lbode@ucsd.edu  
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Signature 
 
Name Lars Bode 
Position  
Date  
  
Research Project title: The use of probiotics in the management of 
Necrotising Enterocolitis in HIV exposed premature and very-low birth 
weight infants 
Contract number: S002863 
Research Period: Sample analysis: Sept 2012 – February 2013 SU Ethical Clearance number: M10/09/035 
 
Material type:  
Human tissue or blood samples [  x ]; Cell components [   ]; Plants or organisms [   ]; Animals [   ]; Genetically Modified Organisms [  
] 
Bioprospecting: [ YES / NO ]                   
Use of indigenous biological resources: [ YES / NO ]    
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1 The Recipient acknowledges that the Material is confidential and proprietary to SU. The transferred 
Materials shall be used solely for non-commercial research purposes to carry out the Research 
Project (clause 15) only at the Recipient’s facility/laboratory under the direction of the Recipient’s 
Scientist. 
 
2 Legal title to the Material will remain with SU. Nothing in this Agreement: (i) grants the Recipient 
any rights over the Material (other than as specifically granted by this Agreement) or under any 
patent, plant breeders’ right or other intellectual property right, nor any right to use, or (ii) permits 
the use of any products or processes containing, using, or directly derived from the Material, for 
profit-making or commercial purposes.  
 
3 The Recipient will not make use of, or permit anyone else to make use of, the Material or a product 
directly derived from the Material for commercial purposes or for any other purposes other than for 
the Research Project without SU’s prior written consent. In such event, it agrees to negotiate in 
good faith with SU for the grant of an appropriate licence or the conclusion of a revenue sharing 
agreement, if justified. SU will have no obligation to grant a licence. 
 
4 It is expressly acknowledged and agreed by the Recipient that the Materials may not be used for 
work on humans, in clinical trials or for diagnostic purposes involving human subjects and that the 
Materials must at all times be used in accordance with all applicable laws and regulations. 
 
5 The Recipient agrees not to transfer, transmit or in any other way provide access to the Materials, 
to any third party without the written consent of SU. Such consent will not be unreasonably withheld 
if the third party is an academic research institution as long as such third party signs an equivalent 
Material Transfer Agreement with SU. Upon request by SU, the Recipient will return such of the 
Material as may be required to the SU or dispose of such Material as directed by SU and Recipient 
shall certify such disposal upon request.  
 
6 Upon request the Recipient will notify SU of the results of the Research Project and provide SU 
with samples of such results developed through the use of the Material. Neither party may register 
or apply for the registration of any intellectual property right with respect to the results of the 
Research Project (including without limitation under patent or plant breeders’ right) without the prior 
written consent of the other party. The Recipient grants SU a fully paid-up, non-exclusive right to 
use any results developed through the use of the Material transferred under this Agreement for its 
own internal, non-profit academic research and teaching purposes.  
 
7 Material delivered pursuant to this agreement by SU to the Recipient is understood to be 
experimental in nature and may have hazardous properties. SU makes no representations and 
provides no warranties of any kind, either expressed or implied by law, with respect to the Material 
or any information associated to it. In particular, SU hereby excludes and disclaims any express or 
implied warranty of reasonable quality, merchantability or fitness for a particular purpose, that the 
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Material or any information associated with it, is free from defects (latent or otherwise), or that use 
of the Material will not infringe any intellectual property right or other third party rights. 
 
8 In no event will SU or its personnel be liable to the Recipient for any direct or indirect losses or 
damages whatsoever,  arising in connection with this agreement, save to the extent that the 
limitation of liability contained herein is not permitted by applicable law.  
 
9 Risk of loss or damage to the Material will pass to the Recipient upon delivery to the transport 
carrier. The use of the Material will be at the sole and exclusive risk of the Recipient. The Recipient 
hereby indemnifies and agrees to hold SU harmless against any and all losses that may arise in 
connection with the Materials, including any loss or damage to the Material in transit. 
 
 
10 The Recipient agrees to treat all information pertaining to the Material as confidential and 
proprietary to SU, including the properties, characteristics, content and composition thereof and the 
potential uses and methods of use thereof and will not disclose any information pertaining to the 
Material to any third party without the written consent of the SU including pursuant to clause 11. 
The Recipient will also ensure that the Recipient’s Scientist and all other persons allowed to access 
the Material comply with this clause. 
 
11 SU recognises the desire of the Recipient to publish details of academic research in scientific 
journals or theses and SU agrees that the Recipient will be free to publish results of the Research 
Project, providing that SU is provided with a copy of any such manuscript or abstract at least thirty 
(30) days prior to submitting such publication to the scientific journal or to exmaminers, to give SU 
the opportunity of requesting the removal of any proprietary confidential information pertaining to 
the Material. Recipient must comply with SU’s removal requirement to the reasonable satisfaction 
of SU prior to submitting such publication. Manuscripts should be sent to SU’s technology transfer 
company, InnovUS Pty Ltd, or its Research Contracts Office, Division for Research Development, 
for review of such proprietary information content. SU agrees to maintain such results, copy of any 
such manuscript or abstract in confidence and not to engage in any written dissemination or in any 
dissemination by other methods of results obtained by Recipient from use of the Materials for the 
purpose described in Clause 6. 
 
However, this clause 11 shall not preclude either party's attribution of authorship in, and distribution 
of academic literature reporting the results of research conducted with the Materials, where 
applicable. 
 
12 The Recipient agrees to provide appropriate acknowledgement of the source of the Materials in all 
publications. Each party agrees not to use or refer to this Agreement in any promotional activity, or 
use the names or marks of the other without express written permission. 
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13 General 
 
13.1 This Agreement shall come into force on the date on which it is signed by both parties and shall 
remain in force for the duration of the Research Period, or as long as the Recipient has possession 
of the Materials if longer. 
13.2 Either the Recipient or SU may terminate this Agreement forthwith by thirty (30) days prior notice of 
termination in writing: 
13.2.1 If either party commits a material breach of this Agreement, which in the case of a breach 
capable of remedy is not remedied within thirty (30) days of the receipt by the party in default of 
notice identifying the breach and requiring its remedy, or.  
13.2.2 Termination without cause  
Upon termination of this Agreement, Recipient’s rights to use the Material will cease and Recipient will 
discontinue all use of the Material, but all other terms hereunder will continue unaffected. 
13.3 Neither party shall assign or transfer any interest in this Agreement without prior written approval of 
the other party. 
13.4 No amendment, consent or waiver of terms of this Agreement shall bind either party unless in 
writing and signed by all parties. Any such amendment, consent, or waiver shall be effective only in 
the specific instance and for the specific purpose given. 
13.5 This Agreement embodies the entire agreement between the parties hereto and no provision of this 
Agreement may be changed except by the mutual written consent of the parties hereto. 
13.6 This Agreement shall be governed by the South African Law and the South African Courts shall 
have exclusive jurisdiction to deal with any dispute which may arise out of or in connection with this 
Agreement. 
13.7 The use of South African biological resources is governed by the National Environmental 
Management Biodiversity Act, Act 10 of 2004 (NEMBA) and its associated subordinate legislation. 
To engage in any bioprospecting activity using biological material with South African origin a 
bioprospecting permit must be obtained from the Department of Environmental Affairs: 
The Director General 
Department of Environmental Affairs 
Private Bag x447 
PRETORIA 
0001 
 
Enquiries: 
The Director: Resource Use 
Mr. Muleso Kharika 
Tel: +27 12 310 3578 / 3451 
Fax: +27 12 320 4087 / 7026 
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Email: Jkharika@environment.gov.za 
www.environment.gov.za  
 
 
14 The Material 
 
This agreement concerns the following types and quantities of material to be provided to the Recipient: 
Type of Material Quantity Place of Origin Already Identified Potential Uses 
Human Breast Milk 180 Tygerberg 
Hospital. Cape 
Town South 
Africa 
Analysis of Oligosaccharides for PhD 
Study  
    
    
Material includes all progeny generated from the Material supplied and that part of all derivatives and the 
derivative’s progeny which contains any of the Material supplied or its progeny. 
 
15 The Research Project 
 
The manner in which and the extent to which the Material may be used by the Recipient are as follows: 
 
 
 
 
 
~ END ~ 
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ADDENDUM C: Data collection forms 
 
MATERNAL INFORMATION
HIV status: Pos =1 Neg=2
CD4 cell count:
PMTCT: HAART =1; TREATMENT IN LABOUR= 2; NO TREATMENT= 3
Duration PMTCT Med:
TB: YES=1; NO=2
TB treatment: YES=1; NO=2
VDRL + : YES=1; NO=2
Syphilis treated: YES=1; NO=2 Treatment completed: YES=1; NO=2
Age:
Race: BLACK=1; COLOURED=2; WHITE=3; OTHER=4 If other - Specify: 
Gravida:
Para:
Mode of delivery: NVD=1; BREECH=2; C-SECTION=3
PROM: YES=1; NO=2
Hypertension/ pre-eclampsia: YES=1; NO=2
Diabetes: Type1= 1; Type 2= 2; Gestational=3;  None=4
Antepartum haemorrhage: YES=1; NO=2
Abruptio placenta: YES=1; NO=2
Other (please state): 
Maternal antibiotics: YES=1; NO=2 Specify: 
State antibiotics: 
Maternal steroids: YES=1; NO=2
Other medication- specify: 
GENDER: Male= 1; Female=2
DOB:
APGAR: 
Birth weight: LENGTH: 
GA- dates: HEAD CIRCUMFERENCE:
GA- BALLARD:
IU GROWTH SGA=1; AGA=2; LGA=3 COMPLETE FENTON GROWTH CHART
VDRL + : YES=1; NO=2
Syphilis treatment: YES=1; NO=2
Respiratory: None:1; RDS/ HMD=2; Wet lung=3; Pneumonia=4; TTN=5; Other=6
Other - specify: 
nCPAP: YES=1; NO=2
Cardiac echo: Normal=1; PDA=2; Other=3; Not done= 4 Other -Specify:
Cranial ultrasound: YES=1; NO=2
Cranial ultrasound results: Normal=1; IVH 1/2=2; IVH 2/3=3
Chest X-ray YES=1; NO=2
Jaundice req Phototherapy: YES=1; NO=2 Total days: 
ARVs YES=1; NO=2;NOT APPLICABLE=3
Nevirapine: YES=1; NO=2 Dose: 
AZT: YES=1; NO=2 Dose: 
ARV Treatment period: 
Antibiotics from birth: YES=1; NO=2 COMPLETE DAILY MONITORING
Bloods taken at birth: YES=1; NO=2 COMPLETE INFECTION SCREENING
Surfactant YES=1; NO=2 
Antibiotics later: YES=1; NO=2 Specify: 
CRP: YES=1; NO=2 
FBC at birth: YES=1; NO=2 FBC later: YES=1; NO=2 COMPLETE INFEC SCREEN
Blood culture YES=1; NO=2 Blood culture later: YES=1; NO=2 COMPLETE INFEC SCREEN
Blood gas at birth: YES=1; NO=2 Blood gas later: YES=1; NO=2 COMPLETE INFEC SCREEN
PCR DAY 14 RESULTS Pos =1 Neg=2  COMPLETE INFECTION SCREENING
        /1min           / 5min        /10min      
   
   
   
M
ED
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A
L
   
   
   
 M
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N
   
BL
O
O
D
S
INFANT INFORMATION
PARTICIPANT NO AND CODE
ENVELOPE NO
DATE OF ENTRY INTO STUDY
M
ED
IC
A
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O
N
CONSENT FORM SIGNED: Y/N
SALIVA SAMPLE TAKEN: Y/N
G
EN
ER
EA
L
Mother's stickerInfant's sticker
   
   
   
 M
ED
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A
L
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Participant no: 
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ADDENDUM D : Fenton-Babson growth chart 17 
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ADDENDUM E: Informed consent forms (English, Afrikaans and Xhosa) 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
TITLE OF THE RESEARCH PROJECT: 
 
THE USE OF PROBIOTICS IN THE MANAGEMENT OF NECROTISING 
ENTEROCOLITIS IN HIV EXPOSED PREMATURE AND VERY-LOW BIRTH WEIGHT 
INFANTS  
 
 
REFERENCE NUMBER: M10/09/035 
 
PRINCIPAL INVESTIGATOR: MISS EVETTE VENTER/ van Niekerk 
 
ADDRESS:  
DIVISION OF HUMAN NUTRITION 
TYGERBERG CAPMUS 
THIRD FLOOR 
TYGERBERG 
7505 
 
CONTACT NUMBER: 
WORK:  021 938 9474 
CELL: 084 941 3832 
 
 
1. INVITATION 
 
You are being invited to take part in a research project.  Please take some time to read 
the information presented here, which will explain the details of this project.  Please ask 
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the study staff or doctor any questions about any part of this project that you do not fully 
understand.  It is very important that you are fully satisfied that you clearly understand 
what this research entails and how you could be involved.  Also, your participation is 
entirely voluntary and you are free to decline to participate.  If you say no, this will not 
affect you or your baby in any way whatsoever.  You are also free to withdraw from the 
study at any point, even if you do agree to take part. 
 
This study has been approved by the Human Research Ethics Committee at 
Stellenbosch University and will be conducted according to the ethical guidelines and 
principles of the international Declaration of Helsinki, South African Guidelines for Good 
Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines for 
Research. 
 
 
WHAT IS THIS RESEARCH STUDY ALL ABOUT? 
Five to ten percent of babies born before 8 months suddenly develop a condition called 
necrotising enterocolitis. It is a very serious condition where large parts of the bowel 
may die and for which the baby may require surgery to remove dead bowel. The exact 
cause of this condition in babies born too early is not clear but we do know that it is 
more common in premature babies who receive formula milk or where there are certain 
germs present in the baby’s intestines. It is also more common in premature babies 
born to mothers who are HIV+. The antiretroviral medication that mothers use and the 
HIV infection itself might increase the risk.  Breast milk stimulates the growth of “good” 
germs in the gut or intestines of babies. Studies have shown that the “good” germs in 
breast milk may protect the gut of a small premature baby against necrotising 
enterocolitis. These so-called “good” germs can be added to breast milk of a mother in 
order to grow in the babies bowel and to prevent “bad” germs causing damage to the 
gut. The live “good” germs that we want to add to your breast milk are called Probiotics. 
In this study we want to see if the “good” germs will help to protect your baby against 
developing necrotising enterocolitis.  
Stellenbosch University  http://scholar.sun.ac.za
 
 
167 
 
 
Babies who are born very early are admitted to Ward G2 in Tygerberg Children’s 
Hospital. Very small premature babies who weigh less than 1250g born to mothers who 
are HIV+ or HIV- will take part in the study. Probiotics (“good” germs) will be given to 
half of the babies in the study for the first 28days. The other half of the babies will 
receive a product that looks similar but with no added bacteria (“good” germs).  
With this study we want to determine if Probiotics (“good” germs) will: 
 help prevent a baby from getting necrotising enterocolitis 
 result in shorter hospitalisation 
 improve the daily weight gain  
This study also wants to determine whether there are differences in the composition 
of breast milk of HIV+ and HIV- women 
 
HOW WILL YOU AND YOUR BABY PARTICIPATE IN THE STUDY? 
If your baby has a birth weight lower than 1250g your baby will be admitted to Ward G2 
while you will be admitted to Ward J5 or J2. We will visit you in the ward after the birth 
of your baby to explain the study to you and to invite you and your baby to participate in 
the study. We will give you a letter which explains the study and if you agree to 
participate, you must consent.  Within a few days after the birth of your baby, you will be 
transferred to stay with your baby in ward G2. Once the baby is bigger, you and your 
baby will be transferred to ward G8 in Tygerberg Children’s Hospital where you will stay 
until your baby is ready to be transferred to another hospital where you will remain until 
your baby weighs more than 1800g and is ready to go home. 
The babies will be divided into two Groups; for the one group Probiotics will be given 
and for the other group a placebo will be given. The placebo looks the same as the 
Probiotic but has none of the “good” germs inside.   
Babies will be in the study for the first 28 days after birth.  
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WHAT WILL HAPPEN TO ME IF I DO TAKE PART? 
Small premature babies are too weak to suckle on the breast. The mother has to 
express milk from her breast which is then given to the baby by means of a thin plastic 
tube that goes from the baby’s mouth to the baby’s stomach. The nurses in G2 baby 
ward will teach you how to express breast milk for your baby. As part of the study, we 
want to measure the quality of some of the components in your breast milk. The most 
important one is oligosaccharride which also helps to protect your baby against 
infection. We will therefore need a 5-10ml sample of your breast milk at specific times. 
The first milk sample we will need from you is on day 4 of life, then on day 10 and again 
on day 28 of life. These 3 milk samples will be frozen before being tested in the 
laboratory. A saliva sample of 2ml will also be needed from you. The sample will be 
collected in a sterile container.  After informed consent is given by you the saliva sample 
will be taken. Only one saliva sample will be needed. The composition of your saliva 
affects the oligosaccharide content of your breast milk. The saliva samples will be 
frozen before being tested in the laboratory.  
Information from your hospital file will be used in the study such as how your baby was 
delivered, what medications you received during your pregnancy, etc. All pregnant 
women in the Western Cape are tested for HIV during pregnancy. As it is important for 
us to know your HIV status, we will obtain your HIV status from your hospital folder.  
 
What will happen to the baby if I give consent?  
Small babies are weighed every day to see if they are getting enough milk. Your baby 
will be weighed daily and his/her length and head size will be measured weekly.  
The study group (the babies that will receive the Probiotics) will receive 5 Probiotic 
drops per mouth once daily, for 4 weeks (28 days). The control group (the babies that 
will receive the placebo without the “good” germs) will receive 5 placebo drops per 
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mouth once daily, for 4 weeks (28 days). Your baby’s folder will be read by the 
researcher every day and the results of laboratory tests will be recorded.  
 
WHY HAVE YOU BEEN INVITED TO PARTICIPATE? 
You have been chosen because you gave birth to a very small baby that was born too 
early, and was admitted to ward G2 at Tygerberg Children’s Hospital (TCH) and you are 
able to express a sample of breast milk.  
 
WHAT WILL YOUR RESPONSIBILITIES BE? 
You will be responsible for expressing milk every day for your baby. On days 4, 10 and 
28. 5ml - 10ml of the breast milk expressed by you, will be frozen and taken to the 
laboratory. A saliva sample of 2ml will also be needed from you. The saliva samples will 
be frozen before being tested in the laboratory. 
 
WILL YOU BENEFIT FROM TAKING PART IN THIS RESEARCH? 
You will benefit from the knowledge that you were a valuable contributor in providing the 
medical team with important information that might help them in their search for the best 
way of feeding “early born” and very small babies and to help prevent necrotising 
enterocolitis. 
 
ARE THERE ANY RISKS INVOLVED IN TAKING PART IN THIS RESEARCH? 
Your baby will be treated exactly the same as any of the other small babies admitted to 
ward G2 at Tygerberg Children’s Hospital. Some of the babies will have Probiotics and 
others will receive a placebo (without the “good” germs). All of the babies (those 
Stellenbosch University  http://scholar.sun.ac.za
 
 
170 
 
receiving the Probiotics and those who receive placebo) will be monitored for signs of 
infection. Babies will be removed from the study should the following happen:  
If the baby does not take any breast milk by mouth for more than 3 days and requires 
the use of special food  
If the baby develops necrotising enterocolitis   
If the baby develops diarrhoea (runny stomach) 
If the baby develops a blood infection from the Probiotics. The risk of developing a 
blood infection from the ‘good” germs is very low. 
 
IF YOU DO NOT AGREE TO TAKE PART, WHAT ALTERNATIVES DO YOU HAVE? 
It is your decision whether you would like to take part or not. If you decide not to take 
part in the study it will not affect the care given to your baby. Furthermore you are free 
to withdraw at any point without explanation or any negative consequences. Your and 
your baby’s routine health care will not be negatively affected 
 
WHO WILL HAVE ACCESS TO YOUR MEDICAL RECORDS? 
Only the researcher, research assistant and persons directly associated with the study 
will have access to your medical records. All information will always be kept confidential.  
The milk samples sent to the laboratory cannot be traced back to you, because your 
name will not be put on any of your milk samples. Only the researcher and research 
assistant will know which milk sample belongs to which mother. The researcher and 
research assistant will treat all information gathered as strictly confidential and no 
information that can indentify you or your baby will be released to any person who is not 
not directly associated with the study.  
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The information obtained/collected will be handled with complete confidentiality and 
anonymity, but will be published in scientific journals and presented at congresses. 
Under no circumstances will your or your baby’s name be revealed.  
 
WHAT WILL HAPPEN IN THE UNLIKELY EVENT OF SOME FORM INJURY 
OCCURRING AS A DIRECT RESULT OF YOUR TAKING PART IN THIS RESEARCH 
STUDY? 
It is unlikely that something will go wrong. If you are not able to express milk at the 
planned collection time, you can try to express milk again later. The researcher will 
inform you of the next appropriate time to express the breast milk. Throughout the study 
standard procedures will be used, thus making the chances that something goes wrong, 
very slim.  
 
WILL YOU BE PAID TO TAKE PART IN THIS STUDY AND ARE THERE ANY 
COSTS INVOLVED? 
No you will not be paid to participate in the study. There will be no costs involved for 
you, if you do participate. 
 
 WHAT HAPPENS WHEN THE RESEARCH STUDY STOPS? 
The information obtained from the study will be published in medical journals. 
 
WHAT IF NEW INFORMATION BECOMES AVAILABLE? 
Sometimes during the course of a research project, new information becomes available 
about the topic that is being studied. If this happens, your researcher will tell you about 
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it and discuss with you whether you want to continue the study. If you decide to 
withdraw, the standard of care that you and your baby receive will not be affected. If you 
decide to continue in the study you will be requested to sign an updated consent form. 
The relevant information that arises during the course of the study will be incorporated 
into documentation where appropriate. 
 
IS THERE ANYTHING ELSE THAT YOU SHOULD KNOW OR DO? 
You can contact Miss Evette Venter at tel 021 938 9474/ 084 941 3832 if you have any 
further queries or encounter any problems. 
You can contact the Committee for Human Research at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by the researchers. 
 
You will receive a copy of this information and consent form for your own records. 
 
Declaration by participant 
 
By signing below, I …………………………………..………..........................…. agree to 
take part in a research study entitled THE USE OF PROBIOTICS IN THE 
MANAGEMENT OF NECROTISING ENTEROCOLITIS IN HIV EXPOSED 
PREMATURE AND VERY-LOW BIRTH WEIGHT INFANTS  
 
I also give consent that my baby ……………………………....................................may 
take part in a research study entitled THE USE OF PROBIOTICS IN THE 
MANAGEMENT OF NECROTISING ENTEROCOLITIS IN HIV EXPOSED 
PREMATURE AND VERY-LOW BIRTH WEIGHT INFANTS  
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I declare that: 
I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
I have had a chance to ask questions and all my questions have been adequately 
answered. 
I understand that taking part in this study is voluntary and I have not been pressurised 
to take part. 
I may choose to leave the study at any time and will not be penalised or prejudiced in 
any way. 
I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as agreed 
to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2011. 
 
 
 ..............................................................   ............................................................  
Signature of participant Signature of witness 
 
Declaration by researcher 
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I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
 I am satisfied that he/she adequately understands all aspects of the research, 
as discussed above 
 I did/did not use a interpreter.  (If a interpreter is used then the interpreter 
must sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2011 
 
 
 
 ..............................................................   ............................................................  
Signature of investigator Signature of witness 
 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to 
explain the information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa. 
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 We encouraged him/her to ask questions and took adequate time to answer 
them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question satisfactorily 
answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……………….. 
 
 
 ..............................................................   ............................................................  
Signature of interpreter Signature of witness 
 
 
 
 
 
DEELNEMERINLIGTINGSBLAD EN -TOESTEMMINGSVORM 
TITEL VAN DIE NAVORSINGSPROJEK: DIE GEBRUIK VAN PROBIOTIKA IN DIE 
BEHANDERLING VAN NEKROTISERENDE ENTEROKOLITIS IN MIV 
BLOOTGESTELDE PREMATUUR EN BAIE-LAE GEBOORTE MASSA BABAS. 
 
VERWYSINGSNOMMER: M10/09/035 
HOOFNAVORSER: MEJ EVETTE VENTER/ van Niekerk 
ADRES: 
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AFDELING MENSLIKE VOEDING 
TYGERBERG KAMPUS 
VLOER 3 
TYGERBERG 
7505 
 
KONTAKNOMMER: 
WERK: 021 938 9474 
CELL: 084 941 3832 
 
UITNODIGING 
U word genooi om deel te neem aan ’n navorsingsprojek. Lees asseblief hierdie 
inligtingsblad op u tyd deur aangesien die detail van die navorsingsprojek daarin 
verduidelik word. Indien daar enige deel van die navorsingsprojek is wat u nie ten volle 
verstaan nie, is u welkom om die navorsingspersoneel of dokter daaroor uit te vra. Dit is 
baie belangrik dat u ten volle moet verstaan wat die navorsingsprojek behels en hoe u 
daarby betrokke kan wees. U deelname is ook volkome vrywillig en dit staan u vry om 
deelname te weier. U sal op geen wyse hoegenaamd negatief beïnvloed word indien u 
sou weier om deel te neem nie. U mag ook te eniger tyd aan die navorsingsprojek 
onttrek, selfs al het u ingestem om deel te neem. 
 
Hierdie navorsingsprojek is deur die Menslike Navorsing Etiek Komitee van die 
Universiteit Stellenbosch goedgekeur en sal uitgevoer word volgens die etiese riglyne 
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en beginsels van die Internasionale Verklaring van Helsinki en die Etiese Riglyne vir 
Navorsing van die Mediese Navorsingsraad (MNR). 
 
WAT BEHELS HIERDIE NAVORSINGSPROJEK? 
Vyf tot tien persent van babas wat gebore is voor 8 maande ontwikkel skielik 'n toestand 
genaamd nekrotiserende enterokolitis. Dit is 'n baie ernstige toestand waar groot dele 
van die derm kan sterf en waarvoor chirurgie vereis mag word om die dooie derm te 
verwyder. Dit is nie duidelik wat die presiese oorsaak van hierdie toestand in die babas 
wat te vroeg gebore is nie, maar ons weet dat dit meer algemeen in premature babas is 
wat ŉ melkformule ontvang of waar daar sekere kieme teenwoordig is in die baba se 
ingewande. Dit is ook meer algemeen in premature babas van moeders wat MIV+ is. 
Die antiretrovirale medikasie wat moeders gebruik en die MIV-infeksie self kan die risiko 
verhoog. Borsmelk stimuleer die groei van "goeie" kieme in die derm of ingewande van 
babas. Studies het getoon dat die "goeie" kieme in borsmelk kan die derm van 'n klein 
premature baba beskerm teen nekrotiserende enterokolitis. Hierdie sogenaamde 
"goeie" kieme kan bygevoeg word in die bors melk van 'n moeder om in die baba se 
derm te groei en om die "slegte" kieme wat skade aan die ingewande veroorsaak te 
voorkom. Hierdie lewende "goeie" kieme wat ons vir die babas wil gee word Probiotika 
genoem. In hierdie studie wil ons sien of die "goeie" kieme sal help om jou baba te 
beskerm teen die ontwikkeling van nekrotiserende enterokolitis 
 
Babas wat baie vroeg gebore word sal toegelaat word tot Saal G2 in Tygerberg Kinder  
Hospitaal. Baie klein premature babas wat minder as 1250g weeg met moeders wat 
MIV + of HIV- is sal deel neem in die studie. Probiotika ("goeie" kieme) sal gegee word 
aan die helfte van die babas in die studie vir die eerste 28 dae. Die ander helfte van die 
babas sal 'n produk ontvang wat soortgelyk lyk, maar dit het geen bygevoeg bakterieë 
("goeie" kieme) nie.                                      
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Met hierdie studie wil ons bepaal of Probiotika ("goeie" kieme) sal:  
• help verhoed dat 'n baba nekrotiserende enterokolitis kry  
• lei tot ŉ korter hospitalisasie tydperk 
• lei tot die verbetering van die daaglikse gewigstoename  
Hierdie studie wil ook bepaal of daar verskille in die samestelling van borsmelk van  MIV 
+ en MIV- vroue is.  
 
Hoe sal jy en jou baba aan die studie deelneem? 
As jou baba het 'n geboorte gewig laer as 1250g het sal jou baba toegelaat word tot 
Saal G2 terwyl jy sal toegelaat word tot Saal J5 of J2. Ons gaan julle in die saal besoek 
ná die geboorte van jou baba om die studie te verduidelik aan jou en vir jou en jou baba 
uit te nooi om deel te neem aan die studie. Ons sal vir jou ŉ brief gee wat die studie 
verduidelik en as jy besluit om deel te neem, moet jy toestemming gee. Binne 'n paar 
dae na die geboorte van jou baba, sal jy oorgeplaas word om by jou baba te bly in Saal 
G2. Sodra die baba groter is, sal jy en jou baba oorgeplaas word na G8 in Tygerberg 
Kinder Hospitaal waar jy sal bly totdat jy jou baba gereed is om oorgeplaas te word na 
'n ander hospitaal waar jy sal bly totdat jy jou baba meer as 1800g weeg en gereed is 
om huis toe gaan. 
 
Die babas sal verdeel word in twee groepe; vir die een groep sal Probiotika gegee word 
en vir die ander groep sal 'n plasebo sal gegee word. Die plasebo lyk dieselfde as die 
Probiotika, maar bevat nie van die "goeie" kieme nie.  
Babas sal in die studie wees vir die eerste 28 dae na geboorte.  
 
Wat sal gebeur met my as ek deel te neem?   
Klein premature babas is te swak om te drink aan die bors. Die ma moet haar bors 
uitmelk en die melk word dan aan die baba gegee deur middel van 'n dun plastiese pyp 
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wat strek vanaf die baba se mond na die baba se maag. Die verpleegsters in Saal G2 
sal jou leer om jou borsmelk uit te melk vir jou baba. As deel van die studie, wil ons die 
gehalte van sommige van die komponente in jou borsmelk meet. Die belangrikste een is 
oligosakkariede wat ook help om jou baba te beskerm teen infeksies. Ons sal dus 'n 5-
10ml monster van jou bors melk benodig op spesifieke tye.  
 
Die eerste melk monster word van jou benodig op dag 4 van die laktasie, dan op dag 10 
en weer op dag 28 van die baba se lewe. Hierdie 3 melkmonsters sal gevries word 
voordat dit getoets word in die laboratorium. 'n Speeksel monster van 2ml sal ook van 
jou benodig word. Die monster sal geneem word in 'n steriele houer. Nadat jy ingeligte 
toestemming gegee het, sal die speeksel monster geneem word. Slegs een speeksel 
monster sal nodig wees. Die samestelling van jou speeksel affekteer die oligosakkaried 
inhoud van jou borsmelk. Die speeksel monsters sal gevries word voordat dit getoets 
word in die laboratorium. 
 
Inligting van jou hospitaal lêer sal gebruik word in die studie. Dit sluit in: inligting van die 
geboorte, medisyne wat jy ontvang het tydens jou swangerskap, ens. Alle swanger 
vroue in die Wes-Kaap word vir MIV getoets tydens swangerskap. Aangesien dit 
belangrik is vir ons om jou MIV status te weet, sal ons jou MIV status verkry van jou 
hospitaal lêer. 
 
Wat sal gebeur met die baba, as ek toestemming gee?  
Klein babas word elke dag geweeg om te sien of hulle genoeg melk kry. Jou baba sal 
daagliks geweeg word en sy/haar lengte en kop omtrek sal weekliks gemeet word. 
Die studie groep (die babas wat die Probiotika ontvang) sal een keer per dag, vir 4 
weke (28 dae), 5 druppels Probiotika per mond ontvang. Die kontrole groep (die babas 
wat die plasebo ontvang sonder die "goeie" kieme) sal een keer per dag, vir 4 weke (28 
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dae), 5 druppels plasebo per mond ontvang. Jou baba se lêer sal elke dag deur die 
navorser gelees word en die resultate van laboratoriumtoetse sal aangeteken word. 
 
3. WAAROM IS U UITGENOOI OM DEEL TE NEEM? 
Jy is gekies omdat jy geboorte geskenk het aan 'n baie klein baba wat te vroeg gebore 
is en opgeneem is in Saal G2 van Tygerberg Kinder Hospitaal. Jy is ook in staat om ŉ 
monster van jou borsmelk uit te melk.  
 
4. WAT SAL JOU VERANTWOORDELIKHEDE WEES?  
Jy sal elke dag verantwoordelik wees vir die uitmelk van jou borsmelk vir jou baba. Op 
dae 4, 10 en 28 sal ŉ monster van 5 – 10ml van die borsmelk uitgemelk word deur jou, 
dit sal gevries word en na die laboratorium geneem word. 'n Speeksel monster van 2ml 
sal ook van jou benodig word. Die speeksel monsters sal gevries word voordat dit 
getoets word in die laboratorium. 
5. SAL U VOORDEEL TREK DEUR DEEL TE NEEM AAN HIERDIE NAVORSING? 
Jy sal voordeel trek uit die wete dat jy 'n waardevolle bydrae gelewer het deur die 
verskaffing van belangrike inligting aan die mediese span wat hulle kan help in hul 
soeke na die beste manier om "vroeë gebore" en baie klein babas te voed en om 
nekrotiserende enterokolitis te voorkom.  
 
6. IS DAAR ENIGE RISIKO'S BETROKKE DEUR DEEL TE NEEM AAN HIERDIE 
NAVORSING?  
Jou baba sal presies dieselfde behandel word as enige van die ander klein babas wat 
toegelaat word in Saal G2 van Tygerberg Kinder Hospitaal. Sommige van die babas sal 
Probiotika kry en ander sal 'n plasebo (sonder die "goeie" kieme) ontvang. Al die babas 
(die wat Probiotika ontvang en diegene wat plasebo ontvang) sal gemonitor word vir 
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tekens van infeksie. Babas sal verwyder word van die studie indien die volgende 
gebeur:  
As die baba nie borsmelk per mond vir meer as 3 dae kan inneem nie en die gebruik 
van spesiale kos nodig het  
As die baba nekrotiserende enterokolitis ontwikkel 
As die baba diarree (loopmaag) ontwikkel 
As die baba 'n bloed-infeksie ontwikkel van die Probiotika. Die risiko van die 
ontwikkeling van 'n bloed-infeksie as gevolg van die "goeie" bakterieë is baie laag. 
7. WATTER ALTERNATIEWE IS DAAR INDIEN U NIE INSTEM OM DEEL TE NEEM 
NIE?  
Dit is jou besluit of jy wil deelneem of nie. As jy besluit om nie deel te neem aan die 
studie nie dit sal geen invloed op die versorging van jou baba hê nie. Verder is jy vry om 
te onttrek op enige stadium sonder enige verduideliking of enige negatiewe gevolge. 
Jou en jou baba se roetine gesondheidsorg sal nie negatief geaffekteer word nie.  
 
8. WIE SAL TOEGANG HÊ TOT JOU MEDIESE REKORDS?  
Slegs die navorser, navorsingsassistent en die persone wat direkte verband het met die 
studie sal toegang hê tot jou mediese rekords. Alle inligting sal altyd vertroulik gehou 
word. Die melk monsters wat na die laboratorium gestuur word kan nie terug gespoor 
word na jou toe nie want jou naam sal nie op enige van jou melk monsters gesit word 
nie. Slegs die navorser en navorsing assistent sal weet watter melk monster behoort 
aan wat moeder. Die navorser en navorsing assistent sal alle inligting wat versamel 
word as streng vertroulik hanteer en geen inligting wat jou of jou baba kan identifiseer 
sal vrygestel word aan enige persoon wat nie direkte verband het met die studie nie.  
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Die inligting wat verkry is/ingesamel word sal hanteer word met volle vertroulikheid en 
anonimiteit maar dit sal gepubliseer word in wetenskaplike tydskrifte en by kongresse 
voorgedra word. Jou of jou baba se naam sal onder geen omstandighede bekend 
gemaak word nie. 
 
9. WAT SAL GEBEUR IN DIE ONWAARSKYNLIKE GEVAL VAN ’N BESERING WAT 
MAG VOORKOM AS GEVOLG VAN U DEELNAME AAN HIERDIE 
NAVORSINGSPROJEK? 
Dit is onwaarskynlik dat daar iets verkeerds sal gaan. As jy nie in staat om uit te melk 
teen die beplande versameling tyd nie, kan jy later weer probeer om uit te melk te. Die 
navorser sal u inlig oor die volgende gepaste tyd om die borsmelk uit te melk. 
Standaard prosedures sal regdeur die studie gebruik word, wat die kanse dat iets 
verkeerd loop baie skraal maak.  
 
 
 
10. SAL U BETAAL WORD VIR DEELNAME AAN DIE NAVORSINGSPROJEK EN IS 
DAAR ENIGE KOSTE VERBONDE AAN DEELNAME?  
Nee, jy sal nie betaal word om deel te neem aan die studie nie. Daar sal geen kostes 
aan jou verbonde wees indien jy deel te neem nie.   
 
11. WAT GEBEUR WANNEER DIE NAVORSING PROJEK EINDIG? 
Die inligting verkry uit die studie sal gepubliseer word in mediese joernale. 
 
12. WAT GEBEUR AS DAAR NUWE INLIGTING BESKIKBAAR RAAK? 
Soms in die loop van 'n navorsingsprojek, kan nuwe inligting beskikbaar raak oor die 
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onderwerp wat bestudeer word. As dit gebeur, sal jou navorser vir jou vertel daaroor en 
met jou bespreek of jy wil voortgaan met die studie. As jy besluit om te onttrek, sal die 
standaard van die versorging wat jy en jou baba ontvang nie geaffekteer word nie. As jy 
besluit om voort te gaan in die studie sal jy versoek word om 'n opgedateerde 
toestemming vorm te onderteken. Die relevante inligting wat ontstaan in die loop van 
die studie sal opgeneem word in dokumentasie waar van toepassing 
13. IS DAAR ENIGIETS ANDERS WAT U MOET WEET OF DOEN? 
Jy kan gerus vir Mej Evette Venter bel by tel 021 938 9474 / 084 941 3832 indien u 
enige verdere navrae of enige probleme ondervind. 
Jy kan die Menslike Navorsing Etiek Komitee by 021-938 9207 kontak indien u enige 
probleme of klagtes het wat nie voldoende aangespreek word deur die navorsers nie. 
 
U sal ’n afskrif van hierdie inligting- en toestemmingsvorm ontvang vir u eie rekords. 
Verklaring deur deelnemer 
 
Met die ondertekening van hierdie dokument onderneem ek, 
…….....................……….....……...……….., om deel te neem aan ’n navorsingsprojek 
getiteld DIE GEBRUIK VAN PROBIOTIKA IN DIE BEHANDERLING VAN 
NEKROTISERENDE ENTERO KOLITIS IN MIV BLOOTGESTELDE PREMATUUR EN 
BAIE-LAE GEBOORTE MASSA BABAS. 
 
Ek gee ook toestemming dat my baba 
……………………………....................................mag deelneem aan ’n navorsingsprojek 
getiteld DIE GEBRUIK VAN PROBIOTIKA IN DIE BEHANDERLING VAN 
NEKROTISERENDE ENTERO KOLITIS IN MIV BLOOTGESTELDE PREMATUUR EN 
BAIE-LAE GEBOORTE MASSA BABAS. 
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Ek verklaar dat: 
Ek hierdie inligting- en toestemmingsvorm gelees het of aan my laat voorlees het en dat 
dit in ’n taal geskryf is waarin ek vaardig en gemaklik mee is. 
Ek geleentheid gehad het om vrae te stel en dat al my vrae bevredigend beantwoord is. 
Ek verstaan dat deelname aan hierdie navorsingsprojek vrywillig is en dat daar geen 
druk op my geplaas is om deel te neem nie. 
Ek te eniger tyd aan die navorsingsprojek mag onttrek en dat ek nie op enige wyse 
daardeur benadeel sal word nie. 
Ek gevra mag word om van die navorsingsprojek te onttrek voordat dit afgehandel is 
indien die studiedokter of navorser van oordeel is dat dit in my beste belang is, of indien 
ek nie die ooreengekome navorsingsplan volg nie. 
 
 
 
 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2011. 
 
 
    
Handtekening van deelnemer Handtekening van getuie 
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Verklaring deur navorser 
 
Ek (naam) …………………………………...……………… verklaar dat: 
 
Ek die inligting in hierdie dokument verduidelik het aan 
…………………….............................................……….. 
Ek hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik het om dit te 
beantwoord. 
Ek tevrede is dat hy/sy al die aspekte van die navorsingsprojek soos hierbo bespreek, 
voldoende verstaan. 
Ek ’n tolk gebruik het/nie ’n tolk gebruik het nie.  (Indien ’n tolk gebruik is, moet die tolk 
die onderstaande verklaring teken.) 
 
 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2011. 
 
 
 
    
Handtekening van navorder Handtekening van getuie 
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Verklaring deur tolk 
 
Ek (naam) …………………………………...……………… verklaar dat: 
 
Ek die navorser (naam) ……….............................…………………. bygestaan het om die 
inligting in hierdie dokument in Afrikaans/Xhosa aan (naam van deelnemer) 
……………………………......................... te verduidelik. 
Ons hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik het om dit te 
beantwoord. 
Ek ’n feitelik korrekte weergawe oorgedra het van wat aan my vertel is. 
Ek tevrede is dat die deelnemer die inhoud van hierdie dokument ten volle verstaan en 
dat al sy/haar vrae bevredigend beantwoord is. 
 
 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2011. 
 
 
 
    
Handtekening van tolk Handtekening van getuie 
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ISIMEMO 
Uyamenywa ukuba uthathe inxaxheba kwiprojekti yophando.  Nceda uthathe ixeshana 
ufunde lenkcazelo ebhaliweyo apha, eyakuthi ikucacisele ngenkcukacha zale projekti.  
Nceda buza kumsebenzi wesisifundo okanye ugqirha nawuphina umbuzo nangayiphina 
indawo ongayiqondiyo.  Kubalulekile ukuba uqonde ngokupheleleyo kwaye waneliseke 
ukuba oluphando lungantonina nendlela onokuthi ubandakanyeke ngayo wena.  
Kwakhona, ukuthatha inxaxheba akusosinyanzeliso kwaphela yaye uvumelekile 
ukuba ungavumi ukuthatha inxaxheba.  Ukuba uthi hayi, lonto ayizokucaphazela wena 
nomntwana nangayiphina indlela.  Uvumelekile ukuba urhoxe koluphando nangaliphina 
ixesha nokuba ubusele uvumile ukuthatha inxaxheba. 
Oluphando luvunyiwe yiKomiti yezophando zoluntu nemimiselo (ethics)  kwiYunivesithi 
yase Stellenbosch yaye luza kuqhutywa ngokwemigaqo yophando olwamkelekileyo 
kwisaziso sehlabathi saseHelsinki, nemigaqo yoMzantsi Afrika yophando 
olwamkelekileyo kwakunye nemigaqo yophando olwamkelekileyo lweMedical Research 
Council (MRC). 
 
OLUPHANDO LUNGANTONI KANYE? 
Isihlanu ukuya kwishumi lepesenti zabantwana abazalwe phambi kwnyanga ezisibhozo, 
ngesaquphe baye baphuhle imeko ekuthiwa kukufa kwamathumbu ( necrotising 
enterocolitis). Le yimeko enxunguphalisayo kakhulu apho amalungu amakhulu  
emathunjini  athi afe kunyanzeleke ukuba umntwana afumane uqhaqho ukususa 
elithumbu lifileyo. Eyonanto eyenziwa yilemeko ebantwaneni abazalwe phambi 
kwexesha ayicacanga ncam kodwa siyazi ukuba ixhaphakile kubantwana abazalwe 
phambi kwexesha abafumana ubisi lwabantwana olusezitotini okanye apho kukho 
intsholongwane zithile ezikhoyo emathumjini omntwana. Kwaye ikwaninzi kubantwana 
abazalwe phambi kwexesha bezalwa ngabazali aba HIV+.  Amachiza okunyanga abathi 
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omama bawasebenzise kunye nokosuleleka yintsholongwane ka gawulayo 
ingawenyusa amathuba okuba semngciphekweni.  Ubisi lwebele  lukhuthaza ukukhula 
kwe ntsholongwane ezilungileyo emathunjini omntwana. Izifundo zibonakalisa ukuba 
intsholongwane ezilungileyo ebisini lwebele zingakhusela amathumbu omntwana 
omcinci ozalwe phambi kwexesha kwesi sifo. (necrotising enterocolitis). 
Ezintsholongwane zibizwa ngokuba zilungile zingafakwa kubisi lwebele lukamama 
ukwenzela zikhule ethunjini lomntwana kwaye zinqande intsholongwane 
ezingalunganga zingenzi umonakalo ethunjini.  Ezintsholongwane zilungileyo zihleliyo 
esifuna ukuzinika iintsana zibizwa ngokuba zi (Probiotics). Koluphando sifuna ukubona 
ukuba ezintsholongwane zilungileyo zingamkhusela na  umntwana angabi safunyanwa 
sesisifo sethumbu elifayo (necrotising enterocolitis).  
 
Abantwana abazalwa phambi kwexesha balaliswa kwi Ward G2 e Tygerberg Children’s 
Hospital. Abantwana abancinci kakhulu bezalwe phambi kwexesha abangumlinganiselo 
ongaphantsi kwe 1250g bezalwa ngomama abanentsholongwane kagawulayo ( HIV+) 
okanye (HIV-) bayakuthatha inxaxheba koluphando. Probiotics (Intsholongwane 
ezilungileyo) ziyakufakwa kwisiqingatha sabantwana abakoluphando intsuku zokuqala 
ebomini eziyi 28. Esinye isiqingatha sabantwana sakufumana into ekhangeleka ifana 
nezi Probiotics kodwa yona ingenazo ezintsholongwane zilungileyo.  
Ngoluphando sifuna ukubona ukuba ingaba iProbiotics (intsholongwane ezilungileyo) 
ziya:: 
Kunceda  ekukhuseleni abantwana bangafunyanwa sisifo sokufa kwamathumbu 
(necrotising enterocolitis),  
Baya kulaliswa ixesha elifutshane esibhedlele. 
 Ukuba ubunzima bomzimba bungcono mihla le.  
Oluphando lufuna nokuqonda ukuba kukho umahluko na kwizinga lobisi lomama 
onentsholongwane yeHIV nongenayo.  
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Wena nomntwana wakho niyakuyithatha njani inxaxheba koluphando 
Ukuba umntwana wakho unobunzima obungaphantsi kwe 1250g umntwana wakho 
uyakulaliswa kwa Ward G2 ngaxeshanye wena ulaliswe kwa Ward J5 okanye kwa J2. 
Siyakundwendwela ewadini emva kokuzalwa komntwana wakho sicacise oluphando 
kuwe yaye sikumeme  wena nomntwana wakho nithathe inxaxheba koluphando. Siza 
kunika ileta eyakuthi icacise oluphando yaye ukuba uyavuma ukuthatha inxaxheba, 
kufuneka wenze isivumelwano.  Ngentsuku ezimbalwa emva kokuzalwa komntwana 
wakho, uyakutshintshwa ukuba uyokuhlala nomntwana wakho kwaward G2. Nje ukuba 
umntwana akhule, wena nomntwana wakho niyakuthi nithunyelwe kwaward G8 e 
Tygerberg Children’s Hospital apho niya kuhlala kude kube umntwana wakho 
ukulungele akuba angatshintshelwa kwesinye isibhedlele apho niya kuhlala khona ade 
umntwana wakho abe unomlinganiselo ongaphezu kwe 1800g yaye ukulungele ukuya 
ekhaya. 
Abantwana bayokwehlulwa babe ngamaqela amabini; iqela lokuqala liyakunikwa 
iProbiotics, elinye iqela linikwe into efana nazo kodwa ingezizo, ebizwa ngokuba yi 
plasibo. Le plasibo ifana nqwa ne Probiotics kodwa ayinazo ezintsholongwane 
zilungileyo. 
Iintsana ziyakuba koluphando intsuku eziyi28 zokuqala emva koba zizelwe.   
 
Kuyakwenzeka ntoni kum xa ndithe ndathatha inxaxheba? 
Abantwana abancinci abazalwe phambi kwexesha abanamandla okuncanca emabeleni. 
Umama kufuneka asenge ubisi emabeleni oluthi lunikwe umntwana ngethumbu 
elibhityileyo lweplastiki ehamba emlonyeni ukuyakutsho esuswini somntwana. 
Abongikazi abakwi wadi labantwana iG2 bayakuthi bakufundise ukuba lusengwa njani 
ubisi ukulungiselela umntwana. Ngokoluphando, sifuna umlinganiselo wokulunga 
nezinga lobisi lwebele lwakho. Eyona nto ibalulekileyo yi “oligosaccharide” ethi nayo 
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incede ukukhusela umntwana wakho ekusulelekeni. Siyakuthi kengoko sifune isampulu 
engange 5-10ml yobisi lwebele ngamaxesha athile. 
Isampulu yobisi yokuqala esizakuyifuna kuwe ingosuku lwesine uncancisa, kwakhona 
ngosuku lweshumi  nangosuku lwe28. Ezisampulu zintathu ziyakufakwa kumkhenkce 
phambi kokuba zihlolwe elebhu. Isampulu yamathe engange 2ml iyakuthi ifunwe kuwe. 
Isampulu zamathe ziyakuthi zifakwe kwisikhongozelo esingenazintsholongwane. 
Ekubeni unike imvume amathe akho aya kuthathwa. Kufunwa isampulu enye qha 
yamathe. Indlela amathe akho ayiyo iyayichaphazela imo ye “oligosaccharide” yobisi 
lwebele lakho. Isampulu zamathe ziyakufakwa emkhenkceni (frozen)  phambi kokuba 
zihlolwe elebhu 
Inkcazelo yexwebhu lwakho esuka kwisibhedlele sakho iyakusetyenziswa kuphando 
enje ngokuba umntwana wabelekwa njani, ngawaphi amayeza owawafumana ngokuya 
wawukhulelwe, njalo,njalo. Onke amakhosikazi akhulelweyo eNtshona Koloni ayahlolwa  
iHIV ngexesha bekhulelwe. Njengokuba kubalulekile ukuba siyazi i HIV status yakho, 
Siyakuyifumana i HIV status kwixwebhu lwenkcukacha zakho lwesibhedle.  
 
Kuzakwenzeka ntoni kumntwana ukuba ndinike isivumelwano?  
Abantwana abancinci bafakwa kwisikali yonke imihla ukubona ukuba balufumana 
ngokwaneleyo ubisi. Umntwana wakho uzakubekwa esikalini ukujongwa ubunzima 
yonke imihla, ubude kunye nomlinganiselo wentloko ziyakulinganiswa qho ngeveki.  
Iqela lophando (abantwana abazakufumana iProbiotics) bazakufumana amathontsi ayi 
5 eProbiotics emlonyeni kanye ngosuku, iveki ezine (intsuku eziyi 28). Iqela lesibini 
(abantwana abazakuthi bafumane iplasibo)  bazakufumana amathontsi ayi 5 eplasibo 
engenazo intsholongwane ezilungileyo ngomlomo kanye ngemini iveki ezine (intsuku 
eziyi 28) . Uxwebhu lwenkcukacha zomntwana wakho ziyakuthi zifundwe ngumphandi 
ntsuku zonke yaye iziphumo zovavanyo lwaselebhu zakubhalwa phantsi.  
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KUTHENI UMENYIWE UKUBA UTHATHE INXAXHEBA? 
Uchongiwe kuba ubeleke umntwana omncinci kakhulu ozelwe phambi kwexesha, 
kwaye walaliswa kwa ward G2 at Tygerberg Children’s Hospital (TCH) yaye uyakwazi 
ukucudisa amabele unikele ngesampulu yobisi lwebele.  
 
ZINTONI EZILINDELEKILEYO KUWE? 
Uyakulindeleka ukuba ucudise amabele kubekho ubisi ntsuku zonke ukulungiselela 
umntwana wakho. Ngezintsuku 4, 10 and 28 isampulu eyi  5ml - 10ml yobisi lwebele 
olunikezelwe nguwe luya kufakwa emkhenkceni kwilebhu. Isampulu yamathe akho 
engange 2ml iyakufunwa kuwe. Lesampulu yamathe iya kufakwa emkhenkceni (frozen) 
phambi kokuba ihlolwe elebhu. 
 
KUKHO INZUZO EKUTHATHENI INXAXHEBA KOLUPHANDO? 
Uzakuzuza ngolwazi kuba wenze umnikelo obalulekileyo ngokunika igqiza lezempilo 
ulwazi olubalulekileyo oluya kuthi lubancede kuphando lwabo xa bekhangela eyona 
ndlela elungileyo yokutyisa abantwana abazalwe “phambi kwexesha” nabantwana 
abancinci kakhulu nokunceda ukukhusela isifo sokufa kwethumbu. (necrotising 
enterocolitis.) 
 
INGABA KUKHO INGOZI EKUTHATHENI KWAKHO INXAXHEBA KOLUPHANDO? 
Umntwana wakho uyakuthi anyangwe kanye kanye njengabanye abantwana abancinci 
abalaliswe kwa-ward G2 e Tygerberg Children’s Hospital. Abanye kwababantwana 
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bakuthi banikwe i-Probiotics abanye bafumane iplasibo (engenazo intsholongwane 
ezilungileyo). Bonke abantwana (abo bafumana i- Probiotics nabo bafumana i- placebo) 
bayakubekwa esweni ukukhangela iimpawu zosuleleko.  Abantwana bayakususwa 
koluphando ukuba kuthe kwenzeka oku kulandelayo:  
Ukuba umntwana akancanci ubisi lwebele ngomlomo kangangentsuku ezingaphezu ko-
3 yaye kufuneka kusetyenziswe ukutya okukhethekileyo  
Ukuba umntwana  uye wafa ithumbu ( necrotising enterocolitis)   
Ukuba umntwana uthe wahambisa (ukubaleka kwesisu) 
Ukuba umntwana uthe wafumana  usuleleko ngegazi (blood infection) kwi- Probiotics. 
Ingozi yosuleleko ngegazi kwi ntsholongwane ezilungileyo iphantsi kakhulu. 
UKUBA AKUVUMI UKUTHATHA INXAXHEBA UNOKUTHINI? 
Isigqibo sesakho ukuba ufuna ukuthatha inxaxheba okanye akufuni. Ukuba ugqiba 
ukuba ungathathi nxaxheba koluphando,lonto ayizokuchaphazela inkathalo eyakuthi 
inikwe umntwana wakho. Ngaphezukoko ukhululekile ukuba urhoxe nagaliphi ixesha 
ngaphandle kokunika inkcazelo kungekho nanto imbi eyakuthi ikwehlele. Impilo yakho 
neyosana lwakho ayisayi kuchaphazeleka kakubi. 
 
NGUBANI OZAKUFIKELELA KWINKCUKACHA ZESIGULO SAKHO? 
Ngumphandi kuphela, umphandi oncedisayo kunye nabantu ababandakanyekayo 
koluphando abayakuthi babenokufikelela kwinkcukacha zesigulo sakho. Yonke  
inkcazelo iyakusoloko igcinwe ngokhuseleko.  
Isampulu zamabisi ezithunyelwe elebhu aziyi kwaziwa ukuba zisuka kuwe ngoba  
igama lakho alizokufakwa kwisampulu zobisi lwakho. Ngumphandi kunye nomncedisi 
mphandi abayakuthi bayazi ukuba ngeyiphi isampulu yobisi yomama ngamnye. 
Umphandi kunye nomncedisi mphandi bayakuyithatha yonke inkcazelo edityanisiweyo 
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ngokuyimfihlelo engqongqo kwaye akukho nkcazelo iyakuchaza ngawe kunye 
nomntwana wakho eyakuthi ikhululwe nakuwuphina umntu ongabandakanyekiyo 
koluphando.  
Inkcukacha efunyenweyo/eqokelelweyo iyakuthi iphathwe ngokhuseleko olukhulu yaye 
ingachazwa, kodwa iyakuthi ipapashwe kwincwadi zogqira yaziswe nakwindibano 
zogqira ezinje nge congressi. Akukho ndlela konke konke apho igama lakho okanye 
lomntwana wakho liyakuthi livezwe khona.  
 
KUYAKWENZEKA NTONI UKUBA KUNOKWENZEKA KUBEKHO INGOZI 
EYENZEKAYO NGENXA YOKUTHATHA KWAKHO INXAXHEBA KOLUPHANDO? 
Akuqhelekanga ukuba kungakho into enokungahambi ngendlela. Ukuba awukwazi 
ukunikela ngobisi ngexesha elibekiweyo, ungazama ukunikela ngobisi ngelinye ixesha.  
Umphandi uyakuthi akwazise ngelinye ixesha elifanelekileyo lokunikela ngobisi.  
 Ngexesha kuqhubeka oluphando imiqathango eqhelekileyo iyakuthi isetyenziswe, lonto 
yenze ukuba amathuba okuba kubekho into engahambi kakuhle, abemancinci kakhulu.  
 
UZAKUHLAWULWA NA NGOKUTHATHA INXAXHEBA KOLUPHANDO OKANYE 
KUKHO INDLEKO EZIBANDAKANYWAYO? 
Hayi, awuzokuhlawulwa ngokuthatha inxaxheba koluphando. Akuyikubakho ndleko 
ezikubandakanyayo, ukuba uyavuma ukuthatha inxaxheba. 
 
 KWENZEKA NTONI XA OLUPHANDO LWESISIFUNDO LUYEKA? 
Inkcukacha efunyenwe koluphando iyakuthi ipapashwe kwincwadi zogqira. (medical 
journals.) 
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KUYAKUTHINI XA KUFUMANEKA INKCUKACHA ENTSHA? 
Ngamanye amaxesha ngexesha leprojekthi yophando, inkcukacha entsha iyafumaneka 
engesihloko eso sifundwayo. Ukuba lento iyenzeka, umphandi wakho uyakuthi 
akuxelele ngayo yaye niyixoxe ukuba ngaba ufuna ukuqhubeka ngoluphando. Ukuba 
ugqibe ekubeni urhoxe, indlela enikhathalelwa ngayo wena nomntwana ayiyi 
kuchaphazeleka. Ukuba ugqibe ekubeni uqhubekeke nophando uyakuthi ucelwe 
utyikitye ifomu ehlaziyiweyo yesivumelwano. Inkcukacha ebandakanyekayo ethi ivuke 
ngexesha kuqhubeka uphando Iya kufakelwa kweso sivumelwano sitsha. 
 
 INGABA IKHONA ENYE INTO OFUNA UKUYAZI OKANYE UKUYENZA? 
Ungaqhakamshelana no Miss Evette Venter ngomnxeba  021 938 9474/ 084 941 3832 
ukuba uneminye imibuzo okanye ufumana ezinye ingxaki. 
Ungaqhakamshelana ne Komiti yezophando zoluntu (Committee for Human Research) 
kwa: 021-938 9207 ukuba unezikhalazo okanye izinto ezingakonwabisanga ezithe 
azadweliswa ngababaphandi. 
Uyakufumana ikopi yalenkcukacha kunye nesivumelwano oyakuthi uzigcinele, 
ezizezakho. 
Isifungo somthathi nxaxheba 
Ngokutyikitya apha ngezantsi, mna……………………..………..........................…. 
ndiyavuma ukuthatha inxaxheba koluphando olubizwa: UKUSETYENZISWA 
KWENTSHOLONGWANE EZILUNGILEYO EKUNYANGENI UKUFA KWETHUMBU 
KWINTSANA EZIZALWE KWIMEKO ZE HIV NEZIZELWE ZINCINCI KAKHULU  
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(THE USE OF PROBIOTICS IN THE MANAGEMENT OF NECROTISING 
ENTEROCOLITIS IN HIV EXPOSED PREMATURE AND VERY-LOW BIRTH WEIGHT 
INFANTS) 
 
Ndikwanika isivumelwano ukuba umntwana wam……....................................angathatha 
inxaxheba koluphando olubizwa: UKUSETYENZISWA KWENTSHOLONGWANE 
EZILUNGILEYO EKUNYANGENI UKUFA KWETHUMBU KWINTSANA EZIZALWE 
KWIMEKO ZE HIV NEZIZELWE ZINCINCI KAKHULU. (THE USE OF PROBIOTICS IN 
THE MANAGEMENT OF NECROTISING ENTEROCOLITIS IN HIV EXPOSED 
PREMATURE AND VERY-LOW BIRTH WEIGHT INFANTS)  
  
 
Ndazisa ukuba: 
Ndiyifundile okanye ndiyifundelwe le nkcukacha neliphepha lesivumelwano yaye 
ibhalwe ngolwimi endiluthethayo yaye endikholisekileyo lilo. 
Ndilifumene ithuba lokubuza imibuzo yaye imibuzo yam iphenduleke ngokwanelisayo. 
Ndiyayiqonda into yokuba ukuthatha inxaxheba koluphando ayisosinyanzelo yaye 
andinyanzeliswanga ukuba ndithathe inxaxheba. 
Ndinako ukukhetha ukulushiya oluphando nageliphina ixesha yaye akukho sohlwayo 
ndiyakusifumana ngenxa yoko. 
Ndinokucelwa ukuba ndilushiye oluphando phambi kwexesha ukuba ugqirha wophando 
ucinga ukuba oko kufanelekile okanye ukuba andithanga ndalandela imigaqo yophando 
njengoko besivumelene. 
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Ityikitywe e (indawo) ......................…........…………….. ngo (umhla) …………....……….. 
2011. 
 
    
Umtyikityo womthathi nxaxheba Umtyikityo wengqina 
 
Isifungo somphandi 
 
mna (igama) ……………………………………………..……… ndazisa ukuba: 
 
Ndiyicacisile inkcukacha equlethwe loluxwebhu ku………………….. 
Ndimkhuthazile ukuba abuze imibuzo ndathatha ixesha elaneleyo ukumphendula. 
Ndanelisekile ukuba uziqondile ngokwanelisayo zonke izinto-yinto zoluphando njengoko 
zixoxiwe ngentla 
Ndiyisebenzisile/andiyisebenzisanga itoliki.  (ukuba itoliki isetyenzisiwe kufuneka 
ityikitye isifungo esisezantsi). 
 
Ityikitywe e(indawo......................…........……………ngo(umhla) …………....………..2011 
 
    
Umtyikityo womphandi Umtyikityo wengqina 
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